-
Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China
•
China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration agreement with global pharmaceutical giant Pfizer (NYSE: PFE). The partnership grants Pfizer’s affiliated companies the exclusive rights to commercialize Xacduro (durlobactam, sulbactam) in mainland China. This collaboration, set to be in effect through November 2028,…
-
Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements
•
The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company Flagship Pioneering, initiated in July 2023, has expanded with two new additions. Ampersand Biomedicines and Montai Therapeutics, both Flagship-founded biotechs, have entered into agreements to identify targeted molecules aimed at treating obesity and non-small cell…
-
Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib
•
US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa Kirin Co., Ltd. (TYO: 4151), granting Kyowa Kirin exclusive commercialization rights to Kura’s menin inhibitor ziftomenib outside of the United States. Kura retains the corresponding rights within the US. Financial Terms and MilestonesAccording to the…
-
CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within its corporate structure. The company’s sub-subsidiary, China Resources Kunming Shenghuo Pharmaceutical CO., Ltd., also known as CR Sanjiu (SHE: 000999), is poised to sell its 51% stake in Shenghuo to another subsidiary of CR Pharma,…
-
Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics
•
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc., a pre-clinical biotech firm specializing in adeno-associated virus (AAV)-based gene therapies for muscle and heart diseases, for a substantial USD 1.1 billion. This strategic move allows Novartis to gain access to Kate’s pre-clinical gene therapy…
-
Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing
•
China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German pharmaceutical giant Bayer AG (ETR: BAYN) regarding HuaTangNing (dorzagliatin tablets, HMS5552), effective January 1, 2025. The agreement, which began in August 2020, focused on the promotion and distribution of the drug in China. Dorzagliatin’s Impact…
-
Sihuan Pharmaceutical’s Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced an exclusive licensing agreement between its subsidiary Huisheng Pharm and MEIYOUNG. The deal pertains to Huisheng’s biosimilar version of Denmark-based Novo Nordisk’s (NYSE: NVO) weight loss drug semaglutide (Ozempic/Wegovy) for the treatment of overweight or obesity in China. Terms of…
-
BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China
•
German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group Co., Ltd (HKG: 1099), granting the latter the rights to promote Boehringer Ingelheim’s Sifrol (pramipexole) and Pradaxa (dabigatran) in China effective from January 1, 2025. Boehringer Ingelheim will retain ownership and manufacturing responsibilities for both…
-
CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store – L.L.C – O.P.C (Pharmalink), a prominent pharmaceutical company based in the United Arab Emirates (UAE), concerning its anti-PD-L1 monoclonal antibody (mAb) sugemalimab. Commercial Rights and Deal TermsUnder the agreement, Pharmalink will acquire the commercial rights…
-
Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion
•
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a private placement of 122,000,000 shares, valued at RMB 960 billion (USD 133 million). This strategic move aims to bolster the company’s financial position and support its research and development (R&D) initiatives. Investment in In-House Drug…
-
Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies
•
US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd (TYO: 4502) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). This collaboration aims to bolster the development of key therapies targeting solid and hematological…
-
Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
•
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with US pharmaceutical major Eli Lilly & Co., (NYSE: LLY), aimed at accelerating the global clinical development of Laekna’s obesity treatment candidate, LAE102. Under the terms of the agreement, Lilly will take on the responsibility for…
-
Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan
•
Germany-based Bayer AG (ETR: BAYN) has announced a significant collaboration and license agreement with US-based Cytokinetics, Incorporated (NASDAQ: CYTK), acquiring exclusive development and commercialization rights to aficamten in Japan. The agreement is subject to certain reserved development rights of Cytokinetics. Phase III Study and Global Trial ExpansionUnder the terms of…
-
Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student
•
French pharmaceutical company Servier and the US-based Dana-Farber Cancer Institute have announced the start of the Servier-funded SHINEDoc program in the United States, with the enrollment of the first PhD student from Dana-Farber. The program, which is set to begin this month, marks a significant step in fostering innovation in…
-
Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million
•
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is poised to conduct an initial public offering (IPO) of 45,398,800 shares on the Hong Kong Stock Exchange (HKEX) on November 26, following the receipt of approval from the exchange earlier this week. The company has priced each share at 12.56, aiming to raise…
-
Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a China-based biopharmaceutical company, has announced a licensing agreement with an undisclosed company due to commercial sensitivity and trade secret considerations. Exclusive Licensing Rights for Greater ChinaAccording to the agreement, Junshi Bio will secure exclusive licensing rights and sublicensing rights to…
-
LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
•
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced another licensing deal, signing an agreement with compatriot firm Sino Biopharmaceutical Ltd (HKG: 1177) for the development and commercialization of LM-108 and other potential bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) in mainland China. The specifics of the…
-
Worg Pharmaceuticals Secures Major Financing for Allergy and Autoimmune Disease Therapies
•
Worg Pharmaceuticals (Zhejiang) Co., Ltd., a China-based biopharmaceutical company specializing in the development of immunotherapies for allergic and autoimmune diseases, has successfully raised hundreds of millions of renminbi in a new financing round. The round saw participation from notable investors such as PICC Investment, Tsing Song Capital, and an undisclosed…
-
Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million
•
Zai Lab Ltd (ZLAB; NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company, is set to raise capital through a secondary public offering of American Depositary Shares (ADSs) valued at USD 230 million. The offering consists of 7,843,137 ADSs, with each ADS representing ten ordinary shares of the company, priced at…
-
Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing
•
Shanghai Leadingtac Pharmaceutical Co., Ltd., a China-based small molecule drug developer, has announced the successful completion of its Series A financing round, raising RMB100 million (USD 13.81 million). The round was led by Beijing Longpan Venture Capital Centre, with additional support from Tian Rui Feng Nian Investment and Shanghai Zhangke…
-
Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502
•
Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered into a licensing agreement with US based Acraris Therapeutics, Inc. (NASDAQ: ACRS). The deal grants Acraris exclusive global rights, excluding Greater China, to Biosion’s BSI-045B and BSI-502, further strengthening the two companies’ layout in the…
-
Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer
•
US-based Ratio Therapeutics Inc. has entered into a global exclusive licensing and cooperation agreement with Swiss pharmaceutical giant Novartis AG (NYSE: NVS) to develop a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer treatment. Details of the AgreementRatio will apply its radioligand therapy discovery and development expertise, along with its…
-
VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC
•
Shanghai-based biotech company VelaVigo, specializing in bispecific/multi-specific antibodies and antibody drug conjugates (ADCs), has announced a global strategic partnership with US oncology firm Avenzo Therapeutics, Inc. This collaboration will facilitate the global development, manufacturing, and commercialization of VelaVigo’s Nectin4/TROP2 bispecific ADC, excluding Greater China, where VelaVigo retains the rights. Details…
-
Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments
•
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered into a strategic cooperation agreement with Yiling Pharmaceutical Co., Ltd (SHE: 002603), marking a significant step into the metabolic diseases field utilizing RNAi technologies. This partnership aims to leverage Youjia’s expertise in nucleic acid drug…
-
Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China
•
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced an additional distribution agreement with Australian firm Sirtex Medical Ltd. The agreement involves Grand Pharmaceutical’s subsidiaries, Beijing Purevalley Biotechnology Co., Ltd, and Chengdu Purevalley Biotechnology Co., Ltd, which will exclusively distribute Sirtex’s SIR-Spheres (Y-90 microsphere)…
-
Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336
•
Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement with UK-based Platina Medicines Ltd (PML). The agreement grants Platina Medicines exclusive global development, manufacturing, and commercialization rights to Keymed’s CM336, excluding mainland China, Hong Kong, Macau, and Taiwan. Financial Terms and ConsiderationsUnder the terms…
-
Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments
•
Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing hearing by The Stock Exchange of Hong Kong Limited for its initial public offering (IPO). While the price and other key details have not been disclosed at this stage, the company’s listing marks a significant…
-
NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology
•
China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership with 3SBio Inc. (HKG: 1530), a compatriot firm, to focus on advancing NK cell therapy technology. This collaboration aims to leverage the complementary technologies and resources of both companies, accelerating the research, development, and commercialization…
-
Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design
•
Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion of its Series A financing round, raising over RMB100 million (USD 13.82 million). The round was led by Qiming Venture Partners, with additional investments from Yonghua Capital, Jingtao Private Equity Fund, and 3E Bioventures, among…
-
Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition
•
Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced the completion of its acquisition of Axonics, Inc. (NASDAQ: AXNX) for a substantial USD 3.7 billion. This strategic transaction is set to bolster Boston Scientific’s presence in the field of sacral neuromodulation (SNM), enhancing the…
-
Shenzhen Weiguang Biological Partners with SUAT to Boost Life Science and Health Industry
•
Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a prominent blood products manufacturer in China, has entered into a strategic partnership with Shenzhen University of Advanced Technology (SUAT). This collaboration, focused on the life and health sector, aims to foster the integration of industry and education, enhance cooperation among industry,…
-
C-Ray Therapeutics Secures Over $100 Million in Series A+ Financing for Radiopharmaceuticals
•
C-Ray Therapeutics, a specialist in radiopharmaceuticals headquartered in Chengdu, has announced the successful completion of a Series A+ financing round, raising over USD 100 million. The funding was co-led by Shenzhen Capital Group’s Manufacturing Transformation and Upgrading New Materials Fund and Tailong Capital, with additional contributions from GL Ventures, 3SBio…
-
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
•
China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in a Series D++ financing round, co-led by a globally renowned industry investment institution and a prominent insurance fund. The funds raised will be directed towards the commercialization of its core product, senaparib, a PARP1 inhibitor,…
-
J&J MedTech Secures Exclusive Distribution Deal with Responsive Arthroscopy
•
Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading player in the US medical technology sector, has announced an exclusive commercial distribution agreement with Responsive Arthroscopy Inc., an innovative medical device company specializing in sports soft tissue repair solutions. This strategic partnership is aimed at bolstering J&J MedTech’s sports medicine…
-
Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China
•
Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its debut in Hong Kong last month, has entered into a market promotion service agreement with Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company in China. This collaboration will see Baheal provide…
-
PegBio Files for IPO on Hong Kong Stock Exchange
•
PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant step towards going public with an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). While the price and other specific details of the offering are yet to be disclosed, the move…
-
Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company
•
Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is poised to merge with US-based Pulmatrix, Inc. (NASDAQ: PULM). The merger will result in a Nasdaq-listed entity focused on advancing targeted protein degradation technology, a promising field in drug development. Cullgen’s uSMITE Technology PlatformCullgen leverages…
-
Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund
•
Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic investment totaling USD 20 million from global pharmaceutical leader Sanofi (NASDAQ: SNY) and Perceptive Xontogeny Venture Fund (PXV Fund I). This investment is a significant component of Zucara’s USD 20 million Series B financing round,…
-
Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed a strategic partnership with the Society for Neuroscience and Neurology, Chinese Research Hospital Association (SNN/CRHA). This collaboration is aimed at conducting comprehensive research into the genetic underpinnings of optic nerve-related diseases, marking a significant step…
-
BioNTech Seals Acquisition of China’s Biotheus for Up to $950M
•
China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ: BNTX), marking a significant expansion of BioNTech’s operations in China. The deal underscores BioNTech’s commitment to enhancing its research and development capabilities and production capacity in the region. Deal Terms and FinancialsUnder the agreement, BioNTech…
-
Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China
•
China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical (TYO: 4536) for the commercialization of ARVN001, an innovative triamcinolone acetonide suprachoroidal injectable suspension. This partnership marks a significant step in the expansion of ophthalmic treatments, with Santen securing exclusive commercialization rights in mainland China…
-
Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881
•
China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has entered into a licensing agreement with UK-headquartered Apollo Therapeutics Group Limited for the development of APL-18881 (HEC88473). This strategic deal grants Apollo exclusive rights to develop and commercialize the drug outside of Greater China, while…
-
Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin off its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm), for an initial public offering (IPO) on the Hong Kong Stock Exchange. This follows an earlier aborted effort to list on Shanghai’s Sci-Tech Innovation Board (STAR)…
-
Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research
•
Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the Mary Tyler Moore Vision Initiative (MTM Vision), marking the first time a pharmaceutical company has joined the MTM Vision Consortium. This partnership signifies a significant step in collaborative research aimed at addressing vision-related complications of…
-
Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia
•
Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership with Mirxes Singapore. Together, they will utilize their combined technological and operational strengths to offer solid tumor origin identification testing services to medical practitioners and patients in Singapore, Malaysia, Thailand, Indonesia, and the Philippines. Collaboration…
-
Vesalius Therapeutics Partners with GSK for Novel Parkinson’s Disease Treatments
•
US-based Vesalius Therapeutics has entered into a strategic agreement with UK pharmaceutical giant GSK plc (NYSE: GSK, LON: GSK) to discover and develop innovative treatments for Parkinson’s disease (PD) and another undisclosed neurodegenerative condition. The alliance leverages Vesalius’ platform to identify novel intervention points in PD and an additional neurodegenerative…
-
Flare Therapeutics and Roche Enter Strategic Collaboration for Oncology Drug Discovery
•
US-based Flare Therapeutics Inc., a clinical-stage biotech company specializing in cancer therapies through the use of transcription factors, has announced a strategic discovery collaboration agreement with Swiss pharmaceutical giant Roche (SWX: ROG). The partnership will utilize Flare Therapeutics’ expertise in proteomics and mass spectrometry, along with its proprietary library of…
-
Schrödinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates
•
New York-based Schrödinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS). This partnership is aimed at advancing multiple development candidates into Novartis’s portfolio for further development. Additionally, the two companies have reached an expanded…
-
Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%
•
Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ: EVO), as per information from Reuters. This news catalyzed a 22% surge in Evotec’s shares on Monday, reflecting market anticipation of the potential deal. Triton’s Interest and ShareholdingTriton Partners has been in the process of…
-
Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
•
China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A financing round, raising over RMB 100 million (USD 13.9 million). The round was led by Fuho Capital, with additional contributions from Jun Yi Investment and AI-driven drug R&D leader XtalPi. The funds will be directed…
-
Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its US partner IDEAYA Biosciences Inc. (NASDAQ: IDYA) has exercised its option for an exclusive worldwide license for Biocytogen’s IDE034. This potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) represents a significant step forward in…
-
ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation
•
ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed a cooperation memorandum of understanding (MoU) with Takeda (TYO: 4502). This partnership aims to jointly explore opportunities in early development, new technology application, and innovative company empowerment, with a focus on oncology, neuroscience, digestive, and…
-
Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
•
Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement with Japan-headquartered Daiichi Sankyo (TYO: 4568). This strategic partnership grants Daiichi Sankyo worldwide rights to utilize Alteogen’s ALT-B4, a novel hyaluronidase based on Hybrozyme Technology, in the development and commercialization of a subcutaneous version of…
-
Baheal Pharmaceutical Group Leads USD 78 Million Investment in ZAP Surgical Systems
•
Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company based in China, has announced its participation in a USD 78 million Series E funding round for ZAP Surgical Systems, Inc., a globally recognized leader in non-invasive robotic brain surgery. The investment will support the commercialization efforts of…
-
Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China
•
At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd, and KYinno Biotechnology Co., Ltd, have jointly announced a cooperation Memorandum of Understanding (MoU) with global pharmaceutical leader Pfizer (NYSE: PFE). The collaboration focuses on the clinical development of innovative treatment solutions for patients with…
-
Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu
•
Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300 million agreement with South Korean biotechnology firm Alteogen to develop a subcutaneous injection version of its cancer drug Enhertu, which is also in collaboration with AstraZeneca. This innovative step aims to enhance patient accessibility and…
-
MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping
•
China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration with the Human Cell Atlas (HCA) consortium, marking a significant step forward in the human cell mapping initiative. This partnership aims to expand access to MGI’s proprietary products within the HCA network by offering discounted…
-
Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million
•
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention to acquire 100% stakes in Xintrum Pharmaceuticals, Ltd, a biologic drug developer, for a consideration of RMB 270 million (USD 37.7 million). Upon completion of the deal, Xintrum will become a wholly owned subsidiary of…
-
Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies
•
Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in Heifei, Anhui province, has reportedly secured RMB150 million (USD21 million) in the first closing of its Series B financing round. The funding was led by Guangzhou Industry Investment, with significant contributions from China Resources International,…
-
Shanghai Henlius Biotech Partners with SVAX to Boost MENAT Region’s Access to Biological Drugs
•
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biotech company, has entered into a strategic partnership with AL-TIRYAQ AL-KHALAWI Medical Company (SVAX), a healthcare unit owned by the prominent Fakeeh family in Saudi Arabia, during the 2024 China International Import Expo (CIIE). This collaboration aims to leverage Henlius Bio’s…
-
Teva Pharmaceutical Expands Partnerships in China’s One Health Sector with New Agreements
•
Israel based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced new partnerships with Chinese firms Zhejiang International Group Co., Ltd. and Jianmin International Co., Ltd. These collaborations aim to enhance Teva’s commercial layout in the “One Health” sector, increasing the availability of quality products for Chinese consumers. Strategic Agreements at…
-
Bayer’s Leap Forward: Implementing Salesforce on Alibaba Cloud for Customer Engagement
•
Bayer (ETR: BAYN) has announced that its China Prescription Medicines business has fully adopted the “Salesforce on Alibaba Cloud” solution, creating an all-new customer interaction platform, OPERA 2.0, for thousands of internal Bayer users. Bayer is one of the first multinational pharmaceutical companies in China to implement a new customer…
-
Shanghai Pharmaceuticals’ MediTrust Health Partners with Eisai for Comprehensive Patient Services
•
Shanghai Pharmaceuticals Holding Co., Ltd’s (HKG: 2607, SHA: 601607) subsidiary, MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a strategic partnership with Japanese pharmaceutical company Eisai (TYO: 4523). This collaboration grants Eisai access to MediTrust Health’s “One-Code Direct Payment-Diversified Payment Platform,” aiming to establish…
-
Boehringer Ingelheim Partners with Wuhan Union Hospital to Enhance Clinical Research and Development
•
Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a strategic partnership with Wuhan Union Hospital, marking a significant step in the realm of clinical research. This collaboration will extend beyond clinical studies to include academic exchanges, patient education, and talent development, among other areas, in alignment with Boehringer…
-
Hainan Haiyao Enters JV with Haikou and Xenios AG to Advance ECMO Technology
•
Hainan Haiyao Co., Ltd (SHE: 000566), a prominent Chinese company, has announced the signing of an initial joint venture (JV) agreement with the Haikou National High-tech Industrial Development Zone Management Committee and Xenios AG, a subsidiary of German healthcare giant Fresenius Medical Care AG. This strategic collaboration is aimed at…
-
Nanjing Leads Biolabs and Aditum Bio Launch Oblenio Bio with Focus on CD19 Tri-Specific Antibody
•
China-based Nanjing Leads Biolabs Co., Ltd and venture capital firm Aditum Bio have announced the establishment of Oblenio Bio, along with an exclusive option and license agreement to develop LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody targeting autoimmune diseases. Aditum Bio will provide funding for Oblenio Bio, and together…
-
Sanofi and Cathay Capital Forge Partnership to Boost Sino-French Pharmaceutical Cooperation
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has signed a partnership deal with Cathay Capital, a global private equity and venture capital investment firm, at the 7th China International Import Expo (CIIE). This collaboration aims to deepen their existing long-term cooperation and serves as a positive step towards promoting Sino-French cooperation…
-
Eisai and GE Healthcare Sign MoU at CIIE to Collaborate on Alzheimer’s Disease Solutions
•
At the 7th China International Import Expo (CIIE), Japan-based Eisai Co., Ltd (TYO: 4523) entered into a Memorandum of Understanding (MoU) with US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC). The partnership, centered on the early detection, precise diagnosis, and treatment of Alzheimer’s disease (AD),…
-
Lohmann & Rauscher Partners with Allmed Medical Products at CIIE for Medical Dressings
•
Lohmann & Rauscher, a medical group with headquarters in Germany and Austria, has entered into a partnership with China-based Allmed Medical Products Co., Ltd. (SHE: 002950) at the 7th China International Import Expo (CIIE). The collaboration aims to leverage the complementary strengths of both companies to provide a more diversified…
-
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
•
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities. Expanding Collaborations in Pharmaceutical InnovationFrance’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially…
-
Bayer HealthCare Partners with China Population Welfare Foundation at CIIE for Public Health Initiatives
•
German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the China Population Welfare Foundation (CPWF) at the 7th China International Import Expo (CIIE). The collaboration aims to enhance public health awareness by promoting health science popularization and advocacy activities. Joint Focus on Health Initiatives Under…
-
Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development
•
US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong Pharmaceutical Co., Ltd. (HKG: 3320) at the 7th China International Import Expo (CIIE). The collaboration is aimed at developing minimally invasive surgical medical equipment to enhance patients’ diagnosis and treatment experience. Focus on GBA Policy…
-
Novartis Forges Partnerships at CIIE to Strengthen Radioligand Therapy Ecosystem in China
•
At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced strategic partnerships with US medical device and life sciences company GE Healthcare Technologies Inc., (NASDAQ: GEHC), and Chinese firms Shanghai Pharmaceuticals Holding Co., Ltd (HKG: 2607, SHA: 601607; SPH) and C.Q. Pharmaceutical Holding Co., Ltd…
-
Vantive Secures Collaborations with Kertone and Qiantang Longyue at CIIE for Dialysis Solutions
•
Vantive, a planned spin-off from U.S.-based Baxter International (NYSE: BAX) specializing in kidney care, has entered into separate collaboration agreements with the Chinese unit of UK’s Kertone Ltd. and Hangzhou Qiantang Longyue Biotechnology Co., Ltd. at the 7th China International Import Expo (CIIE). These partnerships focus on hemodialysis and peritoneal…
-
Northeast Pharmaceutical to Acquire Majority Stake in Dingcheng Peptide Source for RMB 186.8 Million
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced its intention to acquire a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd, a fellow Chinese firm, for a consideration of RMB 186.8 million. This strategic move is aimed at bolstering Northeast Pharmaceutical’s presence in the cell therapy sector.…
-
Shanghai Duoning Biotechnology Partners with Branca Bunús for Transfection Reagents Innovation
•
Shanghai Duoning Biotechnology Co., Ltd, a prominent biopharmaceutical company in China, has entered into a strategic partnership with Ireland-based Branca Bunús Ltd, a leader in gene delivery technology. This collaboration aims to provide biopharmaceutical customers with innovative transfection reagents through resource sharing, focusing on the development, optimization, and application of…
-
Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange
•
Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission’s (CSRC) tightening of IPO rules…
-
Boston Scientific Corporation Announces Acquisition of Cortex, Inc.
•
US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire Cortex, Inc., a medical technology company under the Ajax Health umbrella. The financial details of the agreement have not been disclosed, and the transaction is expected to close in the first half of…
-
Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology
•
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement with compatriot firm Ascendis Pharma A/S (NASDAQ: ASND), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis’ TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary…
-
Mirxes Holding Company Updates IPO Prospectus with 2024 Financials
•
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit products, has submitted an updated initial public offering (IPO) prospectus to the Hong Kong Stock Exchange. The document reveals the company’s financial performance as of June 2024. During the first half of the year, Mirxes…
-
Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline
•
China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving Loan Facility of up to USD 100 million with HSBC, a leading global bank and financial services institution. This customized financing solution is designed to support the expansion of Insilico’s proprietary novel drug discovery pipeline…
-
Boehringer Ingelheim Partners with Broad Institute for Mental Health Treatments
•
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. The joint project aims to address the urgent and unmet needs of individuals living with mental health conditions, with a specific focus on developing…
-
Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan
•
Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and PharmaEngine Inc. have entered into a distribution agreement concerning Liporaxel (paclitaxel oral solution). The agreement grants PharmaEngine exclusive rights to handle the new drug application (NDA) filing, sales, and marketing of Liporaxel in the Taiwan…
-
Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing
•
Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful completion of a Series C financing round, raising hundreds of millions of renminbi. The funding was led by Nanjing Jiangning High Tech Zone Science and Technology Entrepreneurship Investment Management Co., Ltd and Huaxing Kangping Pharmaceutical…
-
Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital
•
Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing round, raising in excess of RMB100 million (USD14.04 million). The funding round was led by China Venture Capital, with participation from Betta Pharmaceuticals Co., Ltd (SHE: 300558) contributing RMB 20 million, Lenovo Capital and Incubator…
-
Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a subscription agreement between its wholly owned subsidiary, Fortvita, and Lostrancos Ventures Ltd. The agreement would have seen Lostrancos acquire a 20% stake in Fortvita for USD 20.5 million. Despite this setback, Innovent Biologics reaffirmed its…
-
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
•
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with EvolveImmune Therapeutics, Inc., an immunotherapy platform company backed by industry giants including Pfizer (NYSE: PFE) and BMS (NYSE: BMY). The partnership will focus on leveraging EvolveImmune’s T-cell engager platform to develop novel antibody-based therapies for…
-
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
•
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20 million milestone payment from its Japanese partner Takeda (TYO: 4502; NYSE: TAK), following the achievement of over USD 200 million in sales of Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC). Fruquintinib, a selective oral inhibitor…
-
HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments
•
Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced a strategic cooperation agreement with Sino Biopharmaceutical Ltd (HKG: 1177), along with controlling shareholder HOB Biotech Group Limited and John Li, chairman and general manager of HOB. The collaboration aims to explore and cooperate in the research and development, production,…
-
Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch
•
China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) to terminate their strategic partnership, which was initially formed in December 2020 to support the launch of the hypoglycemic drug chiglitazar (Bilessglu) for type 2 diabetes in 19 provinces, including Henan,…
-
Jiangsu Yuyue Medical Equipment Partners with TÜV SUD to Boost Medical Device Market Access
•
Jiangsu Yuyue Medical Equipment Inc., (SHE: 002223), a Chinese medical equipment manufacturer, has entered into a strategic partnership with Germany’s TÜV SUD, one of the world’s largest technical inspection institutions. The collaboration aims to enhance their cooperation in the medical device market access and quality system. With over two decades…
-
Allmed Medical Products to Establish Wholly Owned Subsidiary in Indonesia
•
China-based Allmed Medical Products Co., Ltd (SHE: 002950) has announced plans to establish a wholly owned subsidiary in Indonesia with a registered capital of USD 50 million. The new entity, provisionally named PT Ace Medical Products Indonesia, will concentrate on the research and development, manufacturing, and sales of medical products…
-
Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%
•
Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which its wholly owned subsidiary Fortvita will sell a 20% stake to Lostrancos Ventures Ltd. for USD 20.5 million. This news has sparked market controversy, with some investors criticizing the valuation of Fortvita as being too…
-
MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions
•
MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic collaboration with Belgium’s OncoDNA, a company specializing in precision medicine for cancer and genetic diseases. The partnership integrates the OncoDEEP Kit’s comprehensive workflow—including sequencing, secondary analysis, and final interpretation of next-generation sequencing (NGS) data through…
-
Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases
•
U.S.-based Biogen Inc. (NASDAQ: BIIB) has announced a research collaboration with Neomorph to jointly develop molecular glue degraders targeting key areas in Alzheimer’s, rare neurological disorders, and immunological diseases. Leveraging Neomorph’s proprietary molecular glue discovery platform, the partnership aims to enhance the identification and validation of novel small-molecule therapeutic degraders…
-
GSK Secures Global Rights to Chimagen Biosciences’ T Cell-Engager in $850 Million Deal
•
UK pharmaceutical company GSK plc (NYSE: GSK) has entered into a licensing agreement with Chimagen Biosciences, securing all global rights to CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE). GSK will pay an upfront fee of USD 300 million and is committed to making success-based development and commercial…
-
Monte Rosa Therapeutics Strikes Licensing Deal with Novartis for VAV1 Degraders
•
US-based Monte Rosa Therapeutics (NASDAQ: GLUE) has entered into a licensing agreement with Swiss pharmaceutical company Novartis (NYSE: NVS), granting Novartis exclusive global development and commercialization rights to Monte Rosa’s VAV1-targeted molecular glue degraders (MGDs), including the investigational drug MRT-6160. As per the agreement, Novartis will make an upfront payment…
-
GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania
•
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in the United States with the establishment of a multi-purpose facility in Marietta, Pennsylvania. The company will invest USD 800 million to develop a state-of-the-art drug substance manufacturing facility and additional drug product manufacturing capabilities, creating…
-
ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered into a strategic partnership with fellow Chinese firm Yangtze River Pharmaceutical (Group) Co., Ltd. This collaboration aims to strengthen and enhance the development of ImmuneOnco’s investigational pipeline programs. The partnership encompasses a wide range of…
-
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
•
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control over LM-302, an antibody drug conjugate (ADC) targeting Claudin 18.2, from US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY). LaNova had previously signed an agreement with Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to…
-
AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets
•
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing agreement with Gedeon Richter Plc, aimed at strengthening the development of new potential targets for neuropsychiatric conditions. This collaboration builds upon the nearly two decades of successful partnership on central nervous system (CNS) projects, which…
-
3SBio Secures Exclusive Rights to Commercialize Haihe’s Paclitaxel Oral Solution in China and Hong Kong
•
Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have jointly announced a licensing agreement that grants 3SBio the exclusive rights to commercialize Haihe’s paclitaxel oral solution in mainland China and Hong Kong. According to the agreement, 3SBio will pay an undisclosed upfront sum along…
-
NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China
•
NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing agreement with fellow Chinese firm Xiamen Amoytop Biotech Co., Ltd (SHA: 688278). The agreement, valued at up to RMB 145 million (approximately USD 20.37 million) in upfront and milestone payments, as well as royalties, grants…
-
HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy
•
HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that it has received clearance from the US Food and Drug Administration (FDA) to initiate a Phase I clinical study for its allogeneic human induced pluripotent stem cell-derived cardiomyocytes (HiCM-188). This treatment involves administration via intramyocardial…
-
Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies
•
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered its oncology pipeline through the acquisition of Modifi Biosciences, Inc., a biotechnology company specializing in direct DNA modification-enabled cancer therapeutics. This strategic move provides MSD with preclinical compounds aimed at exploiting DNA repair defects in…
-
Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004
•
Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a $60 million payment from AstraZeneca (AZ, NASDAQ: AZN) following the successful achievement of development milestones for ECC5004/AZD5004, including the dosing of the first patient in the Phase 2b trial. This payment is a part of…
-
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
•
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in China, has successfully completed an initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued 14,588,000 shares at a price of HKD 22 each, raising a total of HKD 320 million (USD…
-
Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury
•
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to test investigational ocular surface immunoglobulin (OSIG) eye drops for their potential to treat ocular damage resulting from sulfur mustard exposure. BARDA, which is part of the Administration…
-
GSK and Cambridge University Forge £50 Million Partnership to Tackle Immune Diseases
•
UK pharmaceutical giant GSK plc (LON: GSK, NYSE: GSK) has unveiled a significant five-year partnership with the University of Cambridge and Cambridge University Hospitals, backed by a financial commitment of £50 million. This collaboration aims to enhance research and development efforts targeting immune-related diseases. Dubbed the Cambridge-GSK Translational Immunology Collaboration…
-
InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal
•
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other…
-
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
•
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of its shares in Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), according to a Bloomberg report. The company is said to be working with financial advisors to assess its minority stake in MicroPort after…
-
Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire full rights to the 99mTc GSA Injection and GSA cold kit from domestic rival Rongcheng Medical Technology Wuxi Co., Ltd., for a purchase price of RMB 85 million (approximately USD 11.82 million). The 99mTc GSA…
-
Stem-Cell Startup Xellsmart Secures Over RMB 100 Million in Series B1 Financing for Neurological Therapies
•
Xellsmart, a stem-cell startup headquartered in Suzhou, has reportedly secured over RMB 100 million (USD 14.08 million) in a Series B1 financing round. The round was led by Tialong/Taikun Equity Investment Fund, with additional investments from Septwolves Venture Capital and Sky World Capital, alongside returning investors Frees Fund, Qiming Venture…
-
Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases
•
Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and licensing agreement with Massachusetts-based biotech firm TRIANA Biomedicines. The collaboration aims to develop innovative molecular glue degraders targeting a variety of diseases, with a focus on oncology, according to a press release from TRIANA. Under…
-
Sanofi Invests EUR 300 Million in Joint Venture with Orano Med for Next-Generation Radioligand Therapies
•
Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with Orano Med, a subsidiary of the French Orano Group, to enhance the development of next-generation radioligand medicines. The collaboration aims to accelerate the growth of radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes, which…
-
Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics
•
Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US and Hong Kong, China, has announced a significant investment of USD 30 million by Chinese internet conglomerate Tencent into Insighta, a Hong Kong-based company specializing in early cancer detection. Insighta represents a substantial joint venture…
-
LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline
•
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of a Series C1 financing round, raising RMB 300 million (USD 42.1 million). The funding round was led by Sino Biopharmaceutical Ltd (HKG: 1177), with significant contributions from Shanghai Pudong Venture Capital, Zhangjiang Haoheng Innovative Equity…
-
Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset
•
Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement with Swiss pharmaceutical giant Novartis (NYSE: NVS), according to the Xinhua News Agency. Under this deal, Novartis will acquire the global exclusive rights to develop and commercialize one of Baiyu’s small molecule anti-tumor assets, the…
-
Cryofocus Biotechnology Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D
•
Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the First Affiliated Hospital of Guangzhou Medical University have entered into a collaborative agreement to contribute to the Guangzhou Lab’s project establishment and management. Guangzhou Lab is a cutting-edge research institution dedicated to the prevention and control…
-
Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program
•
French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST), a leading academic institution in China, to include HUST’s PhD students in the Servier Highlighting Innovation through its NEtwork of PhD students and Post-Docs (SHINEDocs) program. This strategic partnership aims to bridge the gap between…
-
Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin
•
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ: VTRS), a deal that extends Viatris’s exclusive commercialization rights to sotagliflozin in all markets outside the United States and Europe across all indications. Lexicon Pharmaceuticals retains the exclusive rights to commercialize sotagliflozin within the US…
-
Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement
•
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health Organization (WHO) Foundation in a significant pledge to enhance access to quality healthcare services for all, particularly targeting vulnerable groups in the Americas who face a heightened risk of suicide. The commitment involves a substantial…
-
Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor
•
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license agreement with Circle Pharma, a US-based firm. This strategic partnership aims to develop a first-in-class cyclin inhibitor, a novel approach that could halt the growth of cancer cells and offer new hope for patients struggling…
-
TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline
•
TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of its Series E financing round, raising RMB 300 million (USD 42.16 million). The financing was co-led by Zhongshan Venture Capital and the AMR Action Fund. The funds raised will be directed towards the late-stage clinical…
-
Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China
•
Bayer AG (ETR: BAYN), a leading German multinational pharmaceutical and life sciences company, has expanded its partnership with Meituan’s medical and healthcare business unit, a major player in China’s delivery services. The new collaboration will concentrate on the skin health sector, with a focus on online retail, digital marketing, and…
-
Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals
•
Lundbeck A/S (VIE: LUNA), a Danish pharmaceutical company, has announced its intention to acquire U.S.-based Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) in a deal valued at USD 60.00 per share in cash. The transaction, on a fully diluted basis, is worth USD 2.6 billion in equity terms and USD 2.5 billion…
-
iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
•
iRegene Therapeutics, a Wuhan-based biotechnology company specializing in the development of AI-enhanced chemically induced cell therapies, has announced the successful completion of its Series B financing round, raising over RMB 100 million (USD 14.15 million). The financing was co-led by Orinno Capital, with additional investments from Optics Valley Industrial Investment…
-
Huawei Partners with Medical University Hospital to Boost Healthcare Innovation
•
The Affiliated Hospital of Xuzhou Medical University has entered into a comprehensive partnership with Huawei Technologies Co., Ltd., a leading global provider of information and communications technology (ICT) solutions. Under this alliance, Huawei will offer a suite of advanced technologies, including network connectivity, transportation support, diverse computing power products, intelligent…
-
Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest
•
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has declared the successful completion of a share placement that has raised USD 250 million. This capital raise has garnered significant attention from international investment firms, with a majority of the final subscribers being long-term and healthcare funds. With this…
-
Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake
•
Sanofi (EPA: SAN; NASDAQ: SNY) has initiated negotiations with private equity firm CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business, marking a significant milestone in the French pharmaceutical giant’s strategic realignment. While no decision has been finalized, Sanofi will provide further updates…
-
JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services
•
JD Healthcare, a subsidiary of China’s e-commerce juggernaut JD.com (NASDAQ: JD), has formed a strategic partnership with Chongqing Genrix Bio Pharmaceutical Co., Ltd. This alliance combines Genrix Bio’s prowess in drug research and development with JD Healthcare’s extensive resource and ecological advantages in medical treatment, medication, health management, and insurance.…
-
Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development
•
Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated…
-
Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries
•
Indian pharmaceutical company Hetero has announced a new partnership with US healthcare giant Gilead Sciences (NASDAQ: GILD), securing a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower-middle income countries (LMICs). This marks a significant step in expanding access to this groundbreaking HIV-1…
-
Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform
•
Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience AG, a subsidiary of Danish biotech Nordic Bioscience, to advance the development of Dual Amylin Calcitonin Receptor Agonists (DACRA). This new class of potential treatments targets obesity and related disorders, marking a significant step in…
-
XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery
•
XtalPi Inc., a leading AI-driven drug discovery firm based in Shenzhen and known as QuantumPharm Inc. (HKG: 2228), has announced a significant licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, for its proprietary AI platform, Ailux Biologics’ XtalFold. This platform, recognized for its innovative approach in…
-
Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a partnership with US biotechnology company OverT Bio, Inc. to develop next-generation cell therapies targeting solid tumors. The collaboration will leverage Nona’s heavy-chain antibody (HCAb) Harbour Mice platform, with no financial specifics disclosed. Nona Bio’s HCAb…
-
Bill & Melinda Gates Foundation Invests $17 Million in CanSino Biologics’ Recombinant Polio Vaccine
•
The Bill & Melinda Gates Foundation has committed USD 17 million to support the development of CS-2036, a recombinant polio vaccine, by China-based CanSino Biologics (SHA: 688185, HKG: 6185). The investment will fund various development efforts, including clinical trials, process development, scaling-up, and the development of a candidate combined vaccine…
-
Beijing Aosaikang Pharmaceuticals Boosts Stake in US Subsidiary AskGene with RMB 220 Million Investment
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced a capital injection of RMB 220 million (USD 31 million) into its US-based subsidiary, AskGene Limited, established in 2012. This investment increases the Chinese firm’s shareholding in AskGene from 59.07% to 62.86%, solidifying its position as the controlling shareholder. Concurrently, TF…
-
HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates
•
China-based HitGen Inc. (SHA: 688222) has entered into a partnership with compatriot firm Ablink Biotech to integrate their world-leading trillion-level DNA-Encoded Libraries (DELs), a comprehensive small nucleic acid drug discovery and production platform, and a 300 billion-level biopharmaceutical molecule library. The collaboration aims to provide research and development services for…
-
Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange
•
China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem cell (PSC) derived cell therapies, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Details of the offering have not been disclosed at this stage. Established in 2017, Zephyrm Bio…
-
Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development
•
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing Huawe Medicine Technology Group Co., Ltd, a move aimed at leveraging synergies in research and development (R&D) and manufacturing resources. The collaboration seeks to reduce drug development costs and enhance product competitiveness in the high-end…
-
Bio-Thera Solutions Ltd Strikes Licensing Deal with Gedeon Richter for BAT1706 Biosimilar
•
Guangzhou-based Bio-Thera Solutions Ltd has announced a licensing agreement with Hungary’s Gedeon Richter Plc for BAT1706, its biosimilar version of Roche’s (SWX: RO) Avastin (bevacizumab). Under the agreement, Gedeon Richter will obtain exclusive commercialization rights for the drug in the European Union (EU), the UK, Switzerland, Australia, and other European…
-
Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline
•
Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A financing last week. Previously operating as Hercules CM Newco Inc., the company was established by a consortium of investors including Bain Capital Life Sciences, RTW Investments, Atlas Venture, and Lyra Capital. The pipeline of Kailera…
-
AstraZeneca Strikes Exclusive Licensing Deal with CSPC Pharma for Oral Lp(a) Disruptor
•
UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced the signing of an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd (HKEX: 01093). The deal grants AstraZeneca the rights to develop YS2302018, a preclinical stage oral Lp(a) disruptor intended for lipid-lowering therapy to treat various cardiovascular disease (CVD)…
-
Innovent Biologics and ASK Pharma Forge Strategic Partnership for Limertinib in Lung Cancer Treatment
•
China-based Innovent Biologics Inc. (HKG: 1801) and Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharma, SHE: 002755) have announced a strategic collaboration and licensing agreement focused on ASK’s limertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed for lung cancer treatment. Under the terms of the deal,…
-
MediLink Therapeutics Partners with Amgen for Clinical Trial in Small Cell Lung Cancer
•
Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced a partnership with US pharmaceutical giant Amgen Inc. (NASDAQ: AMGN). The collaboration will see the two companies conduct a global clinical trial combining MediLink’s B7-H3-targeting antibody-drug conjugate (ADC) YL201 with Amgen’s DLL3- and CD3-targeting bispecific T-cell engager (BiTE) IMDELLTRA for the…
-
Wuhan YZY Biopharma Grants Rights to CD3/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China
•
Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta TianQing Pharma the rights to its CD3/EpCAM bispecific antibody, M701, in Mainland China. Chi Ta Tian Qing Pharma will pay YZY Biopharma an upfront payment of up to RMB 315 million, plus additional development milestone…
-
Regor Therapeutics Strikes Deal with Genentech for CDK Inhibitors, Fetching USD 850 Million Upfront
•
Regor Therapeutics Group, a US-based biotech with significant ties to China, has entered into a licensing agreement with Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG; OTCMKTS: RHHBY) . Under the agreement, Genentech will acquire the rights to develop, manufacture, and commercialize Regor’s next-generation CDK inhibitors, including the…
-
Genor Biopharma to Acquire EOC Pharma Group in a Merger Deal, Eyeing Commercialization Synergies
•
Genor Biopharma Holdings Limited (HKG: 6998) has announced a definitive merger agreement with EOC Pharma Group (China) Co., Ltd. As part of the agreement, Genor Biopharma will acquire EOC Pharma through a share exchange, resulting in a reverse takeover. The company will change its name to “Edding Genor Group Holdings…
-
Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million
•
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in Shanghai Guanhe Pharmaceutical Co., Ltd (hereinafter referred to as “Guanhe Pharmaceutical”) from DiAn Diagnostics (SHE: 300244) and Suzhou Yingkai Xinyun Enterprise Management Consulting Co., Ltd (hereinafter referred to as “Suzhou Yingkai”, a subsidiary of DiAn…
-
Insilico Medicine and Seto Biopartner to Leverage AI in Synthetic Biology and Drug Discovery
•
Insilico Medicine has announced a strategic partnership with Seto Bio (SHE: 300583) to harness cutting-edge AI technology to explore and optimize key steps in the engineering transformation of biological systems, advancing synthetic biology research and innovative drug development. Established in 2014, Insilico Medicine has built over 30 proprietary drug pipeline…
-
FRα ADC Rina-S by Genmab Enters Late-Stage Clinical Trial Following ProfoundBio Acquisition
•
Genmab A/S (NASDAQ: GMAB) has initiated a Phase III clinical trial for its FRα ADC candidate, Rina-S, as registered on ClinicalTrials.gov on October 1, 2024. The trial aims to enroll 530 patients with platinum-resistant advanced ovarian cancer to compare Rina-S head-to-head with chemotherapy, with an anticipated preliminary completion date in…
-
Jiangsu Alphamab Biopharmaceuticals Partners with Shanghai Jinmant Biotech for JSKN003 ADC
•
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced that its wholly-owned subsidiary, Jiangsu Alphamab Biopharmaceuticals Co. Ltd, has entered into a licensing agreement with Shanghai Jinmant Biotech Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Co., Ltd (HKG: 1093), for the development and commercialization of its…
-
Alphamab Oncology Strikes Licensing Deal with CSPC Pharma for HER2 Targeted ADC in China
•
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm CSPC Pharmaceutical Group Ltd (HKG: 1093). The deal grants CSPC exclusive license and sub-license rights to Alphamab’s JSKN003 in mainland China for development, sales, and commercialization related to oncology indications.…
-
Mindray Bio-Medical Partners with Nanjing Drum Tower Hospital to Boost Clinical Research
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical equipment provider, has entered into a partnership with Nanjing Drum Tower Hospital, a prestigious and historically significant hospital in China. The collaboration will focus on key medical disciplines of the hospital and involve clinical study cooperation as part of…
-
Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development
•
Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has reportedly secured over RMB 100 million in a Series B financing round. The funding was provided by multiple family offices. Established in 2018, Whittilong Pharma specializes in the research and development of a diverse range…
-
Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), formerly known as the Shanghai Institute of Planned Parenthood Research (SIPPR). The collaboration aims to enhance collaboration in scientific research and development, achievement translation, team building, and party…
-
OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor
•
Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution agreement with Cardiovascular Systems Inc. (CSI), a subsidiary of U.S. giant Abbott Laboratories (NYSE: ABT). Under this agreement, CSI will serve as the exclusive distributor of OrbusNeich’s coronary and peripheral balloon products in the United…
-
Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals
•
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of a RMB 172 million collaboration payment from Allist Pharmaceuticals Co., Ltd, a fellow Chinese pharmaceutical company. This payment includes a RMB 150 million upfront fee and a RMB 22.79 million R&D compensation. The payment stems…
-
Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into a partnership with Biocre Tech, a specialist in protein and peptide research headquartered in Shenzhen. The collaboration aims to leverage the expertise of both companies, although financial details of the agreement were not disclosed. This…
-
FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism
•
The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline and trospium chloride) as an oral treatment for schizophrenia, marking it as the first therapy with a novel mechanism of action in this indication in several decades within the U.S. KarXT, an oral M1/M4 type…
-
Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm Nanjing JSIAMA Biopharmaceutical Co., Ltd. This deal grants Junshi the rights to research and develop, manufacture, file for regulatory approval, commercialize, and hold other interests…
-
Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China
•
Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S., has entered into a partnership with China’s Shanghai Pharmaceutical Holding Co., Ltd (SHA: 601607; SPH) to establish a long-term collaboration in the vaccine sector. The collaboration will focus on product promotion, introduction of innovative products,…
-
Belief BioMed Partners with Bayer’s AskBio to Explore New Gene Therapies
•
Belief BioMed Inc. (BBM), a Chinese biopharmaceutical company specializing in gene therapy, has announced a strategic partnership with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned subsidiary of Bayer AG. This collaboration aims to harness the potential of new gene therapies. The agreement will see the companies pool their expertise and resources…
-
Shanghai Fosun Pharmaceutical Partners with State-owned Firms to Boost ASEAN Drug Trade
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in China, has entered into a strategic partnership with Zhongheng Group (SHA: 600252) and Nanning Industrial Investment Unified Investment Management Co., Ltd, both of which are controlled by state-owned investment companies. The financial specifics of the…
-
TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China
•
TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with the French pharmaceutical giant Sanofi. This agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize TJ Biopharma’s anti-CD73 antibody, uliledlimab (TJD5), in Greater China. As part of the deal, Sanofi will make an upfront…
-
Sanofi’s Consumer Health Unit Attracts Binding Offers, Potential EUR 15 Billion Deal
•
French pharmaceutical giant Sanofi S.A. (EPA: SAN; NASDAQ: SNY) has reportedly received multiple binding offers for its consumer health care (CHC) division, from private equity firms Clayton Dubilier & Rice and PAI Partners, according to sources cited by Bloomberg. The potential deal could value the business at up to EUR…
-
Beijing Bohui Innovation Biotechnology Ends Rabies Vaccine Partnership with BOAOVAX
•
Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHA: 300318), a leading biopharmaceutical company in China, has announced an agreement with BOAOVAX to terminate their collaborative efforts on the development of a freeze-dried human rabies vaccine cultivated using serum-free Vero cells. As per the agreement, all clinical trials related to the…
-
Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic partnership with U.S. biotechnology company Alkyon Therapeutics, Inc. (AlkyonTx). The collaboration aims to develop next-generation immunotherapy and other targeted therapy applications, leveraging Nona’s proprietary Harbour Mice fully human antibody platform. The financial details of the…
-
Beijing Bohui Innovation and BOAOVAX End Collaboration on Rabies Vaccine Development
•
Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHE: 300318), a biopharmaceutical company based in China, has announced an agreement with domestic firm BOAOVAX to terminate their collaboration on the development of a freeze-dried human rabies vaccine cultivated using serum-free Vero cells. As a result of this agreement, the clinical trials…
-
Winner Medical Expands Global Footprint with Acquisition of Global Resources International
•
China-based Winner Medical Co., Ltd., a prominent manufacturer of disposable medical products, has announced the acquisition of a controlling stake in U.S. medical consumables firm Global Resources International, Inc. (GRI). The transaction values GRI at approximately USD 120 million for a 75.2% ownership interest. Established in 2000, GRI has an…
-
AimingMed Technologies Partners with RekeyMed to Advance Biotech and Organoid Innovations
•
Hangzhou AimingMed Technologies Co., Ltd., a leading organoid specialist based in China, has entered into a strategic partnership with RekeyMed Technology Co., Ltd, a company focused on regenerative medicine biomaterials. The collaboration aims to leverage the complementary strengths of both entities to foster the integration and innovative application of modern…
-
Suzhou’s LongBio Secures RMB 100 Million in Series B2 Financing to Advance Clinical Programs
•
LongBio, a biopharmaceutical company specializing in biomacromolecule drug development and based in Suzhou, China, has reportedly secured nearly RMB 100 million in a Series B2 financing round. The round was led by Qiming Venture Partners, with the funds earmarked to accelerate the clinical trials of its core programs in China,…
-
Janssen and Yuhan Halt Development of Next-Gen EGFR Inhibitor for NSCLC
•
Yuhan, a South Korean pharmaceutical company, and its partner Janssen Biotech, a subsidiary of US healthcare giant Johnson & Johnson (J&J; NYSE: JNJ), have reportedly decided to halt the development of a next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC). This strategic…
-
Tencent’s We Doctor Partners with CHA on National Digital Health Platform and Academic Initiatives
•
We Doctor, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) specializing in online medical services, has entered into a strategic partnership with the Chinese Health Association (CHA). The collaboration aims to explore innovative models focused on ‘common health’ and ‘universal health.’ As part of this initiative,…
-
Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China
•
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing agreement with fellow Chinese firm Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), securing exclusive commercialization rights for Sihuan’s Category 1 drug, janagliflozin, in mainland China. Under the terms of the agreement, Huadong will handle the…
-
JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization
•
JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute Co., Ltd, has entered into a strategic partnership with Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Gilead’s subsidiary Kite Pharma. The collaboration…
-
Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D financing round of fellow Chinese firm Ji Xing Pharmaceuticals, contributing USD 2.75 million for a 0.58% stake in the Shanghai-based company. The investment round also saw contributions from Ji Xing’s founder, RTW Holding Limited, and…
-
Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream
•
US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a Roivant (NASDAQ: ROIV) subsidiary focused on dermatological treatments. The acquisition is primarily driven by Dermavant’s Vtama (tapinarof) cream, a 1% topical formulation approved for plaque psoriasis and currently under regulatory review for atopic dermatitis (AD).…
-
Fidson Healthcare Partners with Chinese Entities to Establish Drug Plant in Nigeria
•
Nigeria-based pharmaceutical manufacturer Fidson Healthcare Plc has entered into a strategic partnership with Jiansu Aidea Pharma, Nanjing PharmaBlock, and the China-Africa Development Fund to establish a state-of-the-art drug manufacturing facility in the Lekki free trade zone near Lagos, Nigeria. This joint venture aims to enhance local production capabilities, particularly for…
-
MGI Tech Joins Forces with Dasa to Enhance Precision Medicine in Brazil Through Advanced Genomic Sequencing
•
MGI Tech Co., Ltd, a leading gene sequencing company based in China, has announced a strategic collaboration with Dasa, Latin America’s largest medical diagnostics company. This partnership aims to integrate Dasa’s extensive patient service network with MGI’s advanced gene sequencing platform, thereby advancing precision medicine in Brazil. The collaboration will…
-
Altamira Therapeutics and Nuance Pharma Expand Bentrio’s Reach in Asia
•
Swiss pharmaceutical firm Altamira Therapeutics Ltd (NASDAQ: CYTO) and its Chinese partner Nuance Pharma have announced an expansion of their licensing agreement for the anti-rhinitis spray Bentrio. The agreement extends the product’s reach to include Singapore, Malaysia, Thailand, the Philippines, Indonesia, Vietnam, and Taiwan, complementing the existing markets of China,…
-
Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med
•
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant licensing agreement with US biotechnology firm RadioMedix Inc. and French company Orano Med, securing global rights to a radioligand therapy (RLT). The agreement centers on AlphaMexi (212Pb-DOTAMTATE), a targeted alpha therapy (TAT) that utilizes a…
-
Fosun Pharma to Acquire Full Stake in Fosun Kite Biotechnology for USD 27 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has disclosed plans to acquire the remaining 50% stake in its joint venture, Fosun Kite Biotechnology Co., Ltd, from Gilead’s subsidiary Kite Pharma for USD 27 million. This transaction will see Fosun Pharma assume full ownership of Fosun Kite, with…
-
Hangzhou-Based Ophthalmic Device Maker MDCO Secures RMB 200 Million in Series B Funding
•
MDCO, an ophthalmic medical device company headquartered in Hangzhou, has reportedly secured nearly RMB 200 million in a Series B financing round. The funding was led by Hangzhou Qiantang Heda Bio-medical Investment Fund, Sunland Capital, and existing investor Decheng Capital. The capital raised will be allocated to bolster the company’s…
-
Beijing Wantai Biological and Fujian Provincial CDC Collaborate on Vaccine Development and Public Health Initiatives
•
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading biopharmaceutical company based in China, has entered into a strategic partnership with the Fujian Provincial Center for Disease Control and Prevention (FJCDC). This collaboration will focus on enhancing efforts in pathogen detection technology, vaccine development, clinical research, scientific outreach,…
-
MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02
•
MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a previous collaboration with the Haihe Laboratory of Cell Ecosystem under the China Academy of Medical Sciences, which commenced under the ‘SEQ ALL’ multi-omics initiative. This partnership initially led to the establishment of a multi-omics DCS…
-
MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research
•
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into a strategic partnership with fellow Chinese firm Sequanta Technologies Co., Ltd, marking a significant step with the establishment of the “Sequanta-MGI DCS Lab.” The DCS Lab is a state-of-the-art facility equipped with cutting-edge technology, including…
-
Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery
•
Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an expansion of their partnership to harness generative artificial intelligence (AI) for drug discovery. While the financial details of the deal remain undisclosed, the collaboration aims to combine Sino Bio’s advanced protein expression and wet-lab expertise…
-
Alibaba Health Forges Strategic Partnerships with Viatris and Chinese Pharma Companies for Digital Health Expansion
•
Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant Alibaba Group, has announced strategic collaboration agreements with a consortium of pharmaceutical companies. The collaborations include US-based Viatris (NASDAQ: VTRS) and Chinese firms Qilu Pharmaceutical, Chongqing Taiji Industry (Group) Co., Ltd (SHA: 600129), Shandong Dyne…
-
Shanghai Bao Pharmaceutical and Subsidiary Secure Commercialization Rights Deal for SJ02 with Organon China
•
Shanghai Bao Pharmaceutical, a Chinese pharmaceutical company, along with its wholly-owned subsidiary Suzhou Centergene Pharmaceuticals, has announced a significant supply and transfer agreement with Organon China, a US-based healthcare firm specializing in women’s health. The agreement grants Organon exclusive commercialization rights for Bao Pharma’s SJ02 in mainland China. SJ02, developed…
-
ChemPartner Pharmatech Enters Strategic Partnership with Malaysian Entities to Develop Innovative Drugs
•
ChemPartner Pharmatech Co., Ltd (SHE: 300149), a leading pharmaceutical company based in China, has joined hands with Universiti Kebangsaan Malaysia (UKM) and Pharma Medical Sdn Bhd (PMSB) from Malaysia to ink a strategic cooperation framework agreement aimed at developing innovative drugs. Financial specifics of the agreement have not been disclosed.…
-
Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic collaboration with US-based Umoja Biopharma to co-develop multi-target antibody therapies. The partnership will leverage Nona’s proprietary fully human heavy chain only antibody (HCAb) technology to create innovative CAR-T cell therapy drug candidates generated in vivo.…
-
Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations
•
MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round, raising hundreds of millions of renminbi. The funding was co-led by Cherami Investment and Shenzhen Capital Group, with participation from Sense Capital and EBI Investment. The capital raised will be directed towards enhancing the company’s…
-
Autobio Diagnostics Partners with MBL to Advance Microbial Mass Spectrometry Technology
•
Autobio Diagnostics Co., Ltd (SHA: 603658), a prominent player in China’s in vitro diagnostic market, has announced a strategic partnership with Japan’s Medical & Biological Laboratories (MBL). This collaboration will focus on advancing technologies in the microbial mass spectrometer field, although specific financial details of the agreement have not been…
-
Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization
•
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a strategic partnership between its controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), and Haier Biomedical. The collaboration will focus on the integration of digitalization, automation, and artificial intelligence (AI) to enhance the digital and…
-
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
•
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on organoid disease models and artificial intelligence (AI), has entered into a strategic partnership with Guangzhou Jennio Biotech Co., Ltd. The collaboration aims to leverage organoid disease models and advance tumor immunotherapy drug development. Financial specifics…
-
CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment
•
CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing round, securing USD 53 million in capital. This financing was co-led by TVM Capital Life Science and China-focused Yonjin Ventures, with significant participation from existing investors including SV Health Investors, Ascension Ventures, First Analysis, Blue…
-
Gilead Sciences Partners with AI Firm Genesis Therapeutics to Develop Novel Small-Molecule Therapies
•
Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into a strategic collaboration with Genesis Therapeutics Inc., an AI-driven drug development firm, to discover and develop innovative small-molecule therapies across a range of therapeutic targets. Under the terms of the agreement, Genesis will receive an…
-
Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies
•
Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage therapies, has announced an expansion of its collaboration with fellow U.S. firm Moderna Inc. (NASDAQ: MRNA). This strategic partnership extension will focus on the development of in vivo CAR macrophage and monocyte (CAR-M) therapies for…
-
Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector
•
Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with two domestic biotechnology companies: Lakeshore Biotechnology, a cell and gene therapy (CGT) focused biotech, and Porton Pharma Solutions, Ltd., a CGT contract research organization (CRO) and contract development and manufacturing organization (CDMO). In July, Itcure…
-
ImmuneOnco Receives Second Payment from Instil Bio, Highlighting Ongoing Licensing Deal
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the receipt of a further payment of USD 5 million from its U.S. partner Instil Bio Inc (NASDAQ: TIL), following an initial USD 10 million payment made last month. These payments are part of a licensing agreement executed in August 2024,…
-
Beijing Centergate Technologies and Bestcomm Pharmaceutical Form Strategic Partnership in Multiple Medical Fields
•
Beijing Centergate Technologies (Holding) Co., Ltd (CENTEK, SHE: 000931), a pharmaceutical manufacturing company in China, has entered into a strategic partnership with Bestcomm Pharmaceutical Co., Ltd. The collaboration aims to leverage their combined expertise in various therapeutic areas, including cardiovascular, anesthesia, neurological, gynecological, digestive, skin, and respiratory medicine. Financial details…
-
Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a five-year strategic partnership with Sichuan Biopharmaceutical Industry Group Pharmaceutical Industry Group Co., Ltd and Sichuan Development Leading Capital Management Co., Ltd. The collaboration aims to pool resources and leverage mutual strengths to…
-
JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development
•
JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200 million (USD 28 million) in a Series B+ financing round. This follows a Series B funding of RMB 100 million (USD 14 million) in May, bringing the total funds raised to RMB 350 million (USD…
-
Candel Therapeutics Acquires Bispecific Antibodies and Secures $370 Million in Financing for Autoimmune Drug Development
•
Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S. firms, Vignette Bio and TRC 2004 Inc. The move allows Candel to secure Vignette Bio’s BCMA/CD bispecific antibody (BsAb) and TRC 2004’s CD3/CD20 BsAb. Vignette Bio, a joint venture between Shanghai-based EpimAb Biotherapeutics, Inc. and…
-
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
•
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a strategic research collaboration agreement with Inimmune Corporation, a U.S. biotechnology firm specializing in immunotherapy and vaccine innovation. Under the terms of the agreement, Inimmune will utilize Insilico’s proprietary generative AI platform, Chemistry42, to accelerate the…
-
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
•
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a strategic partnership with Purpose Africa, a Rwanda-based platform organization comprised of experts from African academia and industry. The collaboration aims to enhance China-Africa cooperation in the realms of clinical research and digital platform development, thereby…
-
Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs
•
Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell its intensive care unit (ICU) business to fellow U.S. firm BD for USD 4.2 billion. This strategic move is accompanied by a global restructuring that will result in layoffs impacting approximately 3% of the company’s…
-
Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership
•
Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray Medical International Limited, a fellow Chinese firm, to collaborate on research and development, manufacturing, and marketing in the field of flow testing. The agreement encompasses a wide range of activities, although financial specifics have not…
-
Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has entered into a research collaboration with Genetic Leap, a U.S. biotech firm specializing in artificial intelligence (AI) and RNA genetic medicine. This partnership expands on a previously successful pilot and will see Genetic Leap apply…
-
Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia
•
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into a license and supply agreement with Japan’s Kissei Pharmaceutical Co., Ltd. The agreement grants Kissei the rights to develop and commercialize Rigel’s Rezlidhia (olutasidenib) across Japan, South Korea, and Taiwan. Rezlidhia is an oral isocitrate…
-
Voyager Therapeutics Secures Licensing Deal with Novartis for Gene Therapy Capsid
•
Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with Swiss pharmaceutical giant Novartis AG (NYSE: NVS). This agreement provides Novartis with access to a novel capsid from Voyager’s TRACER capsid discovery platform for its gene therapy program targeting an undisclosed rare neurologic disease. Under…
-
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
•
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked on a drug discovery partnership with Switzerland’s Haya Therapeutics, a move that underscores its commitment to advancing its anti-obesity portfolio. The collaboration will tap into Haya’s cutting-edge expertise in the dark genome, the largely non-protein-coding…
-
Jiangsu Suzhou Launches $843 Million Biomedicine Fund to Boost Pharma and Medical Device Innovation
•
The Jiangsu Suzhou Biomedicine Industry Special Fund of Fund (FoF), a colossal pharmaceutical investment vehicle with a capitalization of RMB 6 billion (USD 843 million), debuted last week. This 15-year financial instrument is designed to target and catalyze growth in innovative drugs, medical R&D, medical devices, healthcare services, and synthetic…
-
Sage Group Expands into China’s Healthcare Market with Cenponts Healthcare Partnership
•
Sage Group, a UK-based financial advisory powerhouse, has announced a strategic foray into China’s burgeoning healthcare market through a partnership with Shenzhen’s Cenponts Healthcare, a boutique investment bank with a global outlook. This alliance is set to bridge the gap, offering financial advisory services to Chinese life sciences firms aspiring…
-
E-commerce and Physical Stores to Stock Hanmi’s OTC Drugs Following Shanghai Pharma Deal
•
Hanmi Pharmaceutical, a leading South Korean pharmaceutical company, has reportedly entered into a supply agreement with Shanghai Pharma Health Science, a subsidiary of Shanghai Pharmaceutical Group (SHA: 601607). The contract covers the distribution of seven OTC medications, which are planned to be initially marketed through Shanghai Pharma’s e-commerce platform, prior…
-
CGeneTech Secures RMB 100 Million in Series C Financing to Advance Drug Commercialization and Clinical Pipeline
•
CGeneTech (Suzhou, China) Co., Ltd., a biopharmaceutical company based in China, has reportedly secured a Series C financing round totaling RMB 100 million, led by Tongren Boda Investment. The capital raised will be strategically allocated towards the commercial-scale manufacturing and marketing efforts for its flagship product, centagliptin, a Category 1…
-
EpimAb’s EMB-06 Secures $635 Million Licensing Agreement with Vignette for Multiple Myeloma Therapy
•
EpimAb Biotherapeutics, a Shanghai-based biotech firm, has inked a licensing deal with Vignette for the development and commercialization of its T-cell engager (TCE) EMB-06 outside of Greater China. The agreement grants Vignette rights to EMB-06, a BCMA-targeting therapy, in regions excluding mainland China, Hong Kong, Macau, and Taiwan, with EpimAb…
-
Jiangsu Simcere Acquires Exclusive Rights to TargetRx’s TGRX-326 in Licensing Deal
•
SHENZHEN—Shenzhen TargetRx, Inc., a leading developer of small-molecule kinase inhibitors, has entered into a licensing agreement with Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a fellow Chinese pharmaceutical company. The deal concerns TargetRx’s TGRX-326, an ALK/ROS1 dual receptor tyrosine kinase inhibitor currently at the clinical stage. According to the agreement,…
-
Zhejiang Dian Diagnostics Partners with Shanghai Mycology Lab to Advance Fungal Infection Diagnostics
•
SHANGHAI—Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading player in the diagnostics industry, has entered into a strategic partnership with the Shanghai Key Laboratory of Medical Mycology and Molecular Biology. The collaboration aims to delve into multi-center scientific research, product development, and the integration of artificial intelligence (AI) technology…
-
Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024
•
SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry Co., Ltd, has made a notable debut by initiating an initial public offering (IPO) on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). This marks the first pharmaceutical company to go public on this platform…
-
Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials
•
HONG KONG—Duality Biotherapeutics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is planning an initial public offering (IPO) on the Hong Kong Stock Exchange. While the unit price and further details remain under wraps, the company’s ambitions are clear, with a robust pipeline of 12 innovative ADCs…
-
Hybio Pharmaceutical Inks Licensing Deal with Mullan Pharmaceutical for Liraglutide Biosimilar
•
BEIJING—Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese biopharmaceutical company, has entered into a licensing agreement with fellow Chinese firm Mullan Pharmaceutical Co., Ltd, concerning the biosimilar version of Novo Nordisk’s Victoza (liraglutide). The agreement encompasses licensing rights, supply, and distribution for Hybio’s biosimilar, which is a glucagon-like peptide 1…
-
Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region
•
SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with fellow Chinese firm Jacobio Pharma (HKG: 1167), securing rights to Jacobio’s KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 for research, development, manufacturing, regulatory filings, and commercialization in Greater China. The agreement encompasses mainland China,…
-
Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital
•
BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into a new collaborative endeavor with Fuwai Hospital, Chinese Academy of Medical Sciences (CAMS), to establish a joint research and development center focused on myocardial repair and regeneration drugs. This initiative comes in response to the…
-
WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million
•
HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced its intention to acquire the remaining 30% stake in WuXi HaiDe, a non-wholly owned subsidiary specializing in comprehensive end-to-end vaccine contract research, development, and manufacturing organization services. The total consideration for this acquisition is USD…
-
Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources
•
BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd (Chengdu Rongsheng), intends to acquire 100% equity interest in Wuhan Zhongyuan Ruide Biological Products Co., Ltd (Zhongyuan Ruide), a wholly-owned subsidiary of CSL Behring Asia Pacific Limited (CSL Asia Pacific),…
-
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
•
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), will acquire a 100% stake in Shanghai Heart Forever Medical Technology Co., Ltd. The acquisition, valued at up to RMB 380 million, will be executed through a transfer from its sister company,…
-
AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million
•
QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its Qingdao National High-tech Industrial Development Zone facility, dedicated to the production and supply of inhalation aerosols. The undisclosed additional funding follows an initial investment made in March 2023, bringing the total commitment to USD 750…
-
Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases
•
NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE), has entered into a research collaboration with Quotient Therapeutics, a Cambridge, Massachusetts-based biotech firm. The partnership will focus on analyzing somatic mutations in diseased patient tissue, with a goal of uncovering new therapeutic approaches for…
-
Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit
•
LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the US, has once again failed to find a buyer for its China operations, despite valuing the unit at over USD 1 billion. The company, known for manufacturing the painkiller OxyContin, has engaged in at least…
-
Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development
•
CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100 million in a recent financing round spearheaded by Hygeia Capital. The syndicate of investors includes CAS STAR, Chengdu Biocity Jingchuang Equity Investment Fund, CS Ventures, and other prominent firms. The newly raised capital is earmarked…
-
Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech
•
Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347) and Hong Kong (HKG: 3347) stock exchanges, has forged a strategic partnership with the Beijing government. This collaboration is marked by the inauguration of the company’s North Headquarters in the capital city. Under this partnership,…
-
Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China
•
Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing exclusive rights as the agent for NowYon’s YonFlow blood flow guidance device in Greater China. This eight-year partnership marks a significant collaboration between the two Chinese firms. The YonFlow device, recognized as the world’s first…
-
Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million
•
Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active pharmaceutical ingredients (APIs) division to Tibet Duo Rui Pharmaceutical Co., Ltd. for RMB 10 million. Following the transaction, the API unit will establish a supply relationship with Frontier, with a separate purchase agreement to be…
-
Shanghai BDgene Partners with SPH RD to Develop Hemophilia Treatments Using BDlendi Insulator Technology
•
Shanghai BDgene Technology Co., Ltd, a leading gene therapy specialist based in China, has entered into a strategic partnership with SPH RD, a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd focused on rare diseases and pediatrics. The collaboration centers around BDgene’s innovative BDlendi insulator technology, which is slated for the…
-
China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO
•
China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD per share for a total of 2,000,000 ordinary shares. The shares have received approval for listing on the Nasdaq Capital Market and are set to begin trading on August 23, 2024, under the ticker symbol…
-
Shenzhen Salubris Pharmaceuticals Inks Licensing Deal for YolTech Therapeutics’ YOLT-101 Gene Editing Therapy
•
Shenzhen Salubris Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange (SHE: 002294), has entered into a licensing agreement with fellow Chinese firm YolTech Therapeutics. The agreement grants Salubris exclusive rights to research and development, regulatory filings, manufacturing, and commercial sales of YOLT-101 in mainland China.…
-
Guangzhou Boji Medical and CapitalBio Pharma Form Joint Venture to Innovate in Traditional Chinese Medicine
•
Guangzhou Boji Medical Biotechnological Co., Ltd, a Clinical Research Organization (CRO) based in China and listed on the Shenzhen Stock Exchange (SHE: 300404), has entered into a strategic partnership with its wholly-owned Traditional Chinese Medicine (TCM) subsidiary and CapitalBio Pharma, a domestic firm, to collaborate on the research and development…
-
Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and the Hong Kong Stock Exchange (HKG: 2196), has unveiled plans to privatize its subsidiary, Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696). In a cash transaction, Fosun Pharma intends to offer HKD 24.60 per share to…
-
Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round
•
Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for securing a new round of financing that has yielded RMB 100 million. The funding round saw participation from a consortium of investors including TPIC, Legend Capital, and Peakview Capital. The capital raised is earmarked for…
-
ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has received a USD 10 million upfront payment from SynBioTx, the wholly owned subsidiary of US-based Instil Bio Inc (Nasdaq: TIL). This payment is in accordance with a licensing agreement finalized earlier this month. The agreement outlines the potential for an additional USD…
-
Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights
•
Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1477), has declared its intent to proceed with a share repurchase program, targeting 10% of the total issued shares, excluding treasury shares. This initiative, which is not to exceed HKD 200 million, is…
-
Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases
•
Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital fund Versant Ventures to launch Borealis Biosciences, a cutting-edge biotech firm dedicated to pioneering next-generation RNA medicines for kidney diseases. Borealis emerges from incubation with a substantial USD 150 million in Series A financing, bolstered…
-
GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets
•
Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab Emirates, has announced a strategic collaboration with Guangdong Hecin Scientific Inc., a company based in China. As per the agreement, GSC is appointed as the exclusive agent for Hecin in the Middle East, covering key…
-
Changchun GeneScience Pharmaceutical Expands Reach with HuChuang Union Partnership
•
Changchun GeneScience Pharmaceutical Co., Ltd, a Chinese pharmaceutical enterprise, has established a partnership with HuChuang Union, a provider of assisted reproduction solutions. This strategic alliance grants GeneScience Pharma exclusive commercialization rights to HuChuang Union’s marketed product portfolio in designated regions within China. The collaboration extends further, with both parties planning…
-
SynthAsia and Shanghai General Hospital Partner to Advance Diabetic Retinopathy Research
•
SynthAsia has forged a strategic partnership with Shanghai General Hospital, focusing on scientific innovation within the realm of healthcare. The collaboration is set to enhance academic research in the field of diabetic retinopathy, with the dual goals of elevating the field’s academic research standards and propelling academic progress. This partnership…
-
Henlius Biotech Secures Exclusive Rights to Commercialize Convalife’s Generic Neratinib in China and Abroad
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm Convalife Pharmaceuticals. Henlius has secured the exclusive commercialization rights for Convalife’s generic version of Puma Biotechnology Inc’s neratinib in China, along with exclusive negotiation and conditional licensing…
-
Bone Index Secures Financing to Expand Manufacturing and Promote Diagnostic Technology Globally
•
Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was spearheaded by Lynx Financial, a Shanghai-based fund with a dedicated focus on healthcare and life sciences, and was supported by…
-
Johnson & Johnson to Acquire Israeli Cardiovascular Device Maker V-Wave for Upfront USD 600 Million
•
Johnson & Johnson (NYSE: JNJ), a multinational healthcare conglomerate based in the US, has announced a definitive agreement to acquire V-Wave Ltd, an innovative Israeli medical device developer. The acquisition includes an initial payment of USD 600 million, with additional potential payments of up to USD 1.1 billion tied to…
-
Shanghai Henlius Biotech Secures Exclusive Rights to Convalife Pharmaceuticals’ Generic Neratinib in China
•
SHANGHAI—Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm Convalife Pharmaceuticals. The deal grants Henlius the exclusive commercialization rights to Convalife’s generic version of Puma Biotechnology Inc’s neratinib in China, along with exclusive negotiation and conditional…
-
Finland’s Bone Index Partners with Lynx Financial for APAC and North American Market Expansion
•
HELSINKI—Bone Index, a pioneering medical technology company headquartered in Finland, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was led by Shanghai-based Lynx Financial, a fund with a dedicated focus on healthcare and life sciences, and was supported by contributions…
-
Johnson & Johnson to Acquire Israel’s V-Wave Ltd. in a Deal Valued Up to $1.7 Billion
•
NEW YORK—Johnson & Johnson (NYSE: JNJ), a multinational healthcare giant based in the US, has announced a definitive agreement to acquire V-Wave Ltd., an innovative Israeli medical device company. The acquisition is set to bolster J&J’s MedTech segment with an upfront payment of USD 600 million and potential milestone-based payments…
-
Sichuan Kelun Pharmaceutical’s H1 2024 Report Highlights MSD Collaboration Milestones
•
CHENGDU—Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has released its financial report for the first half of 2024, detailing significant updates on its collaboration with US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK). The partnership, focused on the co-development of antibody drug conjugates (ADCs), has seen substantial progress…
-
Jiangsu Hengrui Medicine Expands R&D Footprint with Jinan Innovation Zone Partnership
•
JINAN—The management committee of the Jinan Innovation Zone has entered into a strategic partnership with Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, to collaboratively advance research and development in the fields of novel drugs and devices, as well as high-quality biomedicine industry development. The…
-
Genesis MedTech’s J-VALVE System Transfers to Edwards Lifesciences, Marking a New Era in Aortic Valve Treatment
•
SINGAPORE—In a strategic move to strengthen its position in the global medical device market, Edwards Lifesciences has announced the acquisition of intellectual property and commercial rights to Genesis MedTech’s J-VALVE transcatheter aortic valve system. This acquisition highlights Edwards Lifesciences’ commitment to advancing cardiovascular care and underscores its ongoing expansion strategy.…
-
Multitude Therapeutics and Adcendo ApS Partner on Anti-TF ADC, Targeting Global Cancer Treatment
•
SHANGHAI/COPENHAGEN—In a strategic move to bolster cancer treatment options, Shanghai-based medical technology company Multitude Therapeutics Inc. has entered into a licensing agreement with Denmark’s Adcendo ApS, a specialist in antibody drug conjugates (ADCs). The deal grants Adcendo exclusive global rights to develop and commercialize an anti-human tissue factor (TF) ADC,…
-
Ant Group Eyes Acquisition of Leading Internet Healthcare Platform Haodf.com
•
Ant Group, the China-based fintech powerhouse, is reportedly pursuing the acquisition of Haodf.com, one of the country’s leading Internet healthcare platforms. This shift in negotiations comes after Alibaba Health Information Technology Ltd (HKG: 0241), Ant’s sister company, previously engaged in discussions with Haodf.com, according to local media sources. The two…
-
Bio-Thera Solutions Expands Reach with New Licensing Deal for Biosimilar BAT2306
•
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a new licensing agreement with Russian firm Pharmapark LLC for BAT2306, a biosimilar of Roche’s Cosentyx (secukinumab). Under the terms of the agreement, Pharmapark will hold exclusive commercialization rights for the drug in Russia and the CIS region. Bio-Thera will oversee the…
-
Huadong Medicine Secures Licensing Deal with IMBiologics for Autoimmune Drug Candidates
•
Huadong Medicine Co., Ltd. (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing agreement with South Korea’s IMBiologics, securing development, regulatory filing, manufacturing, and commercialization rights for the autoimmune drug candidates IMB-101 and IMB-102. This agreement spans China and 36 additional Asian countries, excluding Japan, South Korea, and…
-
Shanghai Sanyou Medical to Acquire Full Control of SMTP Technology for RMB 415.7 Million
•
Shanghai Sanyou Medical Co., Ltd. (SHA: 688085), based in China, is set to acquire the remaining 48.2% stake in SMTP Technology Co., Ltd. that it does not already own, in a transaction valued at RMB 415.7 million (approximately USD 58.2 million). SMTP Technology is a high-tech medical device company focused…
-
Shandong Buchang Pharmaceuticals Partners with Lancet for BC001 Licensing in Eurasia
•
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter a licensing agreement with Russia’s Lancet Pharmaceuticals, granting the latter regulatory filing, commercialization, and other rights for Buchang’s pipeline candidate BC001 across the Eurasian Economic Union, which includes Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan, and Uzbekistan.…
-
New Agreement Enhances Myopia Solutions: Hong Kong Polytechnic and Zeiss Collaborate
•
The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement with global optical leader Zeiss, further strengthening their existing partnership. This collaboration will leverage the patented “Defocus Integrated Soft Contact (DISC) Technology for Myopia Management,” developed by Hong Kong Polytechnic University, to enhance Zeiss’ MyoCare…
-
Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China
•
Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic partnership with Alcon Laboratories Inc., a global leader in eye care and a subsidiary of Novartis. Under the terms of the agreement, Alcon will provide Ocumension with research and development, manufacturing, and commercialization rights for…
-
Siemens Healthineers Partners with Cedars-Sinai to Boost Medical Cooperation and Education
•
Siemens Healthineers AG, a global leader in medical technology, has announced a strategic partnership with Cedars-Sinai Medical Center, a prestigious non-profit academic medical institution with a century-long history. Through this alliance, Siemens Healthineers’ China division and Cedars-Sinai will embark on a collaborative journey aimed at enhancing international medical exchange and…
-
TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion
•
TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company plans to issue 47,880,000 shares, priced at HKD 12.1 each, under the ticker symbol 02410. This IPO is expected to raise a total…
-
Mindray Medical Forges Comprehensive Partnership with CUHK-Shenzhen School of Medicine
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a prominent medical device company based in China, has entered into a strategic partnership with the CUHK-Shenzhen School of Medicine. The collaboration aims to foster comprehensive and in-depth cooperation across various domains, including industrial-university research, international academic exchanges, and talent development. The…
-
Shineyo Medical Secures RMB 100 Million in Series A+ Funding for Cardiac and Vascular Devices
•
Shineyo Medical, a Shanghai-based manufacturer of electrophysiological and peripheral interventional devices, has reportedly secured nearly RMB 100 million (USD 13.9 million) in a Series A+ financing round. The funding was spearheaded by Guangzhou Jinkong Fund, with additional investments from Zhuopu Investment fund, Jinxin Capital, and Zhangjiagang Industrial Capital, along with…
-
MSD to Acquire Curon Biopharmaceutical’s CD3 x CD19 Bispecific Antibody CN201 in USD 1.3 Billion Deal
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic acquisition agreement with Shanghai-based biotech firm Curon Biopharmaceutical. Under the terms of the deal, MSD will fully acquire CN201, a cutting-edge CD3 x CD19-targeted T-cell-engager bispecific antibody (BsAb). The transaction includes an upfront payment of USD 700 million, with…
-
Harbour BioMed Reclaims Rights to HBM7008 as Cullinan Therapeutics Cancels Licensing Deal
•
Harbour BioMed (HBM), a biopharmaceutical company with operations in the Netherlands, the United States, and Suzhou, China, has announced that its U.S. partner, Cullinan Therapeutics Inc., will be returning the rights to the pipeline molecule HBM7008. This move cancels the licensing agreement that was initially focused on the development and…
-
Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership
•
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a biotechnology firm based in China, has formalized a partnership with the University of Science, Malaysia (USM). The collaboration aims to enhance academic exchange and scientific translation efforts, among other initiatives. Financial details of the agreement were not disclosed. This strategic partnership builds…
-
Hansoh Pharmaceutical Secures Rights to Lupeng’s BTK Inhibitor LP-168 in Licensing Deal
•
Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm Lupeng Pharmaceutical Ltd for the next-generation Bruton’s tyrosine kinase (BTK) inhibitor, LP-168. According to the terms of the agreement, Hansoh will assume responsibility for research and…
-
WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China, has entered into a three-year strategic research cooperation agreement with Germany’s Medigene AG, an immuno-oncology platform company. The collaboration focuses on the design and research of T-cell receptor (TCR) mediated T cell engagers (TCEs) aimed…
-
AI-Driven Drug Firms Recursion and Exscientia to Merge in a Deal Valued at Approximately USD 850 Million
•
Recursion (NASDAQ: RXRX), a U.S.-based clinical-stage TechBio company, and Exscientia plc (NASDAQ: EXAI), a U.K.-headquartered artificial intelligence (AI)-driven drug design and development firm, have announced a definitive agreement to merge. The combined entity will retain the name Recursion, with its headquarters in Salt Lake City, Utah, and will continue to…
-
Hygeia Healthcare Holdings Acquires Chang An Hospital in Deal Valued at RMB 1.66 Billion
•
Hygeia Healthcare Holdings Co., Ltd, a Shanghai-based medical investment and healthcare group, has announced the completion of an acquisition, securing a 100% stake in Chang An Hospital, a state-owned Class 3A general hospital. The transaction, which is reported to have already been finalized, involved a consideration of approximately RMB 1.66…
-
Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer
•
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S. biotech firm, have announced their intention to enter into a research collaboration aimed at developing novel molecular glue degraders for neurodegenerative diseases and oncology. Eisai will leverage SEED’s expertise in targeted protein degradation (TPD) to…
-
JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies
•
Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership with Sanyou Biopharmaceuticals Co., Ltd. The collaboration aims to uncover new targets in metabolic diseases, including obesity, fatty liver, diabetes, and Alzheimer’s disease, with a focus on developing new pipelines of agonistic antibody drugs based…
-
Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases
•
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered into a licensing agreement with Genentech, a subsidiary of Swiss pharmaceutical giant Roche. The deal is aimed at developing intravenous genomic medicines for the treatment of specific neurodegenerative diseases. Sangamo has provided Genentech with an…
-
Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia
•
Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese pharmaceutical firm Santen Pharmaceutical. The collaboration focuses on the development, manufacturing, and commercialization of Cloudbreak’s investigational drug, CBT-001, across Southeast Asia, including key markets such as Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and…
-
CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology
•
CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with the German pharmaceutical and chemical giant Merck KGaA (FRA: MRK). The agreement pertains to CybernaX’s proprietary technology for efficient lipid storage. While the financial details of the transaction remain undisclosed, the partnership signals a significant…
-
Shanghai Vitalgen BioPharma Partners with Novoprotein to Commercialize AaCas12bMax Gene Editor
•
Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China, has entered into a licensing agreement with Suzhou Novoprotein Scientific Co., Ltd, a provider of protein technology and application solutions. Under the terms of the agreement, Novoprotein will secure manufacturing and marketing licenses for AaCas12bMax…
-
Mabwell Bioscience Partners with Cristália for Biosimilar Denosumab in Brazil
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered into a licensing agreement with Cristália Produtos Químicos Farmacêuticos LTDA, a Brazil-headquartered pharmaceutical company. Cristália will take on the responsibility for the regulatory submission and commercialization of Mabwell’s biosimilars MAILISHU (9MW0311) and MAIWEIJIAN (9MW0321) in…
-
Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079
•
Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic partnership with U.S.-based Merck, Sharp & Dohme (MSD; NYSE: MRK) to include global co-development of an antibody drug conjugate (ADC). This extension incorporates a new T-cell engager, MK-6079, which MSD acquired as part of its…
-
Northeast Pharmaceutical to Acquire Majority Stake in Cell Therapy Specialist Dingcheng Taiyuan
•
Northeast Pharmaceutical Co., Ltd (SHE: 000597), a Chinese pharmaceutical company, has announced plans to acquire a 70% stake in Beijing Dingcheng Taiyuan Biotechnology Co., Ltd, a biotech firm specializing in cell therapies for solid tumors. Financial details of the transaction have not been disclosed. Established in 2014, Dingcheng Taiyuan has…
-
Sihuan Pharmaceutical Gains Exclusive Rights to Cellontech’s Cartilage Treatment in China
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has entered into an exclusive agency agreement with South Korea’s Cellontech Co., Ltd., securing sole agency rights for the distribution of Cellontech’s CartiZol in mainland China. Financial details of the agreement have not been disclosed. CartiZol, a…
-
BioNTech Ends Collaboration with Genmab on Acasunlimab Development
•
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech SE (NASDAQ: BNTX) has opted to discontinue their collaboration on the development of the bispecific antibody (BsAb) acasunlimab. Acasunlimab, which targets the programmed death-ligand 1 (PD-L1) and 4-1BB pathways, was under joint development with both…
-
Genor Biopharma Strikes Licensing Deal with TRC 2004 for Global Rights to GB261 Outside Greater China
•
China-based Genor Biopharma Co., Ltd (HKG: 6998) has entered into a significant licensing and equity agreement with US-based TRC 2004, Inc., bestowing upon TRC 2004 the exclusive rights to develop, manufacture, and commercialize Genor’s innovative drug candidate, GB261, in all global territories excluding Greater China. This strategic partnership is set…
-
Huadong Medicine Secures Exclusive Rights to Immunochina’s CAR-T Therapy in China
•
China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has entered into a licensing agreement with Beijing-based gene therapy specialist Immunochina Pharmaceuticals. The agreement grants Huadong exclusive commercialization rights to Immunochina’s IM19, a promising CD19-targeted autologous chimeric antigen receptor (CAR) T cell therapy, within mainland China. Huadong will make an…
-
United Imaging Healthcare Launches Medical-Grade Hearing Aid uOrigin in China
•
United Imaging Healthcare Technology Co., Ltd (UIH), a leading player in the medical imaging and healthcare industry, has announced the official launch of its medical-grade hearing aid, uOrigin, in the Chinese market. This move marks the company’s expansion into the audiology sector, offering a new solution for individuals with hearing…
-
Bristol-Myers Squibb Terminates Partnership with Agenus on TIGIT/CD96 Bispecific Antibody
•
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its decision to end its collaboration with Agenus Inc. (NASDAQ: AGEN) regarding the development of the TIGIT/CD96-targeted bispecific antibody BMS-986442 (AGEN1777). This move follows an initial decision to advance the antibody to Phase II trials earlier this year, which resulted…
-
CR Sanjiu to Acquire Significant Stake in Tasly Pharmaceuticals in a Deal Valued at $870 Million
•
China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999), has announced its intention to conditionally purchase a substantial 28% stake in fellow Chinese firm Tasly Pharmaceuticals (SHA: 600535). The transaction involves the acquisition of 418,306,002 shares, with a proposed consideration of RMB 14.85 per share, culminating in a total deal value…
-
Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered into a licensing agreement with Suzhou Risen Pharmaceutical, securing comprehensive rights for the latter’s osteoarthritis treatment, RP901, and its companion diagnostics in Greater China. This includes rights for research and development, regulatory filing, commercialization, and…
-
ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with US-based Instil Bio Inc. (Nasdaq: TIL), granting InstilBio development and commercial rights outside China for ImmuneOnco’s proprietary PD-L1- and VEGF-targeted bispecific antibody, IMM2510, and its next-generation anti-CTLA-4 antibody, IMM27M. As per the agreement, a subsidiary…
-
Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia
•
China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the establishment of a new manufacturing facility in West Java, Indonesia. The expansion is part of the company’s global growth initiative and will be operationalized through its subsidiary, PT Fapon Bioindustries Indonesia (PT Fapon). Specializing in…
-
Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus
•
Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of its business strategy in the Asia-Pacific (APAC) region. The company is exiting the China market by selling its operations and out-licensing its portfolio commercialization in other APAC territories to partner companies, retaining rights to only…
-
Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal
•
Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a definitive merger agreement to acquire US-based biotechnology firm Jnana Therapeutics Inc. Upon completion of the deal, Jnana will become a wholly owned subsidiary of Otsuka, with the transaction valued at $800 million in upfront payment…
-
Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations
•
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation of a joint venture named Sagesse Bio, Inc. with US investment firm Gore Range Capital. This strategic partnership is complemented by a patent transfer and license agreement that will see Sirnaomics transferring specific intellectual property…
-
Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program
•
China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA Biosciences Inc. (NASDAQ: IDYA) for the development of Biocytogen’s B7H3/PTK7 program, a potential first-in-class bispecific antibody drug conjugate (BsADC). The agreement grants IDEAYA the option for an exclusive worldwide license to the drug, which has…
-
Pfizer Enters Multi-Year R&D Collaboration with Telescope Innovations to Leverage AI and Robotics
•
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has entered into a multi-year collaborative research agreement with Canada-based Telescope Innovations Corp. (CNSX: TELI). The financial details of the agreement have not been disclosed. The partnership aims to harness Telescope’s expertise in automation, robotics, and artificial intelligence (AI) to expedite…
-
National Comprehensive Cancer Network Renews Partnership with Medlive for Oncology Guidelines Access in China
•
The National Comprehensive Cancer Network (NCCN), a leading non-profit academic organization in the US, has renewed its strategic partnership with Medlive, a Beijing-based medical information service provider focused on clinicians. This collaboration aims to further promote the NCCN Clinical Practice Guidelines in Oncology within China, ensuring they are accessible through…
-
Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline
•
Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful completion of its first round of financing, with the specific amount remaining undisclosed. The round was led by Boehringer Ingelheim Venture Fund and Temasek, with participation from Lenovo Capital and Incubator Group, Fosun Health, and…
-
Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility
•
Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in Suzhou, has reportedly secured “hundreds of millions” of renminbi in a Series B financing round. The round was led by Fuzhe Equity Investment Fund and Jiangsu Trautec Medical Technology Co., Ltd., with additional contributions from…
-
Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business
•
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the completion of its acquisition of the point-of-care (POC) solutions business from UK-based diagnostics firm LumiraDx, following all necessary antitrust and regulatory approvals. Initially announced at the end of 2023, the acquisition involved an upfront payment…
-
GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with Flagship Pioneering, a biotech company based in Cambridge, Massachusetts, known for its role as a bioplatform for innovation across a diverse portfolio of over 40 companies. The collaboration will see an initial joint funding of…
-
Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies
•
Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Guangzhou Geneseed Biotech Co., Ltd., a company specializing in circular RNA (circRNA)-focused CRDMO services. This collaboration aims to expedite the development of innovative circRNA therapies, enhancing technical innovation, clinical translation, and…
-
Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia
•
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture (JV) with Indonesia’s leading pharmaceutical company, PT Kalbe Farma, TBK. The JV, with a registered capital valued at approximately RMB 582 million, will focus on the manufacturing of active pharmaceutical ingredients (APIs) in Southeast Asia.…
-
LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline
•
LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US and China, has reportedly raised more than USD 20 million in a Series A financing round. The funding round was led by Lapam Capital, with participation from GL Ventures as well as existing investors Qiming…
-
Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion
•
Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector, has reportedly secured “hundreds of millions” of renminbi in a Series D financing round. The round was led by CICC Capital, with significant contributions from Guangzhou Industrial Investment and Capital, Oriza Seed, and other investors.…
-
CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab
•
China National Biotec Group Company Ltd (CNBG) has announced a strategic collaboration with the University of Macau, marking a significant step in the biotech sector. The partnership, formalized with a signing ceremony at the Guangdong-Macao in-depth cooperation zone in Hengqin, aims to leverage the university’s cutting-edge research capabilities and CNBG’s…
-
Tigermed Expands Asia Pacific Presence with Acquisition of Japanese CRO Medical Edge
•
Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the acquisition of Medical Edge Co., Ltd, a Japan-headquartered CRO. With this strategic move, Medical Edge will become a wholly-owned subsidiary of Tigermed, enhancing the company’s ability to provide high-quality mathematical statistics and electronic data solutions…
-
Shanghai Escugen Partners with Innolake Biopharma to Develop Novel ADCs Using EZWi-Fit Platfo
•
Shanghai Escugen, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese firm Innolake Biopharma to utilize Escugen’s innovative antibody-drug conjugate (ADC) platform, EZWi-Fit, in the development of ADC products targeting specific antigens selected by Innolake. Under the terms of the agreement, Innolake will employ EZWi-Fit to…
-
CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine
•
CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic partnership with the National Institute of Biotechnology Malaysia (NIBM). The collaboration aims to enhance the development, manufacturing, technology transfer, and talent exchange between the two entities, focusing on mRNA multivalent influenza vaccines and the exploration…
-
Shanghai’s Spectrum Dynamics Medical Secures Major Financing for Molecular Imaging Innovations
•
Spectrum Dynamics Medical, a Shanghai-based specialist in medical molecular imaging, has reportedly secured hundreds of millions of renminbi in a new financing round. The round was led by Shanghai Healthcare Capital (SHC), a prominent municipal industry fund in Shanghai, with the participation of Oriental Fortune Capital. This funding round is…
-
Shanghai GenTech Expands into Life Sciences with Acquisition of Konosai Biotechnology
•
Shanghai GenTech Co., Ltd., a Chinese solutions provider with expertise in flat panel display, LED, PV, fiber optics, and bio-pharmaceutics, has expanded its reach into the life sciences sector through the strategic acquisition of compatriot firm Konosai Biotechnology Co., Ltd. This move signifies GenTech’s commitment to deepening its presence in…
-
Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development
•
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered into a strategic partnership with Wecomput Technology Co., Ltd, a prominent computational contract research organization (CRO) in China with a global footprint. The collaboration aims to harness the power of artificial intelligence (AI) to enhance…
-
United Imaging Healthcare Invests RMB 120 Million in Particle Accelerator Specialist Long Beam Technology
•
United Imaging Healthcare (UIH, SHA: 688271), a leading medical device company in China, has announced that its board of directors has approved a capital investment of RMB 120 million (USD 16.6 million) into Long Beam Technology, a domestic firm specializing in advanced medical technologies. Upon completion of the transaction, UIH…
-
Amoytop Biotech Opts for NASH Drug Candidate KN069 in Licensing Deal with Alphamab Oncology
•
Xiamen Amoytop Biotech Co., Ltd (SHA: 688278), a biopharmaceutical company based in China, has exercised its option rights for KN069, a drug candidate for non-alcoholic steatohepatitis (NASH), under a licensing agreement with fellow Chinese firm Alphamab Oncology (HKG: 9966). The original deal, signed in December 2023, granted Amoytop the choice…
-
Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China
•
Taiwan’s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal with China mainland firm CR Double-Crane. The agreement grants CR Double-Crane a 20-year exclusive license to commercialize Fespixon (ON101), a novel etiology-driven solution designed to regulate macrophages and enhance tissue repair, within the Chinese market.…
-
Agilent Technologies and Shanghai Majorbio Bio-pharm Ink Deal to Transform Life Science Research in China
•
Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, has announced a strategic collaboration with Shanghai Majorbio Bio-pharm Technology Co., Ltd, a prominent biopharmaceutical company in China. This partnership will provide Majorbio with access to Agilent’s cutting-edge sample quality control solutions and its flagship…
-
Nanjing Sanhome Pharmaceutical and China Resource Pharma Deepen Collaboration for Market Expansion
•
Nanjing Sanhome Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, and China Resource Pharmaceutical Commercial Group have been engaged in extensive business discussions across various locations in China, including Tianjin, Chengdu, Hebei, Shanghai, and Shanxi, with the strategic goal of expanding their market presence. The collaboration between the two entities focuses…
-
Edwards Lifesciences to Acquire Peijia Medical’s US Partner JenaValve, Impact on Licensing Deal Minimal
•
China-based Peijia Medical Ltd (HKG: 9996) has announced that its US-based partner JenaValve Technology Inc. will be acquired by Edwards Lifesciences Corporation through a merger agreement. This strategic acquisition comes as part of Edwards Lifesciences’ efforts to strengthen its structural heart portfolio. JenaValve had entered into a licensing agreement with…
-
RemeGen Scales Back Private Placement to Fund New Drug R&D
•
RemeGen (HKG: 9995), a biopharmaceutical company based in China, has revised its private placement plan, reducing the funds raised from the initially disclosed RMB 2.55 billion in June to RMB 1.953 billion. The capital will be directed towards the research and development of new drugs, bolstering the company’s pipeline which…
-
Pinetree Therapeutics Strikes EGFR Degrader Deal with AstraZeneca Worth Over USD 500 Million
•
Pinetree Therapeutics Inc., a Massachusetts-based biotechnology company, has announced the signing of an exclusive option and global licensing agreement with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The deal focuses on a preclinical epidermal growth factor receptor (EGFR) degrader candidate. According to the agreement, Pinetree will receive an initial payment of…
-
Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies
•
Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with California-based biotech firm Dren Bio Inc. to leverage Dren’s expertise in developing bispecific antibodies for cancer treatment. Under this agreement, Novartis is particularly interested in utilizing Dren’s proprietary Targeted Myeloid Engager and Phagocytosis Platform. As…
-
Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328
•
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate AFN0328. This investigational mRNA drug targets tumors associated with human papillomavirus (HPV), particularly HPV16 and/or HPV18 in the cervix, which are…
-
Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies
•
Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally, has entered into a strategic partnership with US medical technology giant Becton, Dickinson and Co. (BD). The collaboration focuses on the single cell instrument HT Xpress and the establishment of a joint laboratory dedicated to…
-
Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China
•
Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into a strategic partnership with Chongqing Kangfude Pharmaceutical Co., Ltd to establish a state-of-the-art peptide drug API and preparation production base in Chongqing. The collaboration involves an investment of RMB 120 million (USD 16.5 million) by…
-
TowardPi Medical Partners with OCULUS Iberia to Introduce Advanced OCTA Technology to Spain
•
TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company specializing in ophthalmic imaging, has secured a partnership with OCULUS Iberia, headquartered in Madrid. This strategic alliance will see TowardPi’s cutting-edge optical coherence tomography angiography (OCTA) technology, with a speed range of 100,000 to 400,000 scans per second, introduced to…
-
Innovax Biotech and GSK Terminate Collaboration on Next-Generation HPV Vaccine
•
Xiamen Innovax Biotech Co., Ltd., a Chinese biopharmaceutical company, and GlaxoSmithKline (GSK, NYSE: GSK), a leading UK pharmaceutical giant, have agreed to terminate their alliance for the development and commercialization of next-generation human papillomavirus (HPV) vaccines. The partnership, which began in September 2019, resulted in the creation of HPV9-AS04, a…
-
China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics
•
Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a strategic partnership with Germany’s BioNTech SE (NASDAQ: BNTX), a leading figure in the biopharmaceutical industry. This collaboration aims to leverage Triastek’s cutting-edge 3D drug printing capabilities to develop a breakthrough oral preparation designed to address…
-
Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development
•
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary of Gilead, have announced plans to bolster their joint venture, Fosun Kite Biotechnology Co., Ltd, through a capital increase. This will be achieved by proportionally converting their existing debt into equity, amounting to USD 28.5…
-
Shanghai Medicilon and Jiangsu Hengrui Join Forces to Advance Pre-Clinical Drug Evaluation
•
Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into a strategic partnership with Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent player in the global pharmaceutical industry. This collaboration aims to leverage Medicilon’s pre-clinical research and development expertise with Hengrui’s innovative drive and…
-
Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D
•
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that it has successfully secured RMB 1.6 billion in funding from the Shenzhen Luye Private Equity Investment Fund. This fund is primarily controlled by the Shenzhen Municipal People’s Government State-owned Assets Supervision and Administration Commission. The…
-
MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has entered into a distribution framework agreement with Dongguan Kewei Medical Instrument Co., Ltd. Kewei, which was acquired by MicroPort Scientific in 2012, has agreed…
-
Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion
•
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered into a co-development and market promotion service agreement with Huadong Medicine Co., Ltd (SHE: 000963) for the development and commercialization of QX005N injection. Under the terms of the agreement, Huadong will participate in the clinical…
-
Eisai Forges Partnerships with Chinese Firms to Strengthen Alzheimer’s Disease Market Presence
•
Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with several Chinese healthcare firms, including iKang Healthcare Group, Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), V-Medical, Kindstar Global (HKG: 9960), and Ribose. These collaborations are aimed at tapping into the Alzheimer’s disease (AD) market in…
-
MedSci Healthcare’s Bioon.com Partners with Wego Group to Boost Local Innovation and Product Promotion
•
MedSci Healthcare Co., Ltd (HKG: 2415), a Chinese healthcare company, has announced that its subsidiary, Bioon.com, has entered into a partnership with Wego Group, a domestic device firm. This strategic collaboration aims to invigorate local innovation and deepen the impact of Wego Group’s high-quality products. The partnership will leverage media…
-
Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies
•
Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a Series A+ financing round led by LongRiver Investments. The funding round also saw participation from Zhaode Investment, Zhongqi Capital, BioTrack Capital, and Lilly Asia Ventures. The company plans to utilize the proceeds to accelerate its…
-
Huadong Medicine to Expand TCM Footprint with Acquisition of Hengba Pharmaceutical
•
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced its intention to acquire a 100% stake in Guizhou Hengba Pharmaceutical Co., Ltd, a traditional Chinese medicine (TCM) firm, for a total consideration of RMB 528.47 million (USD 72.66 million). Established in 1995, Hengba Pharmaceutical has a robust…
-
Beijing X-Magtech Secures Over RMB 100 Million in Series A+ Funding for Magnetic Field Measurement Tech
•
Beijing X-Magtech Technologies, a specialist in ultra-weak magnetic field measurement technology, has reportedly secured over RMB 100 million (USD 13.8 million) in a Series A+ financing round. The funding round was led by the Beijing Robot Industry Development Investment Fund, with participation from CAS Star and existing investors including Everest…
-
BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia
•
Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE: 300676) and Kazakhstan’s Technopark Biogen, has officially commenced operations. The center, located within the Kazakhstan National Biotechnology Center, is well-equipped with state-of-the-art gene sequencing and genetic data analysis machinery, aiming to facilitate early disease diagnosis…
-
Apeiron Therapeutics Sells Rights to CDK7 Inhibitor GTAEXS617 to Exscientia for USD 30 Million
•
Apeiron Therapeutics, a Shanghai-based biopharmaceutical company, has reached an agreement to sell all rights to its oral CDK7 inhibitor GTAEXS617 to Exscientia plc (NASDAQ: EXAI), a US-based AI-driven pharmaceutical company. The total transaction value amounts to USD 30 million, comprising an upfront cash payment of USD 10 million and a…
-
WeDoctor Partners with Shanghai Children’s Medical Center to Enhance Pediatric Care
•
WeDoctor Holdings Ltd, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) that specializes in online medical services, has entered into a strategic partnership with Shanghai Children’s Medical Center. While financial details of the agreement were not disclosed, the collaboration aims to combine WeDoctor’s expertise in digitalization…
-
J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure
•
Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged goods manufacturing company, has reportedly discontinued the development of its pipeline epilepsy therapy ADX71149, according to the company’s latest Q2 2024 financials report and information from FiercePharma.com. ADX71149, a positive allosteric modulator (PAM) of metabotropic…
-
Suzhou New District Hi-tech Industrial Co., Ltd and Subsidiaries to Establish Biopharmaceutical FOF with SND Group
•
Suzhou New District Hi-tech Industrial Co., Ltd (SHA: 600736), a prominent company in China’s high-tech industry, has declared plans for the establishment of a provincial biopharmaceutical special fund of funds (FOF) in collaboration with its subsidiaries, Suzhou Hi-tech Venture Capital, and Suzhou Medical Device Industry Development Group Co., Ltd. This…
-
NeuShen Therapeutics and Livzon Pharma Strike Deal for Greater China Rights to NS-041
•
NeuShen Therapeutics, a Sino-US biopharmaceutical company, has entered into a licensing agreement with Livzon Pharmaceutical Group Inc. (HKG: 1513), a Chinese pharmaceutical firm. The agreement grants Livzon exclusive rights and interests to NeuShen’s small molecule NS-041 in Greater China. NeuShen will retain the lead role in the development and commercialization…
-
Roche’s Genentech Terminates Relay Therapeutics Collaboration for SHP2 Inhibitor
•
In a recent development, Roche Inc.’s subsidiary Genentech has given notice of termination for a license and collaboration agreement with Relay Therapeutics Inc., affecting the development of an oral small-molecule Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitor, RLY-1971, now known as migoprotafib or GDC-1971 . The termination, effective 180…
-
Shanghai Escugen and Sidewinder Therapeutics Form Strategic Alliance for ADC Development
•
Shanghai Escugen, a leading biopharmaceutical company specializing in antibody drug conjugates (ADCs), has announced a strategic partnership with US-based Sidewinder Therapeutics Inc. Under the agreement, Sidewinder has been granted a license to Escugen’s proprietary EZWi-Fit ADC platform, enabling the development of multiple ADC products. This collaboration signifies a significant step…
-
SYNYI.AI Secures New Funding to Accelerate Digital Transformation in Healthcare
•
Shanghai’s SYNYI.AI, a pioneering medical data mining and governance platform, has reportedly closed a new financing round, raising an undisclosed sum. The round saw participation from a roster of prominent investors, including Beijing New Aerotropolis Fund, Changchun Equity Investment Fund, and Changchun Changfa Private Equity Fund, among other state-owned investment…
-
Boston Scientific Secures Silk Road Medical in a $1.16B Deal to Fortify Stroke Prevention Portfolio
•
Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical devices, has announced a definitive agreement to acquire all outstanding shares of Silk Road Medical Inc. (NSDQ: SILK) for a purchase price of USD 27.5 per share in cash. This transaction, with an overall value of USD 1.16 billion, is…
-
China Grand Pharmaceutical Expands with Mitsubishi Tanabe Pharma and Baiji Pharma Acquisitions
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the completion of a 100% stake change registration for Mitsubishi Tanabe Pharma Corporation’s Tianjin subsidiary, as well as for compatriot firms Nanchang Baiji Medicine Technology Co., Ltd. and Jiangxi Bai’an Baiyu Pharmaceutical Technology Co., Ltd, collectively referred to…
-
CR Boya Bio-Pharmaceutical’s Strategic Foray: Acquiring Green Cross HK for $250M to Expand Biopharma Dominance
•
In a significant development for the biopharmaceutical industry, China Resources Medical Holdings Company Limited and its subsidiary, CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294), have entered into a strategic partnership and equity transfer agreement with GC Corp. The agreement facilitates CR Boya’s acquisition of a 100% stake in Green…
-
Guotai Junan and Haitong Securities to Launch $10 Billion in Industry Funds in Shanghai
•
China’s prominent financial institutions, Guotai Junan Securities and Haitong Securities, have revealed plans to establish three industry-focused funds of funds (FoFs) in Shanghai with a combined target pool of RMB 89 billion (approximately USD 13.1 billion). These funds, to be managed by a newly formed entity, Shanghai Guotou Pioneer Private…
-
Eisai Co., Ltd Secures Asia-Pacific Rights for Fungal Drug with Sato Pharma Deal
•
Eisai Co., Ltd, (TYO: 4523) a leading Japanese pharmaceutical company, has entered into a strategic licensing agreement with compatriot Sato Pharmaceutical Co., Ltd for the development and commercial rights of the anti-fungal drug fosravuconazole in the Asia and Oceania regions. This deal includes the 10 ASEAN nations, Australia, New Zealand,…
-
Sionna Therapeutics Secures Cystic Fibrosis Portfolio in Licensing Deal with AbbVie
•
US-based biotechnology company Sionna Therapeutics has announced a significant licensing agreement with fellow US firm AbbVie Inc. (NYSE: ABBV), through which Sionna has acquired rights to two Phase II molecules and one Phase I candidate. These pipeline candidates are all modulators designed to treat cystic fibrosis (CF). The deal includes…
-
Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs
•
Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen’s proprietary RenLite platform. These antibodies will be utilized…
-
Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset
•
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and China, has entered into a lucrative licensing agreement with South Korea-based SK Biopharmaceuticals, granting the latter exclusive global rights to develop, manufacture, and commercialize the radiopharmaceutical FL-091. The deal is valued at USD 571.5 million…
-
MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection
•
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has announced a strategic collaboration with Predica Diagnostics, a Netherlands-based company. Under this partnership, MGI will provide support to Predica in the development of targeted RNA sequencing tests utilizing MGI’s next-generation sequencing platforms. While the financial details of…
-
Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas
•
Shanghai-based Lionco Pharmaceutical Group (SHA: 603669) has entered into a strategic partnership framework agreement with France’s Laboratoire Bailly-Creat, aiming to penetrate international markets. Under this collaboration, Lionco will manufacture GMP-compliant injection and solid preparation products from its portfolio at its Hainan manufacturing base for Bailly-Creat. The French company will take…
-
Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic cooperation agreement with Alaya.bio, a France-based polymer delivery platform company. This collaboration aims to harness their respective strengths to streamline the development, manufacturing, and administration of chimeric antigen receptor (CAR)-T therapies through precision targeting and…
-
Mindray Bio-Medical Partners with Nanjing Municipal Government to Boost Healthcare Innovation
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading player in the global medical device market, has entered into a strategic partnership with the municipal government of Nanjing. This collaboration aims to drive an extensive, multi-tiered, and broad application of scientific research achievements within the healthcare sector, enhancing both…
-
Shenzhen-Based National Biological Manufacturing Innovation Center Breaks Ground
•
Construction has commenced on a pioneering national biological manufacturing industry innovation center in Shenzhen, marking a significant milestone as China forges ahead with its first national-level platform in the field of biological manufacturing. This collaborative endeavor is being established by a consortium that includes national-level scientific research institutions, central state-owned…
-
E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services
•
E-Health Now, a China-based one-stop artificial intelligence (AI)-powered medical health service platform, has reportedly secured nearly RMB 100 million (USD 13.8 million) in a Series C financing round. The funding round attracted notable investors such as Ameba Capital, Ventech China, and Borchid Capital. The capital raised is intended to fuel…
-
AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137
•
AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37 million in a Series A financing round. The round was spearheaded by the InnoPinnacle Fund, with additional investments from a consortium that includes Yuanbio Venture Capital, Hankang Capital, Qiming Venture Partners, and Genesis Capital. The…
-
Shanghai Duoning Biotechnology Partners with BASF SE to Commercialize Medical Materials in China
•
Shanghai Duoning Biotechnology Co., Ltd, a prominent player in China’s biopharmaceutical industry, has entered into a strategic partnership with BASF SE, a German chemical giant. This collaboration aims to enhance the promotion and commercialization of BASF’s medical materials and application products within mainland China. The products in focus include Kolliphor…
-
Baheal Pharmaceutical Group to Launch Industry Fund Focused on Life Sciences
•
China’s leading health services and distribution conglomerate, Baheal Pharmaceutical Group, is venturing into the investment space with the establishment of a new industry fund. This fund is designed to target opportunities in the life sciences and healthcare sectors. In a collaborative effort, Baheal will be partnering with a consortium that…
-
Huadong Medicine Secures Exclusive Rights to Oral Edaravone Candidate TTYP01 in Major Licensing Deal
•
Huadong Medicine Co., Ltd (SHE: 000963), a prominent pharmaceutical company in China, has entered into an exclusive licensing agreement with Suzhou Auzone Biological Technology Co., Ltd, focusing on Auzone’s product candidate TTYP01, an oral formulation of edaravone. This strategic partnership positions Huadong to exclusively develop, regulate, manufacture, and commercialize the…
-
Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit
•
Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell therapy, has reportedly drawn the attention of a potential acquirer. This development sent Legend’s stock price climbing over 12% in a single day, as reported by the news platform Street Insider. The company has allegedly…
-
Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery
•
Beijing Tsingke Biotech Co., Ltd., a prominent player in the DNA/RNA synthesis domain based in China, has entered into a strategic partnership with the Innovation Center of Yangtze River Delta, Zhejiang University. This high-capacity innovation platform is a joint initiative by Zhejiang University and Jiashan county in Jiaxing city of…
-
Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001
•
Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement with Chinese startup Foreseen Biotechnology for the latter’s lead pipeline candidate, FS001. This agreement grants Ipsen exclusive rights to develop, manufacture, and commercialize the antibody-drug conjugate (ADC) on a global scale. As per the terms…
-
Salus Biotech Partners with Xi’an Jiaotong University for Single-Cell Omics Innovation
•
Salus Biotech, a Shenzhen-based biotechnology company, has entered into a strategic partnership with the Single-cell Omics Institute of Xi’an Jiaotong University. This collaboration aims to leverage Salus’s in-house high-throughput sequencing platform and high-resolution spatial transcriptomics platform, integrating proprietary high-throughput sequencing and super-resolution fluorescence imaging technology. The combined technology allows for…
-
Biokin Pharmaceutical Co., Ltd Eyes Secondary Listing on HKEX, Co-Sponsored by Goldman Sachs and Others
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a company listed on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) since October 2022, is reportedly planning a secondary listing on the Hong Kong Stock Exchange (HKEX). The firm’s IPO is being co-sponsored by prominent investment banks Goldman Sachs, J.P. Morgan, and…
-
Allist Pharmaceuticals Faces Arbitration Over Promotion Agreement for Furmonertinib
•
Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received a notice of the initiation of arbitration from the Shanghai International Economic and Trade Arbitration Commission. The applicant in this matter is Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA.600196; HKEX.02196), which is seeking the cancellation of…
-
Digital Health China Partners with Huawei to Launch Intelligent Multimodal Big Data System for Healthcare
•
Digital Health China Technologies Co., Ltd., a leading cloud-based healthcare service provider based in China, has entered into a comprehensive partnership agreement with Huawei Technologies Co., Ltd., a global telecommunications giant. The collaboration aims to jointly launch an intelligent multimodal big data center system solution. This innovative solution harnesses the…
-
Pfizer Collaborates with Evotec for Drug Candidates in Metabolic and Infectious Diseases
•
Pfizer Inc. (NYSE: PFE) has entered into a multi-year collaboration with Germany-based biotechnology company Evotec SE (F: EVT; Nasdaq: EVO), focusing initially on discovering new drug candidates for metabolic and infectious diseases. Evotec, known for its expertise in proteomics and metabolomics, will apply its capabilities to target first-in-class therapeutic approaches…
-
Novo Nordisk Partners with Indonesia’s Bio Farma to Boost Asia-Pacific Diabetes Drug Production
•
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is expanding its insulin manufacturing presence in the Asia-Pacific region. The company has entered into a partnership with Indonesia’s state-owned Bio Farma to collaborate on the production of diabetes medications. As per a memorandum of understanding,…
-
AFT Pharmaceuticals Partners with Hainan Haiyao for Distribution of Crystaderm Cream in China
•
AFT Pharmaceuticals (JSE: AFT, ASX: ASX), a company based in New Zealand, has announced an agreement with Hainan Haiyao Co., Ltd (SZ:000566) to distribute AFT’s Crystaderm cream in China. The cream, a proprietary product of AFT, is designed to treat acne and skin infections through the slow release of hydrogen…
-
BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced that its subsidiary, Heilongjiang BGI Longjiang Medical Laboratory Co., Ltd, has entered into a three-year cooperation agreement with the Health Commission of Heilongjiang Province. This agreement focuses on providing noninvasive prenatal genetic testing services for…
-
GRIT Biotechnology and Quangang Pharmaceutical Co., Ltd Partner to Develop TIL and IL-2 Combination Therapy
•
GRIT Biotechnology, a leading cell therapy specialist based in China, has entered into a strategic partnership with compatriot firm Quangang Pharmaceutical Co., Ltd. The collaboration aims to co-develop a combination therapy for solid tumors, leveraging tumor-infiltrating lymphocyte (TIL) therapy and recombination human interleukin-2 (IL-2). Interleukin-2 (IL-2) products, which are already…
-
Hugo Biotech Partners with Watchmaker Genomics to Develop Infectious Disease Detection Solutions
•
Hugo Biotech, a biotech company based in Beijing, has entered into a partnership with Watchmaker Genomics, a U.S.-based provider of innovative molecular analysis solutions, to collaborate in South Africa. The collaboration aims to combine their respective R&D strengths to develop more sensitive, user-friendly, and cost-effective infectious disease detection products. The…
-
Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan
•
Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has selected Japan’s Mitsubishi Tanabe Pharmaceutical Corp. to establish a co-promotion partnership for Moderna’s mRNA respiratory vaccine portfolio in the Japanese market. The agreement will encompass the promotion of Moderna’s COVID-19 vaccine, Spikevax, and aims to…
-
Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced that it has entered into a definitive acquisition agreement with fellow U.S. firm Morphic Holding Inc. (NASDAQ: MORF). Under the terms of the agreement, Lilly will acquire Morphic in a transaction valued at USD 3.2…
-
Keymed Biosciences Strikes Licensing Deal with Belenos Biosciences for Global BsAb Rights
•
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a licensing agreement with U.S. firm Belenos Biosciences Inc. Under the agreement, Belenos gains exclusive global rights to develop, manufacture, and commercialize Keymed’s in-house developed bispecific antibodies (BsAbs), CM512 and CM536, excluding Greater China. Belenos will…
-
Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab
•
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), has entered into a strategic partnership with Shanghai’s East China Normal University (ECNU). The collaboration aims to establish a state-of-the-art joint laboratory dedicated to advancing research in drug discovery, biochips, drug delivery systems, and drug conjugates (XDCs). Furthermore, the…
-
China Isotope & Radiation Corporation to Establish Cancer Treatment Center in Nigeria
•
China Isotope & Radiation Corporation (CIRC; HKG: 1763), a leading provider of medical equipment and services, has announced plans to supply a substantial amount of medical equipment to Nigeria. The company is tasked with establishing a new cancer diagnosis and treatment center as part of an extensive program. This initiative…
-
Xinzeyuan Medical Technology Secures Over RMB 100 Million in Series B Financing
•
Xinzeyuan Medical Technology Co., Ltd, a Hangzhou-based micro invasive medical device supply chain platform, has reportedly secured over RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by Qiming Venture Partners, with Silicon Paradise also participating in the funding. The company plans to…
-
Innovent Biologics and IASO Biotechnology Amend Partnership, Focusing on CAR-T Therapy Fucaso
•
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a new set of agreements with IASO Biotechnology, a domestic firm, to adjust the terms of their earlier partnership. According to the new deals, IASO will acquire from Innovent its rights to the BCMA-targeted chimeric antigen…
-
Kindstar Global and MGI Tech Co., Ltd. Form Partnership to Establish Multi-Omics Service Center in China
•
Kindstar Global (HKG: 9960), a biopharmaceutical company based in China, has announced a strategic partnership with fellow Chinese firm MGI Tech Co., Ltd. (SHA: 688114). This collaboration will result in the creation of Kindstar’s multi-omics DCS Lab service center, which will be focused on serving the Central China region. Kindstar…
-
Singlera Genomics Secures Over RMB 100 Million in Strategic Financing to Boost R&D and Commercialization
•
Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego, California, and in Shanghai and Yangzhou, China, has reportedly secured over RMB 100 million in a strategic financing round. The funding was led by Yangzhou Guojin, Longchuan Holding, and other municipal state-owned funds based in…
-
Genertec and CTHG Fund Invest in Neusoft Medical Systems to Boost Medical Imaging
•
China General Technology (Group) Holding Co Ltd, commonly referred to as Genertec, has announced plans to invest an undisclosed sum in Neusoft Medical Systems Co., Ltd, in collaboration with the CTHG Fund. Genertec, a centrally administered State-owned enterprise, has a diversified portfolio that includes advanced manufacturing and technical services, medical…
-
Guangzhou Pluslife Partners with Gates Foundation to Combat STIs in Low-Income Countries
•
Guangzhou Pluslife Technology Co., Ltd, a specialist in Point-Of-Care Testing (POCT) based in China, has entered into a cooperation agreement with the Bill & Melinda Gates Foundation. The partnership aims to develop solutions that alleviate the burden of sexually transmitted infections (STIs) in low and middle-income countries. The Gates Foundation,…
-
United Imaging Healthcare to Launch Financial Leasing Arm with RMB 450 Million Investment
•
United Imaging Healthcare (UIH, SHA: 688271), a leading medical equipment company based in Shanghai, has announced plans to establish a wholly owned subsidiary, tentatively named Shanghai United Imaging Medical Equipment Leasing Co., Ltd. The new entity is to be capitalized at RMB 450 million (USD 62 million) and will focus…
-
Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received a USD 100 million option rights payment from its Japanese partner Takeda (TYO: 4502), in accordance with an exclusive option agreement signed earlier last month. In June 2024, Takeda and Ascentage entered into an…
-
CStone Pharmaceuticals Partners with Hengrui for Promotion of Ayvakit in China
•
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a licensing agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), another Chinese pharmaceutical firm. The agreement grants Hengrui exclusive promotion rights to Ayvakit (avapritinib), CStone’s precision therapy, in mainland China. CStone maintains all rights to Ayvakit in…
-
Amgen Secures Commercialization Rights for Avacopan in Asia and Latin America
•
Amgen (NASDAQ: AMGN), a leading biopharmaceutical company, has entered into a licensing agreement with CSL Vifor, securing the commercialization rights to Tavneos (avacopan) in Asia and Latin America, including mainland China. Avacopan is a first-in-class drug for the treatment of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Originally approved in the…
-
GSK Secures Global Rights to CureVac’s mRNA Vaccine Candidates in Expanded Partnership
•
GlaxoSmithKline (GSK, NYSE: GSK) , a UK-based pharmaceutical giant, is poised to expand its partnership with CureVac N.V. (Nasdaq: CVAC), a German mRNA specialist. The revised agreement will grant GSK full global rights to develop, manufacture, and commercialize mRNA candidate vaccines for influenza and COVID-19, encompassing related combination regimens. As…
-
China’s HiRO Expands US Presence with Acquisition of New Jersey-Based DeltaMed Solutions
•
Harvest Integrated Research Organization (HiRO), a China-based ’boutique’ Contract Research Organization (CRO), has expanded its presence in the US through the strategic acquisition of DeltaMed Solutions. DeltaMed, located in Somerset, New Jersey, is a CRO that specializes in a suite of services including biostatistics, programming, data management and monitoring, real-world…
-
Chengdu-Based Vaccine Specialist Maxvax Biotechnology Raises USD 41.3 Million in Latest Funding Round
•
Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series C+ financing round, securing over RMB 300 million (USD 41.3 million). This latest funding round was spearheaded by IDG Capital, with significant participation from Hankang Capital and Qianhai Ark Asset Management. The capital raised in…
-
Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor
•
Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a partnership with Sino-Canadian firm Geneseeq Technology Inc. The collaboration aims to jointly develop and commercialize a companion diagnostic (CDx) reagent for Vcare’s NTRK inhibitor VC004. Financial details of the agreement were not disclosed. Preliminary clinical…
-
Bristol-Myers Squibb Ends Collaboration with Eisai on Farletuzumab Eteribulin
•
Bristol-Myers Squibb (BMS; NYSE: BMY), a prominent US pharmaceutical company, has decided to terminate its collaboration with Japanese pharmaceutical firm Eisai Co., Ltd, which was focused on the co-development of Eisai’s antibody drug conjugate (ADC) farletuzumab ecteribulin (FZEC; MORAb-202). According to a press release from Eisai, BMS’s decision is part…
-
Cryofocus Biotechnology Partners with Boston Scientific for Respiratory Products Distribution in China
•
Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced a strategic distribution agreement with the Shanghai subsidiary of US medical device giant Boston Scientific Corporation (NYSE: BSX). As per the terms of the agreement, Cryofocus is set to become the exclusive marketing partner and sales…
-
PW Medtech Group Ltd Plans Independent Listing of Rekind Medtec on NEEQ to Boost Growth
•
PW Medtech Group Ltd (HKG: 1358), a prominent medical device manufacturer based in China, is planning to spin off its subsidiary, Sichuan Rekind Medtec., Inc., for an independent listing on the National Equities Exchange and Quotations (NEEQ). Established in 2013, Rekind specializes in the research, development, manufacturing, and marketing of…
-
Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round
•
Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly secured RMB 300 million (USD 41.3 million) in a Series C+ financing round. The funding was exclusively provided by SDIC JULI Investment, a state-owned investment fund. Established in 2015, Moon is recognized for possessing the…
-
China’s Henlius Biotech Partners with Sermonix for Japan Development of Breast Cancer Drug
•
Shanghai Henlius Biotech Inc. (HKG: 2696), a prominent biopharmaceutical company based in China, has announced an expansion of its licensing agreement with Sermonix Pharmaceuticals Inc., to include additional territories in Asia for the development and commercialization of HLX78 (oral lasofoxifene). This supplementary agreement facilitates a co-development partnership between Henlius and…
-
MicroPort Endovascular to Fully Acquire Optimum Medical Device in $65M Deal
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading Chinese medical technology company, has declared its intention for its wholly-owned subsidiary, MicroPort Endovastec B.V., to acquire a controlling 72.37% stake in Optimum Medical Device Inc. (OMD) for a transaction valued at USD 65 million. Following the completion of this…
-
Supercede Therapeutics Partners with Shanghai Universities for Anti-Tumor Cachexia Drug Developmen
•
Fudan University and East China Normal University (ECNU) have entered into a global rights cooperation agreement with Supercede Therapeutics, a small-molecule start-up, to develop a novel drug aimed at anti-tumor cachexia and muscle enhancement. Under the terms of the agreement, Supercede will secure the global development and commercialization rights for…
-
Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum
•
A number of healthcare companies are seeking to capitalize on the recovering market conditions by filing for initial public offerings (IPOs) on the Hong Kong Stock Exchange (HKEX), a venue that has been gaining traction among life sciences companies for their public listings. According to the HKEX website, recent IPO…
-
Winning Health Partners with Unicom Digitization Medical to Boost Medical Industry Innovation
•
Winning Health (SHE: 300253), a Shanghai-based company in the medical information industry, has entered into a partnership with Unicom Digitization Medical Technology Co., Ltd. The collaboration aims to combine their respective strengths in the medical and health sector to enhance product, service, and commercial innovation. The joint efforts will focus…
-
Hisense Medical Teams Up with Tianjin Government and Yujin AI for Intelligent Medical R&D
•
Hisense Medical Equipment Co., Ltd, a leading medical equipment provider based in China, has entered into a strategic partnership agreement with the government of Tianjin Binhai New Area and fellow Chinese firm Tianjin Yujin Artificial Intelligence Medical Technology Co., Ltd. The collaboration aims to establish an intelligent medical equipment technology…
-
Cigna & CMB Life Insurance Partners with Cleveland Clinic Foundation to Enhance Medical Diagnosis for Chinese Patients
•
Cigna & CMB Life Insurance Co., a joint venture between Cigna Corporation, a U.S.-based global health service company, and China Merchants Group, a leading Chinese enterprise, has entered into a strategic partnership with the renowned Cleveland Clinic Foundation (CCF). This collaboration aims to address the overseas medical treatment needs and…
-
Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition
•
Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an asset acquisition agreement with South Korean biopharmaceutical company Celltrion (KRX: 068270). The deal focuses on 14 branded products across various pan-Asia countries and regions, as well as the Marketing Authorization Holder (MAH) rights for these…
-
Shandong Junxiu Biotechnology Partners with Swiss Firm Geistlich to Boost Regenerative Medicine
•
Shandong Junxiu Biotechnology Co., Ltd, a Chinese manufacturer of implantable regenerative medicine devices, has entered into a strategic partnership with Swiss biomaterials company Geistlich. The collaboration aims to enhance commercialization efforts, product research and development, market promotion, and overseas operations. Financial details of the agreement were not disclosed. Established in…
-
AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
•
AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics Inc., a biotechnology firm specialized in developing therapies for anti-inflammatory diseases. The transaction involves a cash payment of USD 250 million to acquire all equity interests in Celsius. Through this acquisition, AbbVie will obtain control…
-
Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology
•
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a partnership to an acquisition deal with U.S. biotech firm 2seventy bio Inc. (NASDAQ: TSVT) for the development of a hemophilia A drug candidate. The companies have entered into an asset purchase agreement that will see…
-
China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million
•
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the acquisition of Yusimry, a biosimilar of adalimumab, from U.S. firm Coherus Biosciences (NASDAQ: CHRS) for a purchase price of USD 40 million. This deal includes the marketing approval, patents, and related assets of the drug,…
-
Shanghai Kehua Bioengineering’s Subsidiary to Acquire Remaining Stake in Technogenetics S.P.A.
•
Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a Chinese bioengineering company, has announced that its subsidiary, Technogenetics S.P.A. (TGS), is poised to acquire an additional 20% stake in TGS. The stake is currently held by Altergon Italia S.r.l., and the transaction is valued at EUR 15.34 million (USD 16.4 million).…
-
GenScript Biotech Receives Over USD 410 Million in Milestone Payments for CAR-T Therapy from Janssen Biotech
•
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced that it has received a total of USD 410 million in milestone payments from Janssen Biotech, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). These payments are part of a licensing agreement with its…
-
Jianke.com, China’s Leading Chronic Disease Management Platform, Files for Hong Kong IPO
•
Jianke.com, a China-based smart healthcare service platform, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, with shares priced between HKD 7.6 and 8.36 per share. The company aims to raise HKD 63.07 million (USD 8.01 million) through the IPO of 23.8 million shares. Established…
-
TowardPi Medical Secures RMB 200 Million in Series D Financing Led by Matrix Partners
•
TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company, has reportedly secured RMB 200 million in a Series D financing round. The round was led by Matrix Partners, with participation from GTJA Investment and other investors. Established in 2017, TowardPi Medical’s core technical team comprises numerous graduates from Tsinghua…
-
Amoy Diagnostics Partners with Servier to Develop Companion Diagnostic Reagent for IDH Mutations in China
•
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has entered into a partnership with French pharmaceutical company Servier to co-develop a companion diagnostic (CDx) reagent in China. This reagent is designed for detecting mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. The product will complement Servier’s vorasidenib, which…
-
Shanghai’s Phrontline Biopharma Secures Over RMB 100 Million in Pre-Series A Funding for ADC Development
•
Shanghai-based antibody drug conjugate (ADC) specialist Phrontline Biopharma has reportedly secured over RMB 100 million (USD 13.8 million) in a pre-Series A financing round, with funds exclusively provided by Decheng Capital. The capital raised will be directed towards bolstering research and development efforts, pre-clinical development, and the enhancement of its…
-
Revvity and Sanyou Biopharmaceuticals Deepen Partnership to Advance Biologic Drug Development
•
Shanghai-based biotechnology company Revvity has entered into a comprehensive partnership with Sanyou Biopharmaceuticals Co., Ltd to enhance the development of innovative biologic drugs. The two companies have signed a commercial licensing agreement that will see Sanyou incorporate the TnT transposon system into the CHOSOURCE protein expression platform. Financial details of…
-
CASI Pharmaceuticals Secures USD 15 Million in PIPE Transaction for Anti-CD38 Monoclonal Antibody Development
•
CASI Pharmaceuticals (NASDAQ: CASI), a biopharmaceutical company based in China, has announced the signing of agreements with several investors for a public equity financing (PIPE) transaction, securing a raise of USD 15 million. Concurrently, the company also disclosed plans to submit an Investigational New Drug (IND) filing to the U.S.…
-
Sanofi Invites Bids Starting at $20 Billion for Consumer Health Unit
•
Sanofi (NYSE: SNY) is reportedly inviting bids starting at USD 20 billion for its consumer healthcare division, according to a Bloomberg report citing people familiar with the matter. The French pharmaceutical giant is anticipating initial bids by mid-July. Among the parties showing the most interest are Advent International, a U.S.…
-
Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has announced a drug collaboration agreement with OpenAI, a prominent artificial intelligence (AI) research organization headquartered in San Francisco. As part of this collaboration, Lilly will utilize OpenAI’s advanced generative AI technologies to develop innovative antimicrobial…
-
Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised to acquire a 31.161% stake in fellow Chinese firm Nanjing Nanda Pharmaceutical Co., Ltd for a consideration of RMB 149.57 million (USD 20.6 million). Aidea had previously secured a 19.9646% stake in Nanda Pharma in…
-
Walvax Biotechnology Halts COVID-19 mRNA Vaccine Trials Co-Developed with Abogen Biosciences
•
Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the termination of clinical trials for a COVID-19 mRNA vaccine that was co-developed with Abogen Biosciences Co., Ltd, a specialized developer of messenger ribonucleic acid (mRNA) drugs. This decision also affects the technology development cooperation between…
-
Suzhou Porton Biologics Becomes First Chinese CDMO to Adopt MaxCyte’s ExPERT GTx Platform
•
Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of MaxCyte, Inc.’s cGMP compliant ExPERT GTx flow electroporation technology platform, marking it as the first Contract Development and Manufacturing Organization (CDMO) in China to be equipped with this advanced system. The ExPERT GTx platform is…
-
Jiangsu Jibeier Pharm Completes Private Placement to Fund R&D Center on STAR Market
•
Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566), a Chinese pharmaceutical company, has announced the successful completion of a private placement of 7,446,889 shares at a price of RMB 26.61 per share. The shares will be listed on the Science and Technology Innovation Board (STAR), which is hosted by the Shanghai…
-
Tonghua Dongbao Pharmaceuticals Partners with Sinopharm for Supply Chain and Market Expansion
•
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a strategic partnership with Sinopharm Group Co., Ltd, another Chinese firm. The collaboration encompasses various aspects including distribution channels, logistics delivery, bidding services, and market access. Financial details of the agreement were not disclosed. Sinopharm, leveraging its strengths…
-
Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696) private. According to a stock exchange announcement from the China-based firm, Fosun currently holds 323.7 million shares of Henlius, representing 59.56% of the company’s total shares.…
-
Sun Yat-sen University and KingMed Diagnostics Collaborate on Talent Development and Research
•
On June 20, 2024, the School of Public Health (Shenzhen) of Sun Yat-sen University and KingMed Diagnostics (Guangzhou) signed a cooperation agreement in Guangzhou, marking the beginning of a comprehensive partnership focusing on talent cultivation, scientific research collaboration, and professional practical education. This strategic alliance will see both parties working…
-
AnDiConBio Secures Over RMB 200 Million in Series A Financing to Advance Respiratory and Pain Therapies
•
AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly secured over RMB 200 million in a Series A financing round. The round was led by Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), Huajin Investment, and Huajin Dadao Investment, with participation from Cowin Capital, Wenzhou…
-
ClouDr Secures Exclusive Sub-Licensing Rights for Iloprost Infusion Solution
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), operating under the brand name “ClouDr,” has announced a licensing agreement with Clinect Pty Ltd as the licensor and Bluefly Consulting Limited as the seller. ClouDr has secured exclusive sub-licensing rights for the development, manufacturing, promotion, publicity, distribution, and marketing of…
-
Shanghai Pharmaceuticals’ Subsidiary Shaphar Med Collaborates with Magic Med to Enter Oncology
•
Shanghai Pharmaceuticals Holding Co., Ltd (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in China, has announced that its subsidiary, Shaphar Medical Instruments (Shanghai) Co., Ltd, has entered into a partnership with Magic Med, a Chinese firm. This strategic collaboration signifies Shaphar Med’s inaugural venture into the oncology sector.…
-
Inkon Life Technology Partners with United Imaging to Establish Advanced Medical Centers and Digital Platform
•
Inkon Life Technology Co., Ltd. (SHE: 300143), a Shenzhen-based service provider specializing in stereotactic radiotherapy equipment and operator of tumor medical services, has entered into a partnership with United Imaging Healthcare Technology Co., Ltd (UIH). The collaboration aims to establish a tumor precise diagnosis and treatment integrated demonstration center, a…
-
METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery
•
METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in a Series C financing round. The round was led by CICC Capital, with additional investment from China Taiping Insurance. This latest funding round brings the total capital raised by the Sino-US firm to USD 300…
-
Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation
•
Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China Unicom, aiming to enhance digitalization in enterprise management, product digitization, and global technological empowerment. China Unicom will utilize its network, cloud, communication technology, and AI algorithms to advance the intelligence and digital upgrade of Yuyue’s…
-
Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) for its Phase Ib clinical study of GLP-1/GIP dual-targeted receptor agonist THDBH120 as a hypoglycemic therapy. THDBH120, which is being developed to treat type 2 diabetes…
-
Shineco Inc. Acquires 80% Stake in ‘Internet+Medical Care’ Platform Meitong Tech for USD 20 Million
•
Shineco Inc. (NASDAQ: SISI), a U.S.-based company, has signed an investment agreement with Beijing Dongfang Meitong Technology Co., Ltd, a China-headquartered “Internet+medical care” platform. Shineco is set to acquire an 80% stake in Meitong Tech for USD 20 million. Meitong Tech, a leading shared medical device company in China, offers…
-
DK Medical Technology Secures ‘Hundreds of Millions’ in Series E Financing for Expansion
•
DK Medical Technology Co. Ltd., a Suzhou-based developer of vascular intervention balloon products, has reportedly secured “hundreds of millions” of renminbi in a Series E financing round. The round was co-led by Legend Capital and Qiming Venture Partners, with additional investments from existing shareholders. The funds will be utilized to…
-
Shanghai Fudan-Zhangjiang and Hanhui Pharmaceutical End Marketing Deal for Libaoduo
•
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a Chinese biopharmaceutical company, has reached an agreement with Hanhui Pharmaceutical Co., Ltd’s wholly-owned subsidiary to terminate the market promotion service agreement for its doxorubicin in liposome injection formulation, branded as Libaoduo. The original agreement was signed in October 2018, establishing…
-
Novartis Moves Toward Full Ownership of MorphoSys with Shareholder Squeeze-Out
•
Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, is proceeding to fully acquire MorphoSys AG (OTCMKTS: MPSYF) by initiating a squeeze-out of its minority shareholders. Novartis had made a public takeover offer of EUR 68 per share, valuing the company at an aggregate EUR 2.7 billion (USD 2.9 billion), in…
-
Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of a 6.01% stake in its India-based subsidiary, Gland Pharma Ltd (BOM: 543245), through bulk trading. The transaction raised INR 7.541 billion (USD 90 million) pre-tax, or approximately USD 211 million pre-tax. Following the completion of…
-
Xencor Reclaims Rights to Plamotamab After Janssen Halts Development
•
Xencor Inc. (NASDAQ: XNCR), a U.S.-based biotechnology company, has announced that Johnson & Johnson (J&J, NYSE: JNJ)’s Janssen Biotech Inc. has opted not to proceed with the development of the bispecific T-cell engager plamotamab. As a result, Xencor regains exclusive global rights to the molecule, a CD20 x CD3 bispecific…
-
Genrix Bio and Chongqing Pharmaceutical Group Form Strategic Partnership to Boost Market Launch
•
Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443), a biopharmaceutical company based in China, has entered into a partnership with fellow Chinese firm Chongqing Pharmaceutical (Group) Co., Ltd (CQP). Under this collaboration, Genrix Bio will utilize CQP’s extensive network and digital services to bolster the market launch of its innovative…
-
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
•
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has announced the completion of a significant transaction where it sold a 20% stake in Shanghai RAAS Blood Products Co., Ltd (SHE: 002252) to Haier Group, a Chinese electronics and appliances conglomerate, for RMB 12.5 billion…
-
3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion
•
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term loan credit from the International Finance Corporation (IFC), with the funds designated for the construction of manufacturing facilities and the development of overseas business. This development signifies that 3SBio, the first Chinese biopharmaceutical enterprise to…
-
Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets
•
Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with U.S.-based Belharra Therapeutics, a chemoproteomics company focused on the development of small-molecule cancer drugs targeting high-value, elusive drug targets. As per the agreement, Belharra will utilize its non-covalent chemoproteomics platform to screen for hits against…
-
Day One Biopharmaceuticals Expands Pipeline with MabCare Therapeutics Licensing Deal
•
Day One Biopharmaceuticals (NASDAQ: DAWN), a California-based biotech company that recently celebrated its first drug approval, has announced an expansion of its pipeline through a licensing agreement with Shanghai-based MabCare Therapeutics. Day One will acquire exclusive development, manufacturing, and commercialization rights to MTX-13, an antibody-drug conjugate (ADC) targeting protein-tyrosine kinase…
-
Roche Secures RNA Exon Editing Tech for Neurological Diseases with Ascidian Deal
•
Roche (SWX: ROG; OTCMKTS: RHHBY), a Swiss pharmaceutical giant, is expanding its footprint in the RNA drug development sector through a strategic partnership and licensing agreement with Ascidian Therapeutics, a U.S.-based biotechnology company. The collaboration aims to discover and develop RNA exon editing therapeutics for the treatment of neurological disorders.…
-
Shineco Partners with Tuling Vision to Develop Intelligent Healthcare Solutions
•
Shineco Inc. (NSDQ: SISI), a U.S.-based company, has signed a partnership deal with China-headquartered Tuling Vision to develop intelligent medical products and bring its biotechnology and health solutions to the healthcare market. Shineco operates a Chinese joint venture (JV) that focuses on the research, development, manufacturing, and sales of medical…
-
Wuxi’s Binhu District Partners with Fresenius Kabi to Boost Healthcare Services
•
The Binhu District People’s Government of Wuxi, Jiangsu province, China, has entered into a partnership with Fresenius Kabi, a German healthcare company, to enhance the medical and healthcare industry in the region. Financial details of the agreement were not disclosed. The collaboration aims to strengthen medical service capabilities and medical…
-
Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development
•
Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with China’s Sinovac Biotech Ltd. (NASDAQ: SVA) to jointly engage in the research and development of vaccines. The financial details of the partnership have not been disclosed. This collaboration comes on the heels of a meeting…
-
CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally
•
CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced the successful completion of a new financing round, raising nearly RMB 100 million (USD 13.8 million). This funding round was led by prominent investors Yifeng Capital and Zhiyi Investment, with additional participation from Yuanhe Holdings…
-
Neusoft IntelliRay Secures Over RMB 100 Million in Series C Funding Round
•
Neusoft IntelliRay Technology Co., Ltd, a medical technology company based in Shenyang, has successfully closed a Series C funding round, securing over RMB 100 million (approximately USD 13.8 million). The financing was spearheaded by Leli PE Capital and Neusoft Capital, with the funds earmarked for the advancement and market expansion…
-
Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories
•
Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an option agreement with China-based Ascentage Pharma (HKG: 6855), securing exclusive development and commercialization rights for olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in markets outside of China, Hong Kong, Macau, Taiwan, and Russia. The…
-
AbbVie Strikes Deal with FutureGen for Global Rights to Next-Gen TL1A Antibody FG-M701
•
AbbVie (NYSE: ABBV), a biopharmaceutical giant based in the US, has announced a licensing agreement with Beijing-based biotech FutureGen Biopharmaceutical Co., Ltd. The agreement centers around FutureGen’s preclinical asset, FG-M701, a next-generation TL1A antibody being developed for the treatment of irritable bowel disease (IBD). In this deal, AbbVie secures exclusive…
-
BeiGene to Terminate Partnership with NewBridge Pharmaceuticals for MENA Region
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China, has announced the cancellation of its partnership with NewBridge Pharmaceuticals. The partnership was focused on the sales, distribution, and commercialization of Brukinsa (zanubrutinib) in the Middle East and North Africa (MENA) region. The mutual decision to…
-
Ethypharm Expands in China’s IBD Market with Acquisition of Mesalazine Suppository
•
Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has finalized an acquisition of a mesalazine suppository product from Jiangsu Anbison Pharmaceutical. This product is indicated for the treatment of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. The financial details and other…
-
Sihuan’s Xuanzhu Biopharmaceutical Strikes Licensing Deal with Livzon Pharmaceutical for Fadanafil
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has entered into a licensing agreement with fellow pharmaceutical company Livzon Pharmaceutical Group Inc. (HKG: 1513) for the development and commercialization of fadanafil, a Category 1 chemical compound. Under the terms of the agreement,…
-
Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot
•
Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3 million) in a Series B financing round. The funding round was co-led by Guolian Group and Ince Capital, with contributions from King Star Med LP and existing investor LongRiver. The capital will be utilized to…
-
Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization
•
Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy (CGT) sector, has reportedly secured nearly RMB 200 million in a Series B financing round. The round was led by 3E Bioventures, with participation from HongSheng Capital and existing investors including Beijing Shuimu Guoding Investment,…
-
Zhejiang Dian Diagnostics Partners with Quest Diagnostics to Advance Alzheimer’s Disease Blood Tests
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has entered into a strategic partnership with Quest Diagnostics, a top global provider of diagnostic information services. The collaboration aims to develop and offer blood-based clinical research services specifically tailored for Alzheimer’s disease (AD). Through this…
-
GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow UK biotechnology firm Ochre Bio, announcing this week that it will pay up to USD 37.5 million for access to Ochre Bio’s human liver data. This strategic collaboration aims to bolster the development of hepatology…
-
Chia Tai Tianqing and China Resource Medicine Commercial Holdings Join Forces for Pharmaceutical Industry Expansion
•
Chia Tai Tianqing, a renowned name in the Chinese healthcare industry, has forged a strategic alliance with China Resource Medicine Commercial Holdings Ltd. This partnership aims to delve into various segments of the pharmaceutical industry, including research and development, manufacturing, sales, and distribution. The collaboration is guided by the principles…
-
Pfizer Forges Partnership with Flagship Pioneering for Novel Obesity Treatments
•
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has initiated a strategic partnership with Flagship Pioneering, a life sciences innovation enterprise, to embark on a collaborative quest for groundbreaking obesity treatments in 2023. The alliance will tap into ProFound Therapeutics’ proprietary technology platform, a Flagship-founded entity, to bolster Pfizer’s research and development…
-
Johnson & Johnson to Acquire Biotechnology Firm Yellow Jersey for $1.25 Billion
•
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has entered into a definitive agreement with RTW Biotech Opportunities, a U.S. investment fund, for the acquisition of biotechnology firm Yellow Jersey. Yellow Jersey, a subsidiary of Swiss-based Numab, was previously acquired by RTW in 2021. The cash transaction, valued…
-
Recorna and Starna Therapeutics Join Forces to Advance RNA Gene Editing in Lung Diseases
•
Recorna (Guangzhou) Biotechnology Co., Ltd, a pioneering RNA editing therapy startup based in China, has entered into a strategic partnership with Starna Therapeutics, an mRNA specialist based in Suzhou. This alliance aims to combine their expertise to delve into the research and application of RNA gene editing drugs for lung…
-
China Medical System Secures Exclusive Rights to Baiyiyuan Biotech’s Implant in Greater China
•
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based Baiyiyuan Biotech, securing exclusive rights to promote, market, and commercialize Baiyiyuan’s decellularized matrix implant across Greater China, including the China mainland, Hong Kong, Macau, and Taiwan. The financial details of the agreement were not disclosed.…
-
Shanghai Turtle Technology Partners with Focusgen Biotech to Advance Tumor Liquid Biopsy Innovations
•
Shanghai Turtle Technology Co., Ltd, a leading Polymerase Chain Reaction (PCR) specialist in China, has entered into a strategic partnership with Shanghai Focusgen Biotech Co., Ltd, a company specializing in tumor liquid biopsy devices. This collaboration aims to accelerate advancements in the field of tumor liquid biopsies. Focusgen Biotech’s flagship…
-
MSD Makes Undisclosed Equity Investment in Cancer Diagnostics Firm DELFI Diagnostics
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics, a U.S.-based developer of blood-based cancer tests, without disclosing the financial terms. The investment will enable DELFI to further develop its fragmentomics and artificial intelligence technologies, enhancing early cancer detection and treatment monitoring. DELFI’s proprietary…
-
GSK Finalizes Acquisition of Oligonucleotide Specialist Elsie Biotechnologies for Up to $50 Million
•
GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has announced the completion of the acquisition of Elsie Biotechnologies, an expert in oligonucleotide therapeutics, for a potential total consideration of up to USD 50 million. This strategic move comes as part of GSK’s ongoing efforts to expand its portfolio in…
-
Alphamab Oncology Partners with ArriVent BioPharma for Global ADC Development and Commercialization
•
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research and development (R&D) and commercialization cooperation agreement with ArriVent BioPharma, Inc. (NASDAQ: AVBP), a U.S. biopharmaceutical firm. The collaboration aims to jointly discover, develop, and commercialize innovative antibody-drug conjugates (ADCs) for oncology treatments. According to…
-
3SBio Secures Exclusive Licensing Agreement for Seven Drug Candidates from Subsidiary
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has disclosed plans to enter into an exclusive licensing agreement with its parent company. Under this agreement, Guojian will grant 3SBio the Greater China rights to seven pipeline candidates, including 706, 709, HBT-2002, QY-F10, QY-F11, QY-F07, and…
-
Cloudbreak Pharma Files for Hong Kong IPO with Focus on Ophthalmic Innovations
•
Cloudbreak Pharma Inc., a Cayman Islands-registered pharmaceutical company, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, with key details still under wraps. In 2023, the company reported revenues of USD 880,000 and a net loss of USD 129 million, with research and development (R&D)…
-
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
•
QuantumPharm Inc., operating under the name Xtalpi Inc., has successfully conducted an initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.13 billion (USD 144.5 million). The shares of Xtalpi, listed under the ticker symbol 02228, were priced at HKD 6.03 per share. Xtalpi is a pioneer…
-
Shenzhen Light and Biotechnology Partners with Shenzhen Increcare Biotech in IVD Sector
•
Shenzhen Light and Biotechnology Co., Ltd, a company based in China, has entered into a new partnership with fellow Chinese firm Shenzhen Increcare Biotech Co., Ltd to further their collaboration in the in vitro diagnostic (IVD) field. The financial details of the agreement were not disclosed. The two companies have…
-
OBiO Technology Partners with Shenzhen Innovation Immunotechnology for TCR-T Cell Therapy Development
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading Contract Research Organization (CRO) specializing in gene therapy based in China, has entered into a partnership with Shenzhen Innovation Immunotechnology Co., Ltd. As per the agreement, OBiO will offer preclinical pharmaceutical research services for Shenzhen Innovation’s TCR-T cell therapy candidate, SIIT-T002.…
-
BOE-Backed Genewise Bio Secures RMB 100 Million in Series A Financing for Molecular Diagnostics
•
Genewise Bio, a molecular diagnostics company nurtured by BOE Technology Group, has reportedly secured RMB 100 million in a Series A financing round. Tsing Song Capital led the investment round, with additional investments from Wuhe Capital, Aeonmed, and Pinnacles Medtech. Established in 2021, Genewise Bio has developed a comprehensive independent…
-
Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, has announced that its subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has entered into a strategic partnership with China’s Eye Valley. The collaboration aims to develop innovative and generic drugs in the field of ophthalmology and will lead to the establishment…
-
Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases
•
Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization rights to a portfolio of UNC13A-targeting compounds from QurAlis, a biopharmaceutical company based in the U.S. The portfolio includes the antisense oligonucleotide (ASO) QRL-204, which is considered a potential best-in-class candidate for treating neurodegenerative diseases…
-
Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody
•
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing agreement with Summit Therapeutics Inc. (NASDAQ: SMMT) for ivonescimab, Akeso’s bispecific antibody (BsAb) that targets PD-1 and VEGF. The original agreement, valued at a potential USD 5 billion, was signed in December 2022 and granted…
-
Changchun GeneScience to Distribute TWi Pharma’s Megestrol in China and Southeast Asia
•
Changchun GeneScience Pharmaceutical Co., Ltd, a biopharmaceutical company based in China, has entered into an agency collaboration agreement with Taiwan’s TWi Pharmaceuticals, Inc. for the distribution of the latter’s megestrol in several Asian markets. According to the agreement, the financial details of which were not disclosed, GeneScience will assume the…
-
MSD to Acquire Ophthalmology Specialist Eyebiotech in a Deal Valued Up to USD 3 Billion
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into an agreement to acquire UK-based ophthalmology specialist Eyebiotech Limited for an upfront payment of USD 1.3 billion, plus potential milestone payments of up to USD 1.7 billion. The deal is anticipated to be finalized in the third quarter of 2024,…
-
TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China
•
Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered into a partnership with the medical aesthetics unit of Chinese firm Lancy Co., Ltd (SHE: 002612), known as BRAVOU. In China, medical aesthetics services are categorized as medical care activities, a sector that has been…
-
Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China
•
Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in the field of tumor companion diagnostics (CDx), this time with the German multinational corporation, Bayer. Previously Burning Rock had collaborated with Germany-based Merck KGaA in late 2021 for the development of CDx to support Merck’s…
-
Parexel Partners with Ruijin Hospital Hainan Subsidiary to Enhance Real-World Evidence in Drug Development
•
Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin Hospital’s Hainan subsidiary. This collaboration aims to explore the use of real-world data (RWD) and real-world evidence (RWE) to facilitate the accelerated approval of drugs, thereby increasing Chinese patients’ access to innovative medications and therapies.…
-
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
•
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases, has raised an additional USD 12.5 million in financing. The company is jointly incubated by China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873). Existing investors Engine Ventures and Safar Partners spearheaded the funding…
-
Johnson & Johnson to Acquire Atopic Dermatitis Therapy NM26 in $1.25 Billion Deal
•
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has entered into a definitive agreement to acquire global rights to NM26, a first-in-class bispecific antibody (BsAb) for the treatment of atopic dermatitis (AD), from Switzerland-based Numab Therapeutics. The transaction, valued at $1.25 billion in cash, is anticipated to conclude…
-
HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies
•
HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into a strategic partnership and licensing agreement with Synthego Corporation, a U.S.-based leading provider of CRISPR solutions for cell and gene therapy development. The agreement grants Synthego access to Huida’s high-fidelity Cas12 CRISPR nuclease (hfCas12Max), strengthening…
-
Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended
•
Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) is planning to fully acquire its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696). This strategic move comes as Henlius, a Hong Kong-listed company, has suspended its shares from trading…
-
Jiangxi Rimag Group Sets IPO Price Range for Hong Kong Debut, Aims to Raise Up to USD 2.15 per Share
•
Jiangxi Rimag Group Co., Ltd, a leading medical imaging services provider based in China, has set the pricing range for its initial public offering (IPO) on the Hong Kong Stock Exchange. The price band is set between HKD 14.6 and 16.8 per share, which equates to approximately USD 1.87 to…
-
IVD Medical Holding Ltd Enters Non-Binding MoU with Chinese Chemiluminescence IVD Company for Potential Collaboration
•
IVD Medical Holding Ltd (HKG: 1931), a leading in vitro diagnostic (IVD) company based in China, has announced the signing of a non-binding Memorandum of Understanding (MoU) with a fellow Chinese IVD company, which is yet to be named. The MoU outlines the intention to explore potential collaboration opportunities, including…
-
BMS Strikes Deal with Prothena for Potential Disease-Modifying Neurology Drug PRX019
•
Bristol Myers Squibb (BMS; NYSE: BMY) has executed an exclusive global licensing agreement with Prothena Corporation (NASDAQ: PRTA), a biopharmaceutical company specializing in protein dysregulation, to acquire PRX019, a promising candidate for neurodegenerative diseases. The agreement follows PRX019’s attainment of Investigational New Drug (IND) status in the previous year. Under…
-
Gilead Partners with Cartography Biosciences to Develop Therapies for Triple-Negative Breast Cancer
•
Gilead Sciences (NASDAQ: GILD) has entered into a collaboration agreement with Cartography Biosciences, a US-based biotechnology company, to discover and develop novel therapies for triple-negative breast cancer (TNBC) and adenocarcinoma. Cartography will leverage its computational and genomics platform to identify and validate target antigens and pairs of antigens in cancer,…
-
Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with artificial intelligence-based technologies provided by Bluecrux, a consulting and technology firm based in Belgium. Bluecrux’s solution consolidates all of Sanofi’s data systems into a unified model, enabling comprehensive end-to-end visibility across the company’s supply chain.…
-
Bio-Thera Solutions Partners with STADA for European Commercialization of Golimumab Biosimilar
•
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced a licensing agreement with STADA Arzneimittel AG for BAT2506, a biosimilar version of Johnson & Johnson’s (J&J) Simponi (golimumab). Under this agreement, STADA will secure exclusive commercialization rights for the product across the European Union (EU), the…
-
Roche Extends Long-Standing Partnership with Hitachi High-Tech to Innovate Diagnostic Solutions
•
Roche (SWX: RO), a major Swiss pharmaceutical company, has renewed its 46-year partnership with Japan’s Hitachi High-Tech (TYO: 6501) for an additional 10 years to develop innovative diagnostic solutions. This long-standing collaboration has led to an annual impact of over 21 billion in-vitro diagnostic tests, facilitated by more than 84,000…
-
Asahi Kasei Moves to Fully Acquire Swedish Rare Disease Biopharma Calliditas in All-Cash Deal
•
Japan’s Asahi Kasei Corporation (TYO: 3407) has announced an all-cash offer to fully acquire the Swedish rare disease drug firm Calliditas Therapeutics AB (STO: CALTX). Both companies’ boards have approved the deal, with Asahi Kasei proposing to purchase all outstanding public shares of Calliditas at a price of SEK 416…
-
3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical
•
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement with fellow Chinese firm Hybio Pharmaceutical Co., Ltd (SHE: 300199) for the development of a semaglutide biosimilar. Under this agreement, 3SBio will gain access to Hybio’s preclinical technical results for the drug and will be…
-
Medilink Therapeutics Partners with BioNTech to Develop ADC Products Using TMALIN Technology
•
Medilink Therapeutics, based in Suzhou, has entered into another partnership agreement with German biotechnology company BioNTech SE (NASDAQ: BNTC). This collaboration allows BioNTech to utilize Medilink’s TMALIN ADC technology platform for the development of specific antibody drug conjugate (ADC) products. According to the terms of the deal, BioNTech will make…
-
Sihuan Pharma Halts Xuanzhu Biopharm’s IPO on Shanghai Sci-Tech Innovation Board
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a Chinese pharmaceutical company, has announced the cancellation of an initial public offering (IPO) on Shanghai’s Sci-Tech Innovation Board (STAR) for its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm). Xuanzhu Biopharm, which concentrates on therapeutic areas such as oncology, metabolism, anti-infection, and digestion,…
-
Bayer’s Consumer Health Division to Invest $83 Million in New Supply Center in China
•
Bayer (ETR: BAYN)’s Consumer Health Division has entered into an agreement with Qidong city in Jiangsu province to establish a new supply center. The German multinational pharmaceutical company will invest RMB 600 million (USD 83 million) in the initial phase of the project, with the facility expected to become operational…
-
CStone Pharmaceuticals Expands European Reach with Ewopharma Partnership for Sugemalimab
•
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a strategic partnership with Ewopharma, granting the European firm commercialization rights to its programmed death-ligand 1 (PD-L1) inhibitor sugemalimab across Switzerland and 18 Central and Eastern European Countries (CEECs). The CEECs include EU member states such as Bulgaria,…
-
Beijing’s Cipher Gene Secures RMB 100 Million in Series C Financing to Expand Precision Medicine Services
•
Cipher Gene, a Beijing-based gene big data and precision medicine service provider, has reportedly secured RMB 100 million in a Series C financing round. The funding round was led by Chengdu Jinjiang, with participation from Zhongxi Fund and several existing investors. The capital raised will be utilized to enhance the…
-
Bristol Myers Squibb Invests in UK Immuno-Oncology Firm NeoPhore’s Series B Extension Round
•
Bristol Myers Squibb (BMS; NYSE: BMY) has participated in an oversubscribed Series B extension round for NeoPhore, a UK-based immuno-oncology company. The funds will be utilized by NeoPhore to advance its pre-clinical studies, with the goal of delivering a small-molecule candidate by 2025. The specific amount invested by BMS was…
-
Degron Therapeutics Partners with Takeda for Molecular Glue Degraders Development
•
Degron Therapeutics, a biopharmaceutical company based in China, has entered into a collaboration development and licensing agreement with Takeda (TYO: 4502), a leading pharmaceutical company in Japan. The partnership aims to discover and develop novel molecular glue degraders targeting oncology, neuroscience, and inflammation. According to the agreement, Degron Therapeutics will…
-
China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition
•
Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with China’s Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347). This global collaboration is centered around the application of Veeva’s modern electronic data acquisition system, Vault EDC. The innovative digital solution is designed to enhance…
-
Boehringer Ingelheim and Peking University Deepen Partnership with Joint Drug Research Lab
•
Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking University Health Science Center (PKUHSC) to establish a joint laboratory for human use drug research. This long-term partnership builds upon an initial teaching and scientific research cooperation memorandum of understanding signed back in 2014. Since…
-
Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals
•
Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a US-based developer of anticancer radiopharmaceuticals, to co-develop first-in-class treatments for solid tumors and diagnostic products. Under the terms of the agreement, Aktis is set to receive an upfront payment of USD 60 million, a significant…
-
MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment
•
Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda (pembrolizumab), has entered into a collaborative agreement with Dragonfly Therapeutics for the combination therapy of Keytruda and Dragonfly’s tri-specific natural killer (NK) cell engager, DF9001. The partnership aims to explore treatment options for advanced solid…
-
Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03
•
Amgen’s (NASDAQ: AMGN) dominance in the bone treatment market with its blockbuster drugs Xgeva and Prolia (denosumab) may face a new challenge as Alvotech (NASDAQ: ALVO), an Iceland-based biopharmaceutical company, has licensed its biosimilar candidate AVT03 to India’s Dr. Reddy’s Laboratories (NYSE: RDY) for the European and US markets. This…
-
Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement
•
China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement with US-based cell-engineering company MaxCyte Inc., (NASDAQ: MXCT). The agreement grants Legend Bio a non-exclusive worldwide license to leverage MaxCyte’s Flow Electroporation technology and ExPERT platform. This access will facilitate Legend Bio’s research, clinical development,…
-
C.Q. Pharmaceutical and JD.com Join Forces to Revolutionize Pharmaceutical Supply Chain
•
C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a prominent Chinese pharmaceutical company, has announced a strategic partnership with China’s leading e-commerce platform, JD.com (NASDAQ: JD). The collaboration aims to innovate across various sectors, including consumer goods supply chain, pharmaceutical and medical services, wholesale and retail, warehousing and logistics, and supply…
-
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
•
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement with the UK pharmaceutical giant AstraZeneca. The deal revolves around a pre-clinical monoclonal antibody (mAb) program, marking a substantial step forward in the development of innovative therapies. Under the terms of the agreement, AstraZeneca will…
-
Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in China, has announced that its subsidiary, Fosun Diagnostics (Shanghai) Co., Ltd, has entered into a strategic partnership with Jointown Medical Devices Group Co., Ltd. The collaboration aims to enhance product commercialization and strengthen the supply…
-
Amoy Diagnostics Teams Up with Boehringer Ingelheim for CDx Developmen
•
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in China’s tumor precision medicine space, has entered into a strategic collaboration with Germany’s Boehringer Ingelheim to advance the development of companion diagnostics (CDx). The partnership is aimed at identifying non-small cell lung cancer (NSCLC) patients who are most likely…
-
AI in Pharma: MindRank Ltd Joins Forces with Zhejiang Hisun Pharmaceutical for Drug R&D
•
MindRank Ltd, a China-based artificial intelligence (AI)-driven drug development company, has entered into a strategic partnership with domestic pharmaceutical firm Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267). The collaboration will combine MindRank’s AI platform technology with Hisun Pharmaceutical’s research and development (R&D) capabilities and manufacturing resources to advance the field…
-
Henlius Biotech and Palleon Pharmaceuticals Modify Licensing Agreement for Bifunctional Antibody
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced the revision of a cooperation and licensing agreement initially signed with Palleon Pharmaceuticals Inc. in June 2022. The original agreement was centered around the development of a bifunctional anti-HER2 antibody-sialidase fusion protein and a second…
-
Astellas Pharma Considers Joint Cell Therapy Platform with Yaskawa Electric
•
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it is in advanced discussions with fellow Japanese firm Yaskawa Electric Corporation (OTCMKTS: YASKY) to explore a potential collaboration aimed at developing a cell therapy platform. This strategic partnership would integrate robotics technologies to expedite research and…
-
Sanofi Leads Pharma Industry with AI Collaboration with Formation Bio and OpenAI
•
Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US firms Formation Bio and OpenAI to develop customized artificial intelligence (AI) models designed to expedite drug development. While the financial specifics of the agreement were not disclosed, the partnership signifies Sanofi’s strategic commitment to leveraging…
-
Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations
•
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical Technology, its wholly-owned subsidiary, has introduced a strategic investor, Beijing Daxing Airport Economic Zone Development Fund. The fund has made a substantial investment of RMB 100 million (USD 14 million) in the company. The proceeds…
-
Jiayue Pharmaceutical’s JYP0015 Secures $365 Million Licensing Agreement with Erasca
•
Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing agreement with Erasca (NASDAQ: ERAS), a US-based biopharmaceutical company. Under the terms of this agreement, Erasca has been granted exclusive rights to research, develop, and commercialize Jiayue Pharma’s pan-RAS (ON) inhibitor, JYP0015, excluding China mainland,…
-
Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced a comprehensive strategic partnership with the UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This collaboration will encompass the entire spectrum of drug development, including small molecules, macromolecules, and gene therapies, from…
-
Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services
•
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a strategic partnership with Baidu Health. This collaboration aims to focus on AI intelligent outpatient services, thereby strengthening the digital transformation of medical services. The hospital has demonstrated initial success with its AI intelligent outpatient system,…
-
Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced the sale of its 10.21% stake in Proteologix, a US-based specialist in immune-mediated diseases. The acquisition of Proteologix is set to be completed by healthcare giant Johnson & Johnson (J&J; NYSE:…
-
Fosun Pharma Nods to Fosun Health Spin-Off; IPO Venue and Requirements Under Review
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in China, has announced that its board of directors has given the green light to pre-planning activities for the spin-off of its subsidiary, Fosun Health. The company is currently in discussions regarding the potential initial public…
-
Zhejiang Huahai Pharmaceutical Co., Ltd Plans Capital Raise for Digital Manufacturing Expansion
•
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a leading Chinese pharmaceutical company, has unveiled plans for a private placement of 148,000,000 shares, raising a total of RMB 1.21 billion (approximately USD 170 million). The capital raised from this private placement is earmarked for the construction of digital intelligent manufacturing facilities…
-
Porton Biologics and SAFE Collaborate to Accelerate Pharmaceutical R&D Services
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy of Sciences (CAS) in 2016, Suzhou Institute of Materia Medica, Clinical Service Center, and SPD BANK.…
-
Biocytogen Expands Reach to India with GVSAP Partnership for BioMice Models
•
A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership with GV Safety Assessment Platform (GVSAP), a preclinical Contract Research Organization (CRO) and subsidiary of GV Research Platform (GVRP) in India. This new collaboration will provide Indian researchers with access to Biocytogen’s innovative BioMice models…
-
Sol-Gel Technologies Partners with Shenzhen Beimei for Twyneo Commercialization in China
•
Israel-based dermatology specialist Sol-Gel Technologies Ltd. (NASDAQ: SLGL) has announced the signing of a licensing agreement with Shenzhen Beimei Pharmaceutical Co., Ltd, a China-based partner. According to the agreement, BeiMei will receive commercialization rights for Twyneo (benzoyl peroxide and tretinoin) cream, a treatment for acne vulgaris, in China mainland, Hong…
-
J&J Acquires Immune-Mediated Diseases Specialist Proteologix in a Deal Worth Up to USD 850 Million
•
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has announced a deal to acquire Proteologix, a US-based specialist in immune-mediated diseases, for a base purchase price of USD 850 million with additional potential milestone payments. The transaction is anticipated to be finalized by mid-2024. Proteologix is known for…
-
Huaixi Medical and Beijing HumaDX Tech Join Forces to Boost In Vitro Diagnostics
•
Huaixi Medical, a Nanjing-based specialist in flow cytometry, has entered into a strategic partnership with Beijing HumaDX Tech Co., Ltd., a company renowned for its expertise in multiple flow fluorescence technologies. The collaboration aims to enhance the in vitro diagnostics (IVD) field through a comprehensive integration of laboratory construction, technical…
-
Merck KGaA Subsidiary Teams Up with Aulos Bioscience to Test PD-L1 and Anti-IL-2 Combination
•
Germany’s Merck KGaA (ETR: MRK) has announced that its Switzerland-based subsidiary, Ares Trading, has entered into a partnership with US-based Aulos Bioscience. This collaboration aims to advance the clinical development of Merck’s anti-PD-L1 drug Bavencio (avelumab) in combination with Aulos’s anti-IL-2 antibody candidate, AU-007. The financial details of the agreement…
-
Hengrui Medicine Strikes Deal with Hercules CM Newco to Supply GLP-1 Products for Global Markets
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has entered into a significant agreement to supply a range of glucagon-like peptide-1 (GLP-1) products to Hercules CM Newco Inc., a newly established US firm backed by a consortium of investors including Bain Capital Life Sciences, RTW Investments,…
-
Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support
•
Novo Nordisk’s (CPH: NOVO-B) controlling shareholder, Novo Holdings, has entered into an agreement to purchase a majority stake in Austria-based Single Use Support, a company that supplies equipment and consumables to the biopharmaceutical industry. The financial details of the transaction were not disclosed. As stated in the press release, Single…
-
AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation
•
AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure target discovered by BenevolentAI (AMS: BAI), a UK-based precision drug design company. This milestone achievement marks a significant step in their ongoing partnership, which was initially established in 2019 with a focus on idiopathic pulmonary…
-
Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO
•
Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic preparations for the treatment of cancer and autoimmune diseases, has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued 34,151,800 shares priced at HKD 13.5 per share, resulting…
-
GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment
•
GE HealthCare (NASDAQ: GEHC), a leading medical technology firm, has entered into a cooperation intent letter with the Pudong district of Shanghai, committing an investment of RMB 380 million (USD 52.5 million). This strategic partnership will focus on the introduction of new products, construction of new production lines, green factory…
-
Vision Medicals Raises Hundreds of Millions in Series D+ Round to Advance Molecular Diagnostics
•
Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+ financing round, led by Kequan Investment with participation from Tianxin Fund. The funds raised will be directed towards accelerating the research and development of precision diagnosis products focused on pathogenic molecules. Additionally, the company plans…
-
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
•
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates.…
-
Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China
•
Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion of its clinical partnership with Shanghai East Hospital, a Class 3A general hospital in China. This strategic collaboration aims to address the increasing demand for clinical studies within the country. The two entities initially collaborated…
-
Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round
•
China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in the nation, has reportedly secured nearly RMB 100 million (USD 13.8 million) in a Series A+ financing round. The funding round was co-led by GT (Shanghai) Equity Investment Fund and Guotai Junan Innovation Investment, with…
-
AbbVie and Gilgamesh Pharmaceuticals Join Forces to Develop Psychiatric Disorder Therapies
•
AbbVie (NYSE: ABBV) has announced a partnership with US-based Gilgamesh Pharmaceuticals to develop a portfolio of next-generation therapies targeting psychiatric disorders. Under the agreement, Gilgamesh will receive an upfront payment of USD 65 million, with the potential for up to USD 1.95 billion in milestone payments and sales royalties. AbbVie…
-
Takeda Strikes Deal with AC Immune for Global Rights to Alzheimer’s Immunotherapies
•
Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA (NASDAQ: ACIU), a Switzerland-based developer of advanced immunotherapies, to obtain an exclusive global license for the company’s active immunotherapies that target toxic forms of amyloid beta (Abeta). This strategic partnership positions Takeda at the forefront…
-
Protein Drug Developer B&K Co., Ltd from Qingdao Eyes Hong Kong IPO
•
B&K Co., Ltd, known as Bio-Bank Corp., a biopharmaceutical company specializing in protein drug development and headquartered in Qingdao, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company’s IPO details, including pricing, have not yet been disclosed. Since its establishment in 2012, B&K…
-
Healingovation Raises Over RMB 60 Million in Pre-Series A++ Round for Aquablation Surgical Robot
•
Healingovation, a Beijing-based innovator in surgical robots and intelligent diagnostic and therapeutic equipment, has reportedly secured more than RMB 60 million (USD 8.3 million) in a pre-Series A++ financing round. The round was led by CD Capital, with participation from Legend STAR, and returning investors Shunwei Capital, Lilly Asia Ventures,…
-
Subtle Medical Inc Closes USD 10 Million Series B+ Round to Accelerate Global Expansion
•
Subtle Medical Inc, a medical imaging specialist and Stanford University spin-off, has reportedly raised close to USD 10 million in a Series B+ financing round. The financing was backed by investors including Shanghai-based Wenzhou Capital, Fusion Fund, ENVISIONX Capital, Bluerun Ventures, and other strategic partners across the Asia Pacific region.…
-
Novartis Inks Deal to Acquire Mariana Oncology, Bolstering Radioligand Therapy Portfolio
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) is poised to expand its oncology portfolio by acquiring Mariana Oncology, a US-based specialist in radioligand therapy (RLT). The agreement is subject to customary closing conditions and includes a substantial upfront payment of USD 1 billion, plus potential milestone payments of up to USD…
-
Ribobay Pharma and General Biol to Commence GMP-Grade Oligonucleotide Manufacturing Services
•
Shanghai-based contract research, development, and manufacturing organization (CRDMO) Ribobay Pharma has announced plans to commence offering GMP-level CRDMO services for oligonucleotide manufacturing in the near future. In collaboration with its spin-off company, General Biol (Anhui) Co., Ltd, the companies aim to provide access to Cytiva’s FlexFactory platform for oligo manufacturing.…
-
Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary
•
Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to sell its 24.65% stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation. The assessed value of all shareholder equity, calculated using the income method, is RMB 486 million (USD 67.3 million), marking an…
-
Macera Therapeutics and Innorna Co., Ltd Collaborate on CAR-M mRNA-LNP Technology
•
Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has entered into a partnership with Shenzhen-based Innorna Co., Ltd, a platform company focused on delivery platforms for nucleic acid therapeutics. Under the agreement, Macera will leverage Innorna’s mRNA-LNP technology to advance the development of in…
-
Vazyme Biotech and SPH KDL Health Join Forces to Promote Alzheimer’s Blood Tests
•
Vazyme Biotech Co., Ltd (SHA: 688105), a prominent biotech company based in China, has entered into a strategic partnership with SPH KDL Health to enhance the distribution and promotion of its Alzheimer’s disease (AD) blood test products. The collaboration may lead to the signing of a separate product agency agreement…
-
DSciLab, mRNA Pharma Startup, Bags RMB 100 Million in Angel Financing Led by Fosun Health
•
DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced the completion of an angel financing round worth RMB 100 million. The round was led by Fosun Health Capital, with participation from Shanghai Creation Investment. The funds will be directed towards the advancement of core…
-
Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion
•
France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ: NVAX), aiming to enhance its immunization portfolio. Under the agreement, Sanofi will gain access to Novavax’s Matrix-M adjuvant and secure exclusive rights to combine its influenza vaccines with Novavax’s SARS-CoV-2 vaccine. Sanofi will also co-commercialize…
-
BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody
•
Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech (NASDAQ: BNTX) has exercised a global exclusive option right, securing the rights to globally develop, manufacture, and commercialize Biotheus’s in-house developed pre-clinical bispecific antibody (BsAb) candidate drug. Upon the option exercise, Biotheus will receive option…
-
Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO
•
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the Hong Kong Stock Exchange (HKEX) in anticipation of a public listing. The firm is targeting a minimum capital raise of USD 100 million, aiming for a valuation of at least USD 600 million. This follows…
-
Tonghua Dongbao Pharmaceuticals Inks Licensing Deal for Semaglutide in China
•
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a licensing agreement with fellow Chinese firm Beijing QL Biopharmaceutical Co., Ltd. concerning QL Biopharmaceutical’s glucagon-like peptide-1 (GLP-1) product, semaglutide (ZT001). According to the terms of the agreement, Tonghua Dongbao will secure the exclusive commercialization rights for ZT001,…
-
China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea
•
China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea’s HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH)…
-
Siemens Healthineers AG Forges Expanded Partnership with Xi’an Daixing Hospital
•
Germany’s Siemens Healthineers AG (ETR: SHL) has entered into an eight-year value partnership with Xi’an Daixing Hospital, a top-tier Class 3A medical institution located in Northwestern China. The collaboration aims to delve into various areas, including the construction of an innovative ecosystem, talent development, international exchange initiatives, scientific research consultation,…
-
Citi Pharma Ltd and Hangzhou Newsea Technology Form JV to Boost API Production
•
Pakistan-based pharmaceutical company Citi Pharma Ltd is entering into a joint venture (JV) agreement with China’s Hangzhou Newsea Technology Co., Ltd, in a strategic move designed to expand Citi’s pharmaceutical Active Pharmaceutical Ingredient (API) manufacturing capabilities. The new entity, to be named Etaci Ltd, will see Citi holding a majority…
-
Ono Pharmaceutical Secures Deal to Acquire Deciphera Pharmaceuticals for USD 2.4 Billion
•
Japan-based Ono Pharmaceutical Co., Ltd (TYO: 4528) has announced that it has reached an agreement to fully acquire US-based Deciphera Pharmaceuticals Inc. (Nasdaq: DCPH). According to Ono’s press release, the acquisition will involve Ono purchasing all outstanding shares of Deciphera for USD 25.60 per share in cash, which values the…
-
Biocytogen and BioCopy AG Collaborate on TCR-Mimic Antibody Development for Cancer Therapies
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced an evaluation and potential licensing agreement with BioCopy AG, a research-driven biotechnology firm based in Basel, Switzerland. This agreement grants BioCopy access to a fully human library of TCR-mimic antibodies that target intracellular antigens. These antibodies are…
-
Well Lead Medical’s Stone Removal Sheath Gains Karl Storz as US Sole Agent
•
Well Lead Medical Co., Ltd (SHA: 603309), a Guangzhou-based specialist in medical catheters, has entered into a strategic partnership with Karl Storz, a leading endoscopy company based in Germany. Under the agreement, Karl Storz will serve as the exclusive agent in the US for Well Lead’s ClearPetra suction-evacuation ureteral access…
-
Siemens Healthineers AG Partners with Haidian District Government to Boost Medical Innovation in Beijing
•
Siemens Healthineers AG (ETR: SHL), a leading medical technology company based in Germany, has entered into a strategic partnership with the Haidian district government in Beijing. The collaboration aims to foster international medical talent cultivation, develop a medical technology innovation ecosystem, and enhance medical industry translation cooperation, among other initiatives.…
-
Sino Biological Inc. to Acquire Canadian Bioactive Enzyme Manufacturer SignalChem Biotech
•
Sino Biological Inc. (SHE: 301047), a leading provider of biological research reagents and technical contract research services based in China, has entered into a definitive Share Purchase Agreement to acquire SignalChem Biotech Inc. (SCB), a Vancouver, Canada-based manufacturer of specialized bioactive enzymes. The transaction values 100% of SCB’s shares at…
-
Kexing Pharmaceutical Secures Global Rights for Qingfeng’s Generic Olaparib
•
China’s Kexing Pharmaceutical (SHA: 688136) has secured a global commercialization licensing agreement with Qingfeng Pharmaceutical Group for the latter’s generic version of olaparib. Under this deal, Kexing will obtain commercial rights for the product across an initial batch of 10 international markets. Meanwhile, Qingfeng’s generic formulation is currently awaiting regulatory…
-
Sirnaomics Partners with Hualan Biological to Develop and Commercialize RSV mRNA Vaccine in China
•
Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering Inc., (SHE: 002007), to enhance the clinical development and commercialization of Sirnaomics’ respiratory syncytial virus (RSV) mRNA vaccine, RV-1770, in China. Under the agreement, Hualan will oversee clinical development, industrialization, and commercialization of the vaccine…
-
Neusoft Medical Systems Partners with West China Hospital to Boost Indigenous Medical Tech Innovation
•
China-based Neusoft Medical Systems Co., Ltd has entered into a strategic partnership with West China Hospital to establish the “West China Hospital – Neusoft Medical High-end Medical Equipment and Hospital High-Quality Development Innovation Center.” The collaboration aims to enhance the innovative application of domestic high-end medical equipment and medical imaging…
-
AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China
•
Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received implicit approval for its autologous armored GPC3-targeted chimeric antigen receptor (CAR) T cell therapy, C-CAR031, developed by its subsidiary, Shanghai Cellular Biopharmaceutical Group Ltd. The therapy is intended for the treatment of GPC3+ advanced or…
-
Allgens Medical Technology to Acquire German Dental Implant Maker HumanTech Dental for EUR 3.25 Million
•
Beijing-based Allgens Medical Technology Co., Ltd (SHA: 688613), specializing in regenerative medicine materials and implantable devices, has announced plans to acquire all outstanding shares of HumanTech Dental GmbH, a German dental implant manufacturer, for a consideration of EUR 3.25 million (USD 3.5 million). Established in 2017, HumanTech Dental has been…
-
Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management…
-
Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery
•
China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with compatriot firm invoX Pharma, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The collaboration aims to combine Insilico’s AI and computer-aided drug discovery expertise, including its proprietary PandaOmics target discovery engine, with invoX’s innovative drug…
-
MSD Partners with Hanmi Pharmaceutical to Develop Combination Therapy for Solid Tumors
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi Pharmaceutical (KRX: 128940) to develop a combination therapy using MSD’s top-selling anti-PD-1 therapy Keytruda (pembrolizumab) and Hanmi’s bispecific antibody (BsAb) BH3120 for the treatment of progressive or metastatic solid tumors. The financial details of the…
-
Zhejiang Dian Diagnostics Partners with Henan Institute to Open Neuroimmunity Research Center
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a medical diagnostics company based in China, has entered into a collaboration with the Henan Institute of Medical and Pharmaceutical Sciences to establish the Engineering Technology Research Center for Accurate Diagnosis and Treatment of Neuroimmunity. The new research institute has been officially inaugurated…
-
Shenzhen Wingor Biotechnology Partners with Guangzhou Institute of Respiratory Health for MSC Exos Research
•
Shenzhen Wingor Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a scientific research cooperation agreement with the Guangzhou Institute of Respiratory Health (GIRH). The partnership aims to collaborate on clinical studies focusing on the use of exosomes derived from mesenchymal stem cells (MSC exos) for the treatment of…
-
Kingmed Diagnostics Partners with GenStar Biosolutions to Develop Auto-Antibody Immunofluorescence AI Software
•
Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic partnership with GenStar Biosolutions Co., Ltd, a Beijing-headquartered specialist in immune diagnostic technology. The collaboration aims to jointly develop auto-antibody immunofluorescence AI interpretation software and create an integrated, intelligent immunofluorescence detection platform. Financial details of…
-
Genrix Bio Pharmaceutical Partners with China Resource Medicine for Expanded Market Coverage
•
Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has entered into a strategic partnership with China Resource Medicine Commercial Holdings Ltd. The collaboration aims to enhance channel management and strengthen presence in the healthcare and retail markets. Financial details of the agreement were not disclosed. By…
-
Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
•
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot bank Sumitomo Mitsui to establish a joint venture (JV) aimed at nurturing drug discovery start-ups. The yet-to-be-named JV will leverage the pharmaceutical companies’ expertise to foster innovation in the early stages of drug development.- Flcube.com
-
Bristol Myers Squibb Enhances CAR-T Manufacturing with Cellares Platform, Securing Exclusive Access
•
Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a U.S.-based cell therapy production platform, to bolster its manufacturing capacity for CAR-T therapies. In return for granting exclusive access to several of its fully automated systems, Cellares is set to receive up to USD 380…
-
MSD Strikes Deal with GV20 Therapeutics to Test Anti-PD-1 Combo in Solid Tumor Therapies
•
Merck, Sharp & Dohme (MSD; NYSE: MRK), a global healthcare leader, has entered into a strategic collaboration with GV20 Therapeutics, a biopharmaceutical company specializing in antibody therapeutics with operations in both China and the U.S. The partnership aims to combine GV20’s groundbreaking IGSF8-targeted biologic, GV20-0251, with MSD’s best-selling anti-PD-1 therapy,…
-
CareRay Digital Medical Invests $15 Million for Stake in X-Ray Detector Maker ISID
•
CareRay Digital Medical Technology Co., Ltd, a leading medical technology company based in Jiangsu, has acquired a 30% stake in ISID Ltd, a London-based developer and manufacturer of high-end X-ray flat panel detectors and CMOS sensors, for a consideration of GBP 12 million (USD 15 million). ISID specializes in the…
-
Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs
•
Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD 55.2 million) in a Series D+ financing round. The round was co-led by GTJA Investment and KingRay Capital, a state-owned investor focused on small and micro enterprises. Additional participants in the financing round included Guojin…
-
Beijing Sanbo Hospital and AGE Dr. Hospital Management Group Join Forces in Brain Disease Care
•
Beijing Sanbo Hospital Co., Ltd, a prominent healthcare provider in China, has entered into a strategic partnership with AGE Dr. Hospital Management Group (Boao Yiling), a leading hospital management group. The collaboration will focus on key areas such as department construction, talent development, technical collaboration, and joint scientific research initiatives.…
-
Shanghai Escugen and Anke Bio Partner to Develop ADC Products with EZWi-Fit Platform
•
Shanghai Escugen, a biopharmaceutical company based in China, has entered into a licensing and cooperation agreement with Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009). Under the terms of the agreement, Escugen will grant Anke Bio the rights to its antibody-drug conjugate (ADC) technology platform, EZWi-Fit, for the development of…
-
AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies
•
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based biopharmaceutical firm Medincell (EPA: MEDCL) to develop up to six long-acting injectable treatments across multiple therapeutic areas. As per the agreement, Medincell will receive an upfront payment of USD 35 million, with the potential for…
-
Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare
•
Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced plans to invest RMB 250 million in the establishment of a joint venture (JV) with two Chinese investment firms. The JV, which will have a total capitalization of RMB 500 million, will focus on strategic…
-
Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System
•
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership with the University of Michigan in the United States. Financial details of the collaboration remain undisclosed. The partnership will focus on developing an innovative delivery system for glucagon-like peptide-1 (GLP-1) drug targets, with the University…
-
Vazyme Partners with Yufang Medical to Boost Alzheimer’s Blood Test Sales Online
•
Vazyme Biotech Co., Ltd (SHA: 688105), based in China, has entered into a strategic partnership with Shanghai Yufang Medical Technology (Group) Co., Ltd to enhance their collaboration in the screening and testing sector. Under the terms of the agreement, the two companies will leverage their respective strengths to jointly promote…
-
89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China
•
U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and Manufacturing Organization (CDMO) BiBio Biopharma Engineering to construct an API facility in China. The facility will supply the active pharmaceutical ingredient (API) for 89bio’s lead pipeline candidate, pegozafermin, an investigational FGF21 analog currently in Phase…
-
JD Healthcare Forges Partnerships with Top Medical Device Firms at CMEF
•
The China International Medical Equipment Fair (CMEF), which took place last week in Shanghai, was a significant event for JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD). The company announced a series of strategic partnerships with prominent medical device firms, including Yuyue Medical, Omron, Cofoe Medical, Philips,…
-
Bayer Partners with Hologic to Develop Contrast-Enhanced Mammography Solution for Breast Cancer Diagnosis
•
Bayer (ETR: BAYN), a multinational pharmaceutical and life sciences company headquartered in Germany, has announced a strategic partnership with Hologic (NASDAQ: HOLX), a leading women’s health specialist. The collaboration aims to develop a contrast-enhanced mammography (CEM) solution that serves as a cost-effective adjunct to traditional mammography for breast cancer diagnosis.…
-
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in a $4.9 Billion Deal
•
In a multibillion-dollar deal within the biotechnology sector, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a leader in genetic disease treatment, has entered into an agreement to acquire Alpine Immune Sciences (NASDAQ: ALPN), a U.S.-based company specializing in protein engineering for immunotherapies. The transaction, valued at approximately USD 4.9 billion, is anticipated…
-
LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal
•
The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) has been suspended for review, following the withdrawal of the filing and sponsorship. The Beijing-based company, which specializes in the research and development (R&D), manufacturing, and marketing of medical cone-shaped beam…
-
STRATA Skin Sciences Renews Exclusive Distribution Deals in China and Japan
•
STRATA Skin Sciences Inc. (NASDAQ: SSKN), a U.S.-based dermatology and plastic surgery firm, has announced the renewal of exclusive distribution agreements with its two partners for the China and Japan markets. Each agreement spans three years and includes minimum unit placements and purchases for STRATA’s XTRAC and VTRAC devices. The…
-
Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation
•
France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics (NASDAQ: NRIX), a leader in targeted protein degradation, focusing on the drug target STAT6 for type 2 inflammation. The partners anticipate identifying a clinical candidate within the next year. As part of the collaboration, Nurix…
-
Genesis MedTech Secures Hundreds of Millions in Funding to Boost R&D and Manufacturing in China
•
Singapore-based medical device company Genesis MedTech has raised “hundreds of millions” of renminbi in a recent financing round co-led by Wuxi Capital Group and Wuxi Binhu Industrial Investment and Development, alongside a prominent U.S. medical device firm. The funding will support product research and development at its Wuxi facility, as…
-
Merck Sharp & Dohme Acquires Abceutics for Next-Generation ADC Technology
•
Global healthcare leader Merck, Sharp & Dohme (MSD) (NYSE: MRK) has secured a strategic acquisition of Abceutics, a preclinical biopharmaceutical startup focused on optimizing antibody-drug conjugates (ADCs). The financial details of the transaction remain undisclosed. Abceutics has developed a series of payload-binding selectivity enhancers (PBSEs) designed to increase the safety…
-
Bayer Partners with Google Cloud to Develop AI-Powered Medical Imaging Solutions
•
Germany’s pharmaceutical and life sciences giant Bayer (ETR: BAYN) has joined forces with US technology company Google Cloud (NASDAQ: GOOG) to develop artificial intelligence (AI) driven medical imaging solutions focused on radiology. This strategic collaboration aims to leverage patient data sets to create tools that alleviate the burden of repetitive…
-
Apeloa Pharmaceutical Partners with Heze Pharmaceutical for Semaglutide Biosimilar Development
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a prominent player in the Chinese pharmaceutical industry, has entered into a strategic partnership with Zhejiang Heze Pharmaceutical Technology Co., Ltd to co-develop a semaglutide biosimilar. While the financial terms of the agreement were not disclosed, the collaboration will encompass joint research and development…
-
Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline
•
Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the completion of a Series C+ financing round worth RMB 100 million ($13.8 million). The round was led by Oriza Holdings, with significant contributions from YZ Capital, JianSu Capital, Leader Venture Capital, and returning investor RealHarmony…
-
Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China
•
US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round, marking a significant step in the firm’s expansion plans into the Chinese market. The funding round, co-led by 3E Bioventures and Eight Roads, attracted substantial Chinese investment, highlighting the growing interest in innovative biotech solutions…
-
Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab
•
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent Technologies to co-develop Claudin18.2 companion diagnostic reagents, marking a significant step in the global development of osemitamab combined with nivolumab plus chemotherapy for first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ)…
-
Medicxi-Led Investment Boosts D3 Bio’s Development of Best- in-Class Oncology Therapies
•
UK life sciences investment firm Medicxi has taken the lead in a $62 million Series A+ funding round for D3 Bio, a China-based biotech company focused on developing innovative oncology drugs. The investment, in which Medicxi contributed $40 million, will support the advancement of D3 Bio’s pipeline, including three molecules…
-
Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates
•
German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life Sciences’ research unit, Caris Discovery, to uncover novel oncology targets and develop first-in-class antibody-drug conjugates (ADCs). The partnership aims to harness Caris’ precision medicine expertise and Merck’s ADC technology to accelerate the discovery and development…
-
Johnson & Johnson Acquires Shockwave Medical in a Landmark Deal to Expand Cardiovascular Portfolio
•
Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced the acquisition of Shockwave Medical (NASDAQ: SWAV), a specialist in cardiovascular diseases, in a deal valued at approximately USD 13.1 billion. The acquisition, which is expected to close by mid-year 2024, will bring Shockwave’s innovative technologies into J&J’s medical technology…
-
Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI) to introduce BI’s innovative cancer therapies to the mainland China market. Under the terms of the agreement, Sino Bio will provide support for the co-development and co-commercialization of several clinical-stage drugs, including brigimadlin, zongertinib, and…
-
Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space, has entered into a strategic partnership with Hangzhou Medical College to establish a graduate education base focused on biology and medicine. This collaboration aims to create a conducive environment for the next generation of medical…
-
Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation
•
Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass spectrometry and multi-omics, has successfully raised hundreds of millions of renminbi in a Series C financing round. The funding round was led by GF Xinde Investment, with participation from Sun Rock Capital. The capital raised…
-
Siemens Healthineers and Siemens China Partner with Fudan Hospital Logistic Service on Green Imaging Centers
•
Germany-based Siemens Healthineers AG, along with its subsidiary Siemens China, has entered into a strategic partnership with Fudan Hospital Logistic Service Co., Ltd. The collaboration aims to delve into product, technology, and service cooperation, with a focus on jointly creating innovative green imaging centers. Under the terms of the agreement,…
-
Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration
•
Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource Medicine Commercial Holdings Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co. Ltd. The partnership aims to expand and unite efforts to carry out in-depth cooperation in traditional medicine, innovative projects, patient management, internet healthcare,…
-
Genmab Acquires Profound Bio for $1.8 Billion, Targeting Expanding ADC Pipeline
•
Denmark-based biotech Genmab A/S (NASDAQ: GMAB) has announced a significant all-cash acquisition of Sino-US biotech Profound Bio, targeting its antibody drug conjugate (ADC) pipeline in a deal valued at $1.8 billion, set to close in the first half of 2024. The agreement has received approval from the boards of both…
-
Gilead Extends Collaboration with Nurix Therapeutics for Targeted Protein Degradation by Two Years
•
Gilead Sciences (NASDAQ: GILD) has announced a two-year extension of its 2019 collaboration with Nurix Therapeutics (NASDAQ: NRIX) focused on the discovery, development, and commercialization of targeted protein degradation therapies. As part of the agreement, Nurix will receive a USD 15 million extension fee for identifying novel agents that induce…
-
RemeGen Plans RMB 2.55 Billion Private Placement to Fund Innovative Drug Development
•
China-based RemeGen (HKG: 9995) has announced plans to raise RMB 2.55 billion (approximately USD 280.5 million) through a private placement. The funds will be directed towards supporting clinical studies and the development of innovative therapies, including candidates RC18, RC48, RC28, RC88, RC148, and RC198. With a robust product portfolio featuring…
-
Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production
•
Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen Pharmaceutical have entered into a comprehensive agreement with Swiss pharmaceutical giant Novartis. The agreement covers technology transfer, manufacturing, and clinical supply services for the co-developed therapy Carvykti (ciltacabtagene autoleucel; cilta-cel). As per the terms, Novartis…
-
China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases
•
China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement with US-based Incyte Pharmaceuticals Inc. (NSDQ: INCY), focusing on Incyte’s selective oral JAK1 inhibitor, povorcitinib. CMS has secured the exclusive rights to research, develop, file for regulatory approval, and commercialize the drug in Greater China,…
-
ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs
•
ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a Series B+ financing round. The initial phase of this funding round was co-led by the AZ-CICC Fund and another Wuxi-based fund, with participation from Wuxi Capital. The capital raised will be directed towards the construction…
-
Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries
•
Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost for key industries in the region. In the first quarter of 2024, a total of 420 major investment projects, each valued at over RMB 100 million (USD 13.8 million), were executed, culminating in a total…
-
Beijing’s Changping District and State-owned Capital Firm Launch RMB 20 Billion Healthcare Fund
•
The Changping district of Beijing municipality has reached an agreement with Beijing State-owned Capital Operation and Management Co., Ltd to establish a medical and healthcare industry fund worth RMB 20 billion (USD 2.77 billion). This Beijing-based fund will focus on pivotal sectors including innovative drugs, innovative medical devices, and emerging…
-
Gilead Strikes Deal with Xilio Therapeutics for Tumor-Activated IL-12 Candidate
•
Gilead Sciences (NASDAQ: GILD) has announced an in-licensing agreement with fellow US biotechnology company Xilio Therapeutics (NASDAQ: XLO) to acquire an early-stage tumor-activated interleukin 12 (IL-12) for the treatment of solid tumors. Gilead will pay an initial sum of USD 43.5 million for the exclusive development and global commercialization rights…
-
BeiGene and GenFleet Join Forces for DLBCL Trial Combining Brukinsa and GFH009
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotechnology company, has entered into a clinical research and drug supply cooperation agreement with fellow Chinese firm GenFleet Therapeutics. The partnership will kick off a Phase Ib/II clinical trial to evaluate the safety and efficacy of a combination regimen featuring…
-
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
•
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into separate partnerships with domestic companies Binhui Biopharmaceutical and Innoforce Pharmaceuticals Co., Ltd. In collaboration with Binhui, Medicilon aims to explore innovative areas including oncolytic viruses, nucleic acid drugs, and protein therapeutics. Meanwhile, the partnership with…
-
BeiGene Terminates Partnership with Shoreline Therapeutics for NK Cell Therapies
•
A close examination of BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) recent annual report has revealed that the company has terminated its earlier partnership with US biotech firm Shoreline Therapeutics Inc. The agreement, which was set to be effective from the first quarter of 2024, did not provide a specific…
-
Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced a strategic partnership aimed at the joint development of innovative adjuvant vaccine technologies. The collaborative project, headquartered in Shanghai, will see Recbio contribute its independently developed new adjuvant based on their proprietary adjuvant technology platform.…
-
Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai
•
Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the M Lab Collaboration Center in Shanghai, which is the largest among its global network of 10 such centers. This significant expansion represents an additional investment of EUR 14 million, resulting in the addition of a…
-
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China, has entered into a strategic agreement with UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) and the Daxing district government of Beijing. The collaboration is focused on the vaccine sector, aiming to introduce new vaccines to the…
-
AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline
•
AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company specializing in autoimmune diseases. The deal includes an upfront payment of USD 137.5 million plus a potential clinical milestone payment of USD 75 million, with the transaction expected to close in the second quarter of…
-
Shanghai Pharmaceuticals, SHC, and CEMCS CAS Renew Partnership to Incubate Pharmaceutical Innovations
•
Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in China, has renewed its partnership with Shanghai Healthcare Capital (SHC) and the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences (CEMCS, CAS). The trio initially agreed to establish an innovative…
-
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Deal Amid Biotech Pressures
•
U.S.-based biotech Nuvation Bio Inc. (NYSE: NUVB) has announced a definitive agreement to acquire China-based AnHeart Therapeutics Inc. in an all-stock transaction, which has received approval from the boards of both companies. The deal is contingent upon approval from AnHeart’s shareholders and is anticipated to close in the second quarter…
-
Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services
•
China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s Adventist Medical Center, aiming to leverage their combined resources and expertise to enhance medical services in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Under the terms of the agreement, both organizations will intensify collaboration in…
-
Biocytogen and ABL Bio Forge Partnership to Advance Bispecific ADC Development
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South Korea’s ABL Bio Inc. (KOSDAQ: 298380) to advance the development of bispecific antibody drug conjugates (ADCs). ABL Bio is a research-driven biotechnology firm recognized for its pioneering work in bispecific antibodies aimed at treating immuno-oncology…
-
HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups
•
China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science and biotechnology startup incubation platform; BioLabs, an international network of membership-based shared laboratory and office spaces; and MBC BioLabs, a provider of shared laboratory facilities. Recognized as a leader in DNA-encoded library (DEL) technology and…
-
Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio
•
Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a leading expert in RNA biology focused on the prevention, repair, and reversal of cardiovascular diseases (CVDs). The deal, valued at EUR 1.025 billion, which includes upfront and milestone payments, is anticipated to finalize in the…
-
Novo Nordisk Expands Benzalkonium Chloride Distribution with Actylis Across Europe
•
Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with U.S. raw materials supplier Actylis. The agreement facilitates the distribution of Novo’s benzalkonium chloride (BKC) in Germany, Ireland, Spain, Portugal, and the UK, expanding upon an existing deal for North American markets. Benzalkonium chloride is…
-
OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in gene therapy, has entered into a strategic partnership with Shanghai Saierxin Biomedical Technology Co., Ltd. Under the terms of the agreement, OBiO will offer non-registered clinical trial sample preparation and testing services for Saierxin Bio’s…
-
Zhejiang Dian Diagnostics Partners with Haihe Laboratory to Advance Hematology Diagnostics
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a company based in China, has entered into a strategic partnership with the Haihe Laboratory of Cell Ecosystem under the China Academy of Medical Sciences. The collaboration aims to drive research translation, standardize disease diagnosis and treatment, advance digital healthcare, and enhance discipline…
-
Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments
•
Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China, has reportedly secured “hundreds of millions” of renminbi in a Series D financing round. The round was led by ZhongPing Capital, with participation from Shanghai Healthcare Capital, Dingxin Capital, and Morning Spring Venture. The funds…
-
Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a significant licensing agreement with German healthcare giant Bayer. Under the terms of this agreement, Joincare has obtained development, commercialization, and manufacturing rights to Bayer’s small-molecule inhibitor in the respiratory field within China. The financial specifics…
-
AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China
•
AriBio Co., Ltd, a South Korea-based pharmaceutical company, has announced an expansion of its previous licensing agreement with Samjin Pharmaceutical (KRX: 005500) to include the China market for its Alzheimer’s disease drug candidate, AR1001. The new deal, which grants exclusive marketing rights to the drug in China, is valued at…
-
Sino Biological Partners with Rapid Novor to Market mAb Sequencing Services Across Asia
•
Sino Biological Inc. (SHE: 301047), a leading supplier of reagents based in China, has announced a partnership with Canada-based Rapid Novor Inc. Under the terms of the agreement, Sino Biological will market select services from Rapid Novor across multiple Asian markets, including China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, the Philippines,…
-
Astra Biotech Raises Tens of Millions in Pre-Series B Funding to Expand Diagnostic Capabilities
•
Astra Biotech, a developer of single molecule immunodiagnostic technology based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series B financing round. The round was led by Zheng Xuan Investment, with participation from BioTrack Capital, Chuangshou Equity Investment, and others. The funds will be utilized to…
-
Horimed Secures Tens of Millions in Financing to Advance OCT Imaging Technologies
•
Horimed, a Tianjin-based manufacturer of OCT imaging equipment, has reportedly raised “tens of millions” of renminbi in a recent financing round. The round was led by existing investor Tasly Capital, with contributions from Haihe Fund and Haitai Capital. The proceeds will be allocated to research and development, manufacturing, regulatory filings,…
-
Beijing Varnotech Biopharm Secures RMB 600 Million in Series B Funding for Vaccine Development
•
Beijing Varnotech Biopharm Ltd, a China-based specialist in human vaccines, has successfully raised RMB 600 million (approximately USD 83 million) in a Series B financing round. The round was co-led by the Beijing Medical and Health Industry Investment Fund and Huayin Financial Investment, with additional contributions from Watere Capital, Beijing…
-
PoreSpect Secures Tens of Millions in Angel Funding Led by Forcefield Ventures
•
PoreSpect, a Guangdong-based manufacturer of devices and consumables, has reportedly secured “tens of millions” of renminbi in an angel financing round. The funding was led by Forcefield Ventures, with additional contributions from Tiantu Capital and Yael Capital. Founded by a team of pioneers in solid-state nanopore preparation and detection, PoreSpect…
-
Baidu Health Partners with Yibang to Enhance Operations for Brick-and-Mortar Pharmacies
•
Baidu Health has entered into a strategic partnership with Shanghai Yibang Medicine Information Technology Co., Ltd., aiming to leverage Baidu’s extensive capabilities in search, mapping, health, artificial intelligence, and e-commerce to enhance operations for brick-and-mortar pharmacies across China. Financial terms of the agreement were not disclosed. The collaboration will focus…
-
Edan Instruments Partners with Global Health Labs to Develop AI-Enhanced Handheld Ultrasound
•
Shenzhen-based Edan Instruments Inc. has forged a strategic partnership with Global Health Labs Inc. to collaboratively develop an AI-driven, cost-effective handheld ultrasound device, leveraging their combined expertise and cutting-edge technology resources. This alliance aims to innovate handheld ultrasound technology by integrating artificial intelligence, making it accessible and affordable for grassroots…
-
Sinopharm and Fresenius Kabi Expand Partnership to Enhance Drug Distribution and Healthcare Services
•
China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s Fresenius Kabi, enhancing collaboration across various sectors including drug sales, warehousing and distribution, as well as big health, medical care, and wellness. Financial details of the agreement were not disclosed. This partnership marks a continuation…
-
Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology
•
Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader Thermo Fisher Scientific (NYSE: TMO) to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) aimed at enhancing precision cancer therapies. Financial terms of the collaboration remain undisclosed. According to the press release, the diagnostic tests…
-
China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA
•
China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton, Dickinson and Co. (BD) to develop a specialized channel for drugs and medical devices in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Under this partnership, China Resources Guangdong Pharmaceutical will capitalize on its strengths to…
-
VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology
•
VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a licensing agreement with Swiss Contract Manufacturing Organization (CMO) Lonza, securing access to Lonza’s innovative bYlok bispecific pairing technology. Financial terms of the agreement were not disclosed. Lonza’s bYlok technology addresses the prevalent industry challenge of…
-
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
•
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo’s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines,…
-
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Kunshi Biotechnology (Shenzhen) Co., Ltd. The collaboration aims to expedite the Investigational New Drug (IND) filing for Kunshi’s drug candidate RR-M01, marking a significant step forward in the development of third-generation…
-
Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation
•
Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has announced a strategic merger with Silver Mars, a Suzhou-based high-tech firm specializing in bionic materials. The merged entity falls under the umbrella of YinKe Holding, a technology conglomerate with a focus on the healthcare sector.…
-
AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion
•
AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion Pharmaceuticals (NASDAQ: FUSN), a Canada-based developer of radioconjugate (RC) therapies, in a deal valued at up to USD 2.4 billion, including upfront and potential contingent value payments. The acquisition is expected to be finalized in…
-
Bio-Thera Solutions and SteinCares Ink Licensing Deal for LatAm Biosimilar Distribution
•
Bio-Thera Solutions (SHA: 688177), a Chinese biopharmaceutical company, has entered into a licensing agreement with SteinCares, a Costa Rican healthcare provider. Under the terms of the deal, SteinCares will obtain exclusive rights to distribute and market two of Bio-Thera’s biosimilars across Brazil and the Latin America (LatAm) region. The financial…
-
C&Y Pharmaceutical Teams Up with GigaCeuticals to Form AI-Driven Drug Development JV
•
Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254), a Chinese pharmaceutical company, is venturing into a joint venture (JV) with Beijing-based AI-driven drug developer GigaCeuticals. The new JV, valued at RMB 120 million (USD 16.7 million), aims to collaborate on the research and development, industrialization, and commercialization of innovative drugs…
-
uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors
•
uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU) Wisdom Lake Academy of Pharmacy to develop innovative chimeric antigen receptor natural killer (CAR-NK) cell therapies. The collaboration aims to advance the field of immunotherapy by creating two distinct types of CAR-NK cell treatments. The…
-
Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia
•
Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license agreement with Sosei Group Corporation (TSE: 4565), a Japanese firm. This strategic partnership aims to develop and commercialize Sosei Heptares’ portfolio of first-in-class GPR52 agonists, targeting a novel G protein-coupled receptor (GPCR) to address the…
-
Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080
•
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has announced a licensing agreement with domestic firm Biotheus. Under the terms of the agreement, Hansoh will secure exclusive global rights to develop, manufacture, and commercialize Biotheus’s bispecific antibody (BsAb) HS-20117/PM1080, along with sub-license rights. The…
-
Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices
•
Microenergy Medical Technology Co., Ltd, a Hangzhou-based manufacturer of active intervention medical devices, has reportedly secured “tens of millions” of renminbi in a pre-Series A financing round. The funding was led by TigerYeah Capital, with contributions from TriWise Capital and HUAGAI Capital. Established in 2021, Microenergy Medtech has a presence…
-
Getein Biotech Partners with Dymind Biotechnology to Advance IVD Market Presence
•
Getein Biotech Inc., (SHA: 603387), a company based in China with a focus on in vitro diagnostic (IVD) solutions, has entered into a strategic partnership with Dymind Biotechnology Co., Ltd. Both firms are dedicated to the IVD sector, and this collaboration aims to enhance resource sharing and capitalize on their…
-
CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development
•
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into a strategic partnership with Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a Contract Development and Manufacturing Organization (CDMO). This collaboration is designed to drive the development of cutting-edge technologies that align with market demands. The…
-
AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline
•
AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt Pharma for an upfront payment of $800 million, with an additional potential milestone payment of $250 million. The transaction is anticipated to close by the third quarter of 2024, pending customary regulatory approvals. Amolyt Pharma…
-
Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy
•
Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo Nordisk’s controlling shareholder, Novo Holdings, have participated in a EUR 30 million (USD 32.6 million) Series A financing round for Sweden-based Asgard Therapeutics. Asgard Therapeutics specializes in in in vivo cell reprogramming for cancer immunotherapy,…
-
Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia
•
Swire Pacific, a Hong Kong-based conglomerate, is gearing up to focus on healthcare investments in China and Indonesia, according to its 2023 annual report. This strategic shift follows a record year for the firm, which saw underlying profits reach HKD 36.2 billion (USD 4.63 billion). In March, Swire reached an…
-
Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline
•
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a subsidiary of US biopharmaceutical company IFM Therapeutics, for an upfront payment of $90 million, with potential milestone payments totaling up to $745 million. This acquisition builds on a 2019 agreement in which Novartis financed IFM…
-
Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development
•
Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a strategic partnership with SPH RD, a wholly owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607, HKG: 2607). This collaboration aims to leverage BDgene’s advanced carrier technology and gene therapy R&D achievements alongside SPH…
-
BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery
•
BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou Biopharmaceuticals Co., Ltd. The collaboration aims to harness their combined expertise in generative AI technology for target discovery, with the goal of developing IND-stage drugs and creating an advanced AIGC-driven antibody drug discovery platform. The…
-
Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish a RMB 5 billion (USD 695 million) fund in collaboration with seven other investors, with Shenzhen FOF expected to contribute 50% of the total funding. The initiative aims to enhance resource sharing and cooperation between…
-
MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl Bio, a synthetic biology company, to leverage Pearl’s genomically recoded organisms (GROs) platform. This platform is designed for the discovery and development of biologic molecules that incorporate non-standard amino acids, enabling the targeting of previously…
-
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ: IDYA), a US-based biotechnology company, to clinically develop the combination of MSD’s top-selling anti-PD-1 therapy Keytruda (pembrolizumab) with IDEAYA’s potential first-in-class poly (ADP-ribose) glycohydrolase (PARG) inhibitor IDE161. The collaboration focuses on treating microsatellite instability-high (MSI-high)…
-
VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions
•
VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership with Minaris Regenerative Medicine, a cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Japan-headquartered Showa Denko Materials Co., Ltd. This collaboration aims to integrate VectorBuilder’s superior R&D and…
-
Kexing Pharmaceutical Secures Rights for Chia Tai Tianqing’s Generic Ibrance in 11 Countries
•
Kexing Pharmaceutical (SHA: 688136), based in China, has entered into an international collaboration agreement with fellow Chinese firm Chia Tai Tianqing, securing commercialization rights for Chia Tai’s generic version of Pfizer’s Ibrance (palbociclib). This agreement encompasses an initial batch of 11 countries. Palbociclib, recognized as the world’s first CDK4/6 inhibitor,…
-
Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline
•
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an initial public offering (IPO) of 12,046,400 shares on the Hong Kong Stock Exchange, with a pricing range set between HKD 19.8 and HKD 20.2 per share. The company anticipates raising between HKD 239 million and…
-
Gilead Nears Completion of CymaBay Acquisition After Waiting Period Expires
•
Gilead Sciences (NASDAQ: GILD) has moved one step closer to finalizing its cash tender offer for the acquisition of fellow US company CymaBay Therapeutics (NASDAQ: CBAY), following the expiration of a mandatory waiting period under local laws last week. The two companies had previously submitted regulatory filings for approval of…
-
Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal
•
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has officially activated its licensing and cooperation agreement with U.S. pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) for the development of Biokin’s BL-B01D1 antibody-drug conjugate (ADC) candidate, effective February 8, 2024. As of March 7, the company confirmed receipt of the USD 800…
-
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
•
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised RMB 200 million (approximately USD 27.8 million) in a Series A+ financing round. The round was led by Youshan Capital, with participation from SIP Oriza Seed Fund, PagodaTree Partners, and Triwise. The company’s pipeline features…
-
Shandong Luoxin Pharmaceutical Partners with Xbiome to Access Microbiome Transplantation Technology
•
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a pharmaceutical company based in China, has entered into a strategic partnership with Xbiome, a compatriot firm specializing in AI-based microbiome drug development. This collaboration grants Luoxin access to Xbiome’s advanced intestinal microbiota transplantation medical technology, marking a significant step in…
-
Everest Medicines to Establish Integrated Kidney Disease Diagnosis and Treatment Ecosystem
•
Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to create an innovative and integrated ecosystem focused on the diagnosis and treatment of kidney diseases. The company anticipates the imminent launch of a commercially valuable IgA kidney disease detection reagent, offering nephrologists and patients effective…
-
Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio
•
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices, has announced a series of licensing and investment agreements with U.S. device manufacturer Avinger. The partnership aims to expand Zylox-Tonbridge’s portfolio of peripheral vascular intervention devices. According to the agreement, Zylox-Tonbridge will secure exclusive rights…
-
BeiGene Subsidiary Pi Health Cayman to be Merged in Deal Valued at $41.8 Million
•
BeiGene (NASDAQ: BGNE) has announced that Delaware-based Pi Health Inc. is set to absorb and merge its wholly-owned subsidiary Pi Health Cayman at a mutually agreed valuation of USD 41.8 million. Following the merger, BeiGene will directly hold the corresponding equity in Pi Health. Concurrently, Pi Health plans to bring…
-
Proviva Therapeutics Secures $18 Million in Series A Financing to Advance PTX-912
•
Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a Series A financing round led by Lapam Capital, Ennovation Ventures, and Sangel Capital. The funds raised will be directed towards the clinical advancement of the company’s core product, PTX-912. Specializing in the development of next-generation…
-
Gilead and Merus Form Strategic Oncology Alliance to Develop Trispecific T-Cell Engagers
•
Gilead Sciences Inc., (NASDAQ: GILD), has entered into a strategic partnership with Netherlands-based Merus N.V. (NASDAQ: MRUS) to discover two to three trispecific T-cell engagers in the field of oncology. Merus is set to receive an upfront payment of $56 million, an equity investment worth $25 million, and is eligible…
-
Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment
•
Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary Zhaoke Ophthalmology Ltd. (HKG: 6622) a distribution and supply agreement with Malaysian pharmaceutical corporation Pharmaniaga. The agreement pertains to Zhaoke’s generic version of AbbVie’s Ganfort, a combination of bimatoprost and timolol maleate eye drops used…
-
Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech. The collaboration aims to establish an antibody drug conjugate (ADC) platform that offers a range of diversified antibodies, highly active small molecule payloads, and linker technology. The…
-
ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine
•
Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has entered into a partnership with CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company specializing in treatments for cardiovascular and cerebrovascular diseases and endocrine disorders. Under this strategic alliance, ClouDr will serve as the general agent…
-
MGI Tech Lands Eurofins Genomics Deal for T20 Ultra-High Throughput Sequencer in Europe
•
MGI Tech (SHA: 688114), a China-based sequencing company, has announced a significant collaboration with Eurofins Genomics Europe Genotyping A/S, headquartered in France. As part of the deal, Eurofins has placed a corporate order for MGI’s DNBSEQ-T20×2 (T20) ultra-high throughput sequencer, which is accompanied by the genomics data center ZTRON Appliance,…
-
Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases
•
California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement with China’s Biotheus Inc. The partnership aims to explore the development of innovative drugs that modulate the immune system and inflammatory responses, with a specific focus on targeting cardiovascular diseases (CVDs). By combining Bitterroot’s knowledge…
-
Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics
•
Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore arbitration court in a dispute with Canada’s Antibe Therapeutics (OTCMKTS: ATBPF). The arbitration centered on a February 2021 agreement where Nuance acquired development and commercial rights for Antibe’s otenaproxesul (ATB-346), an innovative pain relief drug…
-
Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion
•
Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and backed by the Chinese Academy of Sciences (CAS), has reportedly secured over RMB 100 million (USD 14.5 million) in strategic financing. The round was reportedly supported by Sinowisdom, Guangzhou Industrial Investment Fund, and Speedfox. The…
-
Merck Teams Up with C4 Therapeutics for Targeted Protein Degraders in Oncology
•
Merck (NYSE: MRK), a Germany-headquartered science and technology company, has entered into a partnership with C4 Therapeutics (NASDAQ: CCCC), a U.S.-based protein degradation, to discover two targeted protein degraders aimed at oncogenic proteins of interest. Merck will be responsible for funding the research expenses of the programs and has agreed…
-
Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms
•
Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the cell and gene therapy (CGT) sector, has reportedly secured RMB 100 million (USD 14.5 million) in a Series B financing round. The round was led by Dalton Venture, with additional investment from Qikun Fund and…
-
ArkBio Partners with SDODT to Boost ADHD Treatment Marketing and Commercialization
•
Shanghai Ark Biopharmaceutical Co., Ltd (ArkBio), a Chinese biopharmaceutical company, has entered into a partnership with SDODT, a domestic innovator in digital therapeutics technology. The collaboration aims to enhance the marketing and commercialization efforts for products targeting Attention Deficit Hyperactivity Disorder (ADHD) treatment. ADHD is a prevalent chronic neurodevelopmental disorder…
-
Beijing Tinavi Medical Technologies to Form Radiotherapy Equipment JV with IM INNO and Celestial Oncology
•
Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has announced its intention to establish a joint venture (JV) with IM INNO and Celestial Oncology Inc. The new entity is to be capitalized with RMB 30.7 million (USD 4.4 million) for registration purposes. The joint venture is intended to concentrate its…
-
Haihe Pharmaceuticals Licenses Glumetinib to Taiho for Exclusive Development in Japan and Asia
•
Shanghai Haihe Pharmaceutical Co., Ltd has entered into a licensing agreement with Taiho Pharmaceutical Co., Ltd, granting the Japanese company exclusive rights to develop, manufacture, and commercialize glumetinib, a MET-targeted tyrosine kinase inhibitor (TKI), in Japan and other Asian countries (excluding China) and Oceania. Haihe has already submitted a market…
-
CANbridge Pharmaceuticals Partners with Peking Union Medical College to Advance Rare Disease Research
•
CANbridge Pharmaceuticals Inc. (HKG: 1228), a specialist in rare diseases based in China, has announced a partnership with Peking Union Medical College Hospital to collaborate on an innovative study spanning drug discovery to clinical translation for rare diseases. The partnership aims to establish a rare disease innovation development platform focused…
-
Takeda Partners with Biological E to Boost Production of Dengue Vaccine QDenga
•
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based Biological E (BE) with the aim of increasing production capacity for its dengue tetravalent vaccine, QDenga. This strategic partnership is part of Takeda’s broader plan to manufacture 100 million doses of the vaccine annually. QDenga,…
-
Viatris Secures Late-Stage Programs from Idorsia with Potential for Future Asset Additions
•
US pharmaceutical company Viatris (NASDAQ: VTRS) has entered into a licensing agreement with Swiss drugmaker Idorsia (SWX: IDIA), in-licensing two late-stage programs with the option to add two more innovative assets in the future. Viatris will pay Idorsia an upfront fee of USD 350 million, along with potential milestone payments…
-
Angitia Bio Secures USD 40 Million in Series B+ Financing to Advance Musculoskeletal Disorder Therapies
•
Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced the successful completion of a Series B+ phase II financing round, securing USD 40 million in funds. The round was led by YueKai Health Venture, with the proceeds earmarked to propel the global development of…
-
BMS Taps into Circular RNA Potential with Shanghai Circode Bio Agreement
•
Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) to investigate the application feasibility of circular RNA technology within a specific therapeutic area. This collaboration aims to capitalize on Circode Bio’s proprietary circular RNA technology platform and BMS’s extensive…
-
AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230
•
AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE) to develop the potential first-in-class immunotherapy OSE-230, which is currently in the pre-clinical stage for the treatment of chronic and severe inflammation. Under the terms of the agreement, AbbVie will acquire exclusive global rights to…
-
Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies
•
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced an antibody drug conjugate (ADC) discovery cooperation agreement with South Korea-based ADC specialist Boostimmune, Inc. The financial details of the agreement have not been disclosed. As per the terms…
-
Shanghai Fosun Pharmaceutical Partners with Nanning City to Broaden Collaboration in Biopharma and Beyond
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196，HKG: 2196), a Chinese pharmaceutical heavyweight, has entered into a strategic partnership with Nanning City in Guangxi province, China’s gateway to the ASEAN region. The collaboration aims to explore opportunities in biopharmaceuticals, intelligent manufacturing, finance and insurance, commerce, culture, tourism, and other sectors.…
-
Novo Nordisk Partners with Neomorph to Target Undruggable Diseases with Molecular Glue Degraders
•
Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has entered into a partnership with US-based Neomorph to discover, develop, and commercialize molecular glue degraders targeting specific indications in cardiometabolic and rare diseases. Neomorph will be responsible for the discovery and pre-clinical development of the candidates, for which it will receive up…
-
Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development
•
Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company’s market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800…
-
Kelun-Biotech Launches Clinical Trials for SKB264, Triggering $75 Million Milestone Payment from MSD
•
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) has announced the initiation of clinical trials for SKB264 (MK-2870), an antibody-drug conjugate (ADC) co-developed with Merck, Sharp & Dohme (MSD, NYSE: MRK) for the treatment of non-small cell lung cancer (NSCLC) and endometrial carcinoma (EC). This development triggers a clinical milestone payment…
-
b-ONE Ortho Partners with THINK Surgical to Expand MOBIO Knee System in U.S. Market
•
b-ONE Ortho Corp., a developer of artificial joint replacements with operations in the U.S. and China, has entered into a partnership with U.S.-based THINK Surgical to advance the market for its MOBIO total knee joint system alongside THINK’s orthopedic surgical robots in the United States. The MOBIO system, known for…
-
CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System
•
CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a regulatory study for its 7.5F 2D intracardiac ultrasound imaging system (ICE), successfully enrolling dozens of patients. This ultrasound catheter model is smaller than any currently marketed ICE products globally, nearing the industry’s design limits. The…
-
Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal
•
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation agreement with Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), securing exclusive commercialization rights for Austedo (deutetrabenazine) in mainland China. Austedo, a vesicle monoamine transporter 2 (VMAT2) inhibitor, received its initial approval in the U.S. in 2017…
-
Tencent Hands Over Two Former CSIG Employees to Authorities on Embezzlement Allegations
•
Chinese internet conglomerate Tencent has announced via its anti-fraud department’s official channel that former employees Zhang Meng and Liu Yunting from the Cloud and Smart Industries Group (CSIG) have been handed over to public security authorities. The two are suspected of misusing their positions to embezzle company assets and to…
-
Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries
•
China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic firm Yabao Pharmaceutical Group Co., Ltd. (SHA: 600351) to distribute a generic version of Bayer (ETR: BAYN)’s Nexavar (sorafenib). Under this agreement, Kexing will serve as the exclusive agent for the tyrosine kinase inhibitor (TKI)…
-
Mabwell Bioscience Cancels Licensing Agreements with Yangtze River Pharma for Two Drug Candidates
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced the cancellation of licensing agreements with Yangtze River Pharmaceutical Group for two of its drug candidates: 8MW0511, a recombinant (yeast secreted) human serum albumin human granulocyte colony-stimulating factor (I) fusion protein for injection, and 9MW1111,…
-
Boehringer-Ingelheim Partners with CBmed to Accelerate First-in-Class Cancer Medicines Development
•
Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed GmbH Center for Biomarker Research in Medicine (CBmed). The collaboration aims to leverage translational medicine approaches to expedite the development of first-in-class oncology drugs, with the ultimate goal of transforming the lives of cancer patients…
-
Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal
•
China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing…
-
AstraZeneca Secures Shareholder Approval for $1 Billion Acquisition of Gracell Biotechnologies
•
The proposed acquisition of China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) by UK pharmaceuticals giant AstraZeneca (AZ, NASDAQ: AZN) has received approval from Gracell’s shareholders during an extraordinary general meeting held on February 19, 2024. An overwhelming 99.9% of shareholders voted in favor of AstraZeneca’s $1 billion acquisition, with potential total…
-
HitGen’s Vernalis Partners with Hox Therapeutics to Develop Novel Cancer Inhibitors
•
HitGen Inc. (SHA: 688222), based in China, announced that its wholly owned subsidiary Vernalis (R&D) Ltd will collaborate with Hox Therapeutics Ltd, a private biotech firm dedicated to developing highly targeted cancer therapies, to create inhibitors aimed at undisclosed targets. Vernalis will leverage its advanced protein science capabilities and Hit…
-
Immune-Onc Therapeutics Partners with Roche for Phase Ib/II Study of IO-108 in Liver Cancer
•
Immune-Onc Therapeutics Inc., based in the U.S., is entering into a collaboration with Roche (SWX: ROG) to conduct a Phase Ib/II clinical study evaluating its LILRB2 (ILT4) monoclonal antibody (mAb) IO-108 in combination with Roche’s PD-L1 mAb atezolizumab and VEGF mAb bevacizumab. This study aims to target first-line localized advanced,…
-
Innovent Biologics Partners with ImmVirX to Launch Clinical Study Combining Tyvyt and IVX037
•
Innovent Biologics Inc. (HKG: 1801), based in China, has announced the signing of a clinical study and supply cooperation agreement with ImmVirX Pty Ltd. This strategic partnership will facilitate a clinical study that combines Innovent’s Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor already approved in China for seven different indications,…
-
Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion
•
Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in China, has successfully raised over RMB 300 million (approximately USD 41.7 million) in a Series B+ financing round. The funding was led by Yuexiu Capital, with notable participation from Fortune Capital, Guangdong Technology Financial Group,…
-
BMS and Sichuan Biokin Commence Joint Development of EGFR/HER3-Targeted ADC
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced that a licensing and cooperation agreement with US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has officially come into effect as of February 8, 2024, following the expiration of the waiting period for the deal. The agreement…
-
Everest Medicines Terminates Agreement with Providence Therapeutics, Retains mRNA Rights
•
Everest Medicines (HKG: 1952), a biopharmaceutical company based in China, has announced the termination of a cooperation and licensing agreement with Providence Therapeutics (PTx), a Canadian RNA medicines company. Following the termination, Everest Medicines will independently continue the development of preventative and therapeutic mRNA products using the mRNA platform, holding…
-
Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody evaluation and option agreement with Gilead Sciences, Inc. This deal grants the US pharmaceutical major access to Biocytogen’s comprehensive fully human antibody library, which has been developed against a broad spectrum of therapeutic targets. Over…
-
Sinovent Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization
•
Sinovent Inc., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital,…
-
Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies
•
Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with U.S.-based biotech company Kelonia Therapeutics. The partnership, established through Astellas’ subsidiary Xyphos Biosciences, will leverage Kelonia’s proprietary in vivo gene placement system (iGPS) to engineer advanced lentiviral particles for targeted genetic delivery, in conjunction with…
-
Akeso Biopharma to Acquire 35% Stake in AD Pharmaceuticals for RMB 267 Million
•
Akeso Biopharma (HKG: 9926) is poised to acquire a 35% stake in AD Pharmaceuticals Co., Ltd., a joint venture with Dawnrays Pharmaceutical (HKG: 2348), for a total consideration of RMB 267 million (USD 37.5 million). Upon completion of the transaction, AD Pharmaceuticals will become a wholly-owned subsidiary of Akeso. AD…
-
I-Mab to Become U.S.-Based Biotech, Divesting All China Assets for Up to $80 Million
•
I-Mab (NASDAQ: IMAB), a biotech company transitioning to a U.S.-based entity, has announced plans to divest all its assets in China. The company has entered into agreements with I-Mab Biopharma (Hangzhou) Co., Ltd and a consortium of Chinese investors to sell its operations in China, including its remaining equity interest…
-
AbbVie Expands Licensing Agreement for Innovative sCAR-T Platform with Scripps Research
•
AbbVie (NYSE: ABBV) has expanded its collaboration with Scripps Research’s Calibr-Skaggs Institute, securing licensing rights to the institute’s investigational switchable CAR-T (sCAR-T) platform, which has shown promising early-stage results. The agreement entails an upfront payment, along with potential milestone payments and royalties, allowing AbbVie to access the program for up…
-
Yantai Dongcheng Acquires Full Rights to Alfatide II, Targeting Diagnostic and Therapeutic Applications
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its acquisition of all rights to alfatide II across all diagnostic and therapeutic fields and indications. Alfatide II, initially developed by Dr. Chen Xiaoyuan and previously licensed to Jiangsu Xinrui Pharmaceutical Co., Ltd. for further development, is currently in the…
-
Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion
•
Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical firm MorphoSys (FSE: MOR; NASDAQ: MOR) for €2.7 billion. The transaction is anticipated to finalize in the first half of 2024, pending the fulfillment of customary conditions. By acquiring MorphoSys, Novartis aims to incorporate two…
-
Bayer Partners with TetraScience to Enhance Data Management in Product Development
•
Germany-based Bayer (ETR: BAYN) has announced a partnership with data management firm TetraScience to collect and process cloud-based scientific data, facilitating enhanced insights for its researchers in product development across various sectors, including cell and gene therapy, biopharma, and crop sciences. This collaboration is a key component of Bayer’s digital…
-
Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical
•
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development (R&D) collaboration and licensing agreement with fellow domestic entity Affinity Biopharmaceutical Co., Ltd. Under the terms of the agreement, Affinity grants Anglikang exclusive rights for R&D, manufacturing, and commercialization of QHL-1618, a fully water-soluble small-molecule…
-
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
•
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive agreement to acquire contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) for $16.5 billion. The transaction is expected to be finalized by the end of the year, pending customary regulatory conditions. This acquisition comes…
-
Jiangsu Wuzhong Pharmaceutical Partners with SPH KDL Health to Boost Aesthetics Product AestheFill
•
Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a leading Chinese pharmaceutical company, has announced a strategic partnership agreement with domestic firm SPH KDL Health. The collaboration aims to enhance the marketing efforts of Wuzhong Pharmaceutical’s medical aesthetics subsidiary’s polylactic acid facial filler, AestheFill. The partnership encompasses commercial distribution, expansion of…
-
Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea
•
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with South Korean firm Myung In Pharm. Under the agreement, Myung In Pharm has been granted commercialization rights to Luye’s rivastigmine twice-weekly transdermal patch (LY03013) in South Korea. The drug is indicated for the treatment of…
-
Abbisko Therapeutics Secures $70 Million Upfront Payment in Licensing Deal with Merck KGaA
•
Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has declared the successful conclusion of the initial phase of a licensing agreement with Merck KGaA, concerning its proprietary colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). As part of this agreement, Abbisko has received an upfront payment of USD 70…
-
Baidu Health Partners with Souyao to Boost Offline Pharmacy Services in China
•
Baidu Health has entered into a partnership with Beijing-based pharmaceutical business service provider Souyao. The collaboration will capitalize on Baidu’s resource advantages in areas such as search engines, map navigation, health services, artificial intelligence (AI), and e-commerce to offer comprehensive technical and operational services for brick-and-mortar pharmacies. The goal is…
-
Johnson & Johnson’s Kenvue Partners with Tencent for Integrated Health Services in China
•
Johnson & Johnson (J&J, NYSE: JNJ)’s consumer health spinoff Kenvue and its Chinese partner Tencent have announced an updated strategic partnership aimed at accelerating digital transformation in the healthcare sector. The collaboration will focus on the joint development of integrated online and offline health education and service solutions for patients…
-
Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004
•
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that Sino-US biotech Inmagene Biopharmaceuticals has exercised its option to license two drug candidates discovered by HutchMed, IMG-007 and IMG-004, under the terms of a strategic partnership signed on January 11, 2021. Upon the exercise of these options and subject to…
-
Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics
•
Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in China, has reportedly secured “hundreds of millions” of renminbi in a Series C+ financing round. The investment was led by a state-owned fund in Yuhang, Zhejiang province, and other undisclosed participants. The funds raised will…
-
China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with fellow Chinese firm WinHealth Investment (HK) Ltd concerning Velphoro (sucroferric oxyhydroxide). Initially, CMS entered into a licensing agreement with WinHealth in June of the previous year, which granted WinHealth exclusive rights for regulatory filing, import,…
-
Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion
•
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S. origins, has confirmed speculation in the market by announcing its intention to spin off its Active Pharmaceutical Ingredient (API) division, TAPI. This strategic move is part of Teva’s ‘pivot to growth’ initiative, aiming to streamline…
-
Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development
•
Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan University Shanghai Cancer Center to intensify their collaboration on clinical trials for innovative drugs. The agreement leverages Chia Tai Tianqing’s comprehensive industrial chain strength in scientific and technological innovation and the Shanghai Cancer Center’s leading…
-
Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology firm Graviton Bioscience, securing a right of first negotiation for Graviton’s clinical-stage ROCK2 inhibitor candidates in immunological and metabolic syndrome indications. Graviton’s lead program, GV101, is a potential best-in-class ROCK2 inhibitor capable of crossing the…
-
HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development
•
HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug Delivery Co., Ltd through its subsidiary, Sichuan Xiandong Pharmaceutical Co., Ltd. This alliance is aimed at the research and development (R&D) and manufacturing of nucleic acid drugs, marking a significant step forward in the field…
-
Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments
•
Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan University Shanghai Cancer Center, signaling a continuation of their strategic partnership. The two entities have committed to an extensive collaboration in scientific research, platform development, and other key areas, with a particular focus on advancing…
-
Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally
•
Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the successful closure of a Series A++ financing round worth USD 10 million. The round was led by Med-Fine Capital, with participation from Puhua Leading Investment. The funds raised will be allocated towards the global promotion…
-
Junde Pharmaceuticals Licenses Weight-Reducing Capsule JTX-102 to Changchun GeneScience
•
Xiamen Junde Pharmaceutical Technology Co., Ltd., a China-based pharmaceutical company, has entered into a licensing agreement with Changchun GeneScience Pharmaceutical Co., Ltd., granting the latter exclusive commercialization rights for JTX-102, a gastric volume-occupying and weight-reducing capsule, across China, including mainland China, Hong Kong, and Macau. Under the terms of the…
-
Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens
•
Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is…
-
Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the signing of an authorized agency and technical transfer cooperation agreement with a company based in Bangladesh. The undisclosed Bangladeshi company will collaborate with Kangtai Bio on the 23-valent pneumococcal polysaccharide vaccine semi-finished stock solution. The…
-
Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China
•
Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation agreement with Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd, granting the latter exclusive market promotion rights for its recombinant human thyroid stimulating hormone (rhTSH) in the thyroid and breast surgery markets within China. The financial…
-
MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies
•
MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with Shanghai Henlius Biotech Inc. (HKG: 2696), a fellow Chinese firm, to co-develop AI-driven antibody drug conjugate (ADC) and anti-aging therapy platforms. This alliance combines Henlius’s comprehensive biopharmaceutical platform, specialized in antibody and Linker Payload technologies,…
-
Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse
•
Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered into a strategic partnership with the College of Radiology at Shandong First Medical University. The collaboration aims to encompass several key initiatives: The duo will jointly construct China’s inaugural “Medical Imaging Metaverse Immersive Teaching and…
-
WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has entered into a strategic partnership with Shanghai-based antibody drug conjugate (ADC) specialist, Multitude Therapeutics. Additionally, WuXi XDC has signed a memorandum of understanding (MOU) with…
-
Regeneron Pharmaceuticals Acquires 2seventy Bio to Boost Cell Therapy Capabilities
•
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the acquisition of U.S. biotechnology company 2seventy Bio Inc. (NASDAQ: TSVT), securing all development and commercialization rights to the latter’s drug discovery platform, clinical manufacturing platform, and investigational innovative cell therapies. In conjunction with this acquisition, Regeneron will establish a new unit, Regeneron Cell…
-
Shanghai CureGene Pharmaceutical Secures USD 14 Million in Series B Financing to Advance Cardiovascular Treatments
•
Shanghai CureGene Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has announced the successful completion of a Series B financing round, raising RMB 100 million (USD 14 million). The financing was led by Tailong Capital, with additional investments from Elikon Venture and TigerYeah Capital, as well as participation from existing investors…
-
Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China
•
Ping An Healthcare and Technology Co., Ltd (HKG: 1833), commonly referred to as PingAn Good Doctor, has entered into a strategic partnership with Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), another Chinese firm. The collaboration aims to combine the business acumen and technical prowess of both companies to…
-
Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center
•
Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research partnership with Fudan University Shanghai Cancer Center. The collaboration, initiated in July 2021, focuses on advancing research cooperation, nurturing talent, enhancing hospital management, and constructing robust platforms for scientific exchange. The partnership has seen significant…
-
Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program
•
Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS) by amending it to accelerate their joint program on the anti-TIGIT monoclonal antibody (mAb) domvanalimab. The amendment includes an additional investment of USD 320 million, which increases Gilead’s ownership stake in Arcus to 33% and…
-
SANDT Secures Nearly RMB 200 Million to Boost X-ray System Development and Manufacturing
•
SANDT, a Shanghai-based specialist in X-ray systems, has reportedly secured nearly RMB 200 million (USD 28 million) in a recent financing round. The investment was led by Zhongxin Capital, with participation from other undisclosed investors. The funds raised will be allocated towards research and development, as well as the manufacturing…
-
Joincare Pharmaceutical Group Secures USD 100 Million Loan from IFC for Expansion
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced securing a loan of USD 100 million from the International Finance Corporation (IFC). The funds will be directed towards the construction of new manufacturing and research and development facilities in Henan and Guangdong provinces. Additionally, the…
-
South Korean Duo GC Wellbeing and YooYoung Pharmaceutical Target Chinese Filler Market
•
South Korean health and functional food manufacturer GC Wellbeing and YooYoung Pharmaceutical have formed a strategic partnership to enter the Chinese filler market, as reported by Koreabiomed.com. YooYoung, an established manufacturer of hyaluronic acid (HA) formulations, will utilize its HIVE (Hybrid Technology Improving Viscosity and Elasticity) technology to develop a…
-
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
•
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company reported revenues of RMB 44 million and a loss of RMB 312 million in 2022, primarily generated through a licensing agreement with Livzon Pharma. In the first…
-
3D Medicines Partners with Sino Cellbiomed to Advance Tumor Immunotherapy Development
•
3D Medicines (HKG: 1244), a China-based oncology specialist, has entered into a partnership with Sino Cellbiomed, a Qingdao-based cell therapy firm, to collaborate on the development of tumor immunotherapies. Financial terms of the agreement have not been disclosed. Since its debut on the Hong Kong Stock Exchange in December 2022,…
-
Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion
•
Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12% stake in APT Medical Inc., a Shenzhen-based specialist in cardiac electrophysiology that went public on Shanghai’s STAR market in 2021. The acquisition will cost Mindray approximately RMB 6.652 billion (USD 926.6 million). Additionally, Mindray will…
-
Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101
•
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement with fellow Chinese firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its in-house developed long-acting monoclonal antibody (mAb) BA2101. According to the agreement, Joincare will obtain exclusive rights to develop, regulate, and commercialize…
-
Zhaoke Ophthalmology Strikes Distribution Deal with South Korea’s Kwangdong Pharmaceutical for Brimochol PF
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has announced a distribution and supply agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. The agreement pertains to Brimochol PF, a preservative-free fixed dose of carbachol and bromonidine tartrate, which serves as…
-
Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a strategic cooperation and licensing agreement with Jiangsu QYuns Therapeutics Co., Ltd concerning QX008N, a monoclonal antibody (mAb) that targets thymic stromal lymphopoietin (TSLP). According to the agreement, Joincare will secure exclusive rights to research and…
-
Formosa Pharmaceuticals Strikes Licensing Deal with Cristália for Ocular Surgery Pain Treatment in Brazil
•
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based Cristália Produtos Quimicos Farmaceuticos Ltda. According to the agreement, Formosa will grant Cristália the commercialization rights for its product candidate APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil, which is being developed as a potential…
-
Wuxi National Hi-Tech District Welcomes Synthetic Biology Industrial Park and East China’s First R&D Center
•
The Wuxi National Hi-Tech District (WND) has welcomed the opening of a new synthetic biology industrial park, marking a significant step forward for the region’s bio-industry. Within this park, Hunan Norchem Pharmaceutical Co., Ltd is preparing to establish the inaugural synthetic biology research and development center in East China, reinforcing…
-
Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories
•
Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to form a joint venture (JV) with MegaRobo Technologies, a Beijing-based firm renowned for its integration of robotics and artificial intelligence (AI) in life sciences. This strategic partnership aims to pioneer industry-standard medical laboratory automation solutions,…
-
MSD Partners with Variational AI to Harness Generative AI for Drug Discovery
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian company Variational AI to leverage the latter’s generative AI-powered model for drug discovery initiatives. Through this partnership, MSD will have early access to Variational AI’s platform, which utilizes text prompts to generate novel small molecules…
-
Shanghai Pharmaceuticals and HKSTPC Launch 01LABS@Hong Kong Incubator
•
01LABS@Hong Kong, a Shanghai-Hong Kong innovation incubator, has officially commenced operations. The incubator was jointly established by China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; HKG: 2607; SPH), Shanghai Biopharmaceutical Frontier Industry Innovation Center Co., Ltd, a subsidiary of SPH, and the Hong Kong Science & Technology Parks Corporation (HKSTPC).…
-
GSK In-Licenses Elegen’s Cell-Free DNA Tech to Advance Next-Gen Gene Therapies and Vaccines
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has this week in-licensed US partner Elegen’s cell-free DNA manufacturing technology to bolster the potential development of next-generation mRNA, cell, and viral gene therapies, as well as RNA-based vaccines. Elegen will receive upfront fees, purchase commitments, potential equity investment, and milestone payments…
-
China Anti-Cancer Association Forms Consortium for Standardizing Cancer Research Ethics Reviews
•
The medical ethics professional committee of the China Anti-Cancer Association (CACA) has announced the formation of the China Cancer Clinical Research Medical Ethics Review Mutual Recognition Consortium. This consortium aims to streamline and standardize the ethical review process for clinical research in cancer treatment across China. The founding members of…
-
Alphamab and 3D Medicines License Envafolimab Rights to Glenmark for Multiple Regions
•
Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244), two Chinese pharmaceutical companies, have announced a licensing agreement with Glenmark Pharmaceuticals Ltd (NSE: GLENMARK). The agreement grants the Indian company exclusive development and commercialization rights to the co-developed drug envafolimab (KN035) in India, Asia Pacific (excluding Singapore, Thailand, Malaysia), Middle…
-
Sanofi Acquires Rare Disease Candidate INBRX-101 in $1.7 Billion Deal
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced the acquisition of INBRX-101, a promising candidate for rare genetic diseases, from U.S. biotechnology firm Inhibrx (NASDAQ: INBX). INBRX-101, currently in Phase II trials for alpha-1 antitrypsin deficiency (AATD), is a recombinant human AAT-Fc fusion protein designed to restore serum AAT activity,…
-
Shanghai’s Reunion Biotech Secures Series B Funding to Advance Hydrogel Products
•
Reunion Biotech, a Shanghai-based medical hydrogel manufacturer, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B financing round. The funding was led by Dingxin Capital, with existing investors Qiming Venture Partners and Conson Financial Holdings contributing to the oversubscribed round. The proceeds will be allocated…
-
Beijing Sun-Novo and Zhejiang Anglikang Deepen Ties with New Drug Development Partnership
•
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a pharmaceutical company based in China, has entered into another partnership with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940). The two companies had previously agreed to collaborate on the development of modified drugs and are now expanding their collaboration…
-
WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced a cooperation memorandum of understanding (MOU) with South Korean firm Celltrion Inc. (KRX: 068270) to provide comprehensive services for the development and manufacturing of…
-
Shanghai Pharmaceutical and Sino Biopharmaceutical Form Strategic Partnership for Pharmaceutical Services
•
Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607), a leading pharmaceutical company based in China, has entered into a partnership with fellow Chinese firm Sino Biopharmaceutical Ltd (HKG: 1177). Under the agreement, Sino Bio will prioritize Shanghai Pharma as its strategic partner in the Chinese region under equal conditions,…
-
Tencent’s WeDoctor Teams Up with Guiyang for Digital Health Community Initiative
•
The municipal government of Guiyang has entered into a strategic partnership with WeDoctor Holdings Ltd, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700), to establish a digital health community and develop a national demonstration zone in Guiyang. The collaboration also includes the launch of a health…
-
Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment
•
Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab), a biosimilar referencing Roche (SWX: RO) unit Genentech’s Lucentis, from US-based Coherus Biosciences (NASDAQ: CHRS). This transaction, valued at a USD 170 million upfront payment, is anticipated to conclude in the first half of 2024.…
-
Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a strategic licensing and partnership agreement with Saudi Arabian pharmaceutical firm SPIMACO. The agreement pertains to Recbio’s recombinant 9-valent human papillomavirus (HPV) vaccine, REC603. Under the terms of the deal, SPIMACO will secure exclusive rights to…
-
Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements
•
Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered into a strategic partnership with Hopstem Biotechnology Co., Ltd, a neural stem cell specialist founded by a team of neuroscientists and stem-cell biologists from Johns Hopkins University. The collaboration aims to enhance the quality and…
-
Digital Precision Medicine Secures Over $28 Million in Series C Financing
•
Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of Sciences (CAS) and comprising Beijing Digital Precision Medical Technology Co., Ltd, and Zhuhai Dipu Medical Technology Co., Ltd, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The…
-
Endoso Life Raises Over $14 Million in Series A to Expand Endoscope Product Lines
•
Endoso Life, a developer of high-end medical endoscope systems headquartered in Hangzhou, has reportedly secured more than RMB 100 million (USD 14 million) in a Series A financing round. The round was led by WEGO’s fund, with additional investment from Lapam Capital. The funds raised will be directed towards expanding…
-
Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI
•
Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing in artificial intelligence (AI), quantum mechanics, and molecular simulation algorithms, have announced a strategic partnership agreement. This collaboration aims to revolutionize the drug discovery process by combining cutting-edge AI capabilities with advanced molecular dynamics simulation.…
-
AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics
•
Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into a partnership with Hutao Tech, a Beijing-based life science data specialist. The collaboration aims to combine Hutao’s market resources and industry expertise in life science data with Insilico’s AI drug development platform, Pharma AI, and…
-
Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China
•
Lee’s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics Inc., (NASDAQ: WINT) to develop and commercialize multiple cardiovascular disease (CVD) treatments in the Greater China region. The agreement includes the development of istaroxime, a Phase III-ready, first-in-class dual-mechanism SERCA2a activator for acute heart failure…
-
AbbVie Grants Enigma Biomedical Group Rights to Next-Generation PET Imaging Biomarkers
•
AbbVie (NYSE: ABBV), a leading pharmaceutical company in the US, has licensed to Canada-based Enigma Biomedical Group (EBG) its cutting-edge F18 PET imaging biomarkers. These biomarkers are designed to detect the presence of four-repeat (4R) tau protein in patients who may have neurodegenerative diseases. The agreement holds potential for aiding…
-
Shaanxi Panlong Pharmaceutical Partners with Xi’an Medical University for Multifaceted Collaboration
•
Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864), a leading pharmaceutical company based in China, has announced the signing of a cooperation framework agreement with Xi’an Medical University. This strategic partnership will see the two entities leveraging their respective resources to collaborate across various fields. Under the agreement, Panlong Pharma…
-
Danaher Corporation to Establish Northern China Headquarters in Beijing’s Changping District
•
The Changping District People’s Government of Beijing Municipality has entered into a strategic cooperation agreement with Danaher Corporation (NYSE: DHR), a leading science and technology services provider based in the United States. The agreement encompasses the establishment of Danaher’s northern China headquarters in the district, along with the development of…
-
Glorious Med and Illumina Join Forces for Advanced Urinary Tract Infection Detection
•
Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has entered into a partnership with US genomics giant Illumina (NSDQ: ILMN). The collaboration aims to advance the precise diagnosis of urinary tract pathogens and drug resistance genes through the use of Illumina’s Urinary Pathogen/Drug Resistance…
-
Meinian Onehealth Collaborates with Huawei Cloud and Runda Medical on AI Health Robot
•
Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with Huawei Cloud and Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) to develop “Healthy Little Beauty,” a health management artificial intelligence (AI) robot. This initiative marks the creation of China’s first AI robot…
-
Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer
•
Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors has unanimously resolved to dismiss a nominal offer by UK-based private equity firm Alternative Liquidity Index LP to acquire up to 10 million of the company’s shares for USD 0.03 each. The board asserts that…
-
Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a cooperation intention agreement with the United Arab Emirates’ Gulf Medical University. The collaboration aims to encompass talent exchange, channel construction, scientific research, and commercial translational research, among other areas. Financial details of the agreement have…
-
Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals
•
Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans to sell 2,910,501 shares of EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT), representing a 5.96% stake in the US company. The transaction is expected to generate proceeds of USD 56.66 million (HKD 443 million). EyePoint Pharmaceuticals, established…
-
China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi Xihong Biopharma Co., Ltd, granting CMS exclusive promotion, marketing, and commercialization rights for Xihong Biopharma’s injectable polycaprolactone microspheres filler and injectable hydroxyapatite microspheres filler in China mainland, Hong Kong, Macau, and Taiwan. Both Category III…
-
Wuhan EasyDiagnosis Biomedicine Partners with Ailex Technology Group for Global Glycated Hemoglobin Testing Market
•
Wuhan EasyDiagnosis Biomedicine Co., Ltd (SHE: 002932), a Chinese biomedicine company, has announced a strategic partnership with Ailex Technology Group Co., Ltd. The collaboration aims to combine the companies’ respective strengths in technology, product development, market reach, and management expertise to make inroads into the global glycated hemoglobin testing market.…
-
SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China
•
SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces with SPH Health Commerce Co., Ltd and Hi Dr to establish an Internet hospital. The tripartite partnership aims to leverage digital healthcare solutions, although no financial details of the agreement have been disclosed. SciClone, known…
-
Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution
•
Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based Substipharm Biologics. The partnership centers around Substipharm’s Japanese encephalitis (JE) vaccine, Imojev. Zuellig Pharma will offer marketing and distribution support, aiming to make the vaccine accessible to patients across nine Asian markets, including Brunei, Cambodia,…
-
XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China
•
Sino-US AI drug development company XtalPi has entered into a strategic partnership with Switzerland-based ABB Robotics, aiming to manufacture a series of automated laboratory workstations within China. These workstations, featuring ABB’s GoFa robots, are anticipated to enhance the productivity of R&D processes across biopharmaceuticals, chemical engineering, chemistry, and new energy…
-
Mindray Partners with WakeMed for Comprehensive Patient Monitoring Solutions
•
Shenzhen-based medtech company Mindray has announced a procurement agreement with WakeMed Health & Hospitals in North Carolina, USA, for its patient monitoring systems. Under the terms of the deal, WakeMed will implement Mindray’s BeneVision Distributed Monitoring System (DMS) and BeneVision N-Series Patient Monitoring Systems across three of its hospitals. The…
-
China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to acquire a 63% stake in Chongqing Duoputai Pharmaceutical Co., Ltd for RMB 442 million (approximately USD 62 million). This acquisition will elevate CGP Pharma’s ownership in Duoputai to 90%, granting the company full control over…
-
Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline
•
Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout from Merck that specializes in targeting interleukin-15 (IL-15). Under the terms of the deal, Calypso will receive an upfront payment of USD 250 million, along with potential milestone payments totaling up to USD 175 million.…
-
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
•
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big Pharma companies keen on its promising pipeline in cardiovascular and neuromuscular diseases. Sources indicate that Novartis (NYSE: NVS) was initially leading the charge against competitors AstraZeneca (AZ, NASDAQ: AZN) and Johnson & Johnson (J&J, NYSE:…
-
BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs
•
Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC) technology from Portugal-based biotechnology company CellmAbs. The agreement marks Portugal’s first billion-dollar transaction in the life sciences sector. Under the terms, CellmAbs will receive undisclosed upfront and near-term payments, potential milestone payments reaching several hundred…
-
NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference
•
At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a new collaboration with Amgen (NASDAQ: AMGN)’s subsidiary, deCode. This partnership will see deCode leverage NVIDIA’s advanced supercomputers and the BioNeMo generative artificial intelligence (AI) platform to bolster the development of its genomic foundational models. BioNeMo,…
-
Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis
•
Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ: GOOGL), has entered into its inaugural pharmaceutical collaborations, signing separate agreements with Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS). These partnerships are aimed at discovering small-molecule therapeutics for multiple undisclosed targets. Under the terms…
-
Boai NKY Medical Holdings Partners with HuaDao Biopharma for CAR-T Therapy Incubator
•
Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic partnership with compatriot firm HuaDao Biopharma. Under the agreement, HuaDao will guide Boai NKY in establishing a GMP-aligned chimeric antigen receptor (CAR) T-cell therapy development incubator. HuaDao has agreed to prioritize Boai NKY for the…
-
Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion
•
EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of renminbi in a Pre-Series A financing round. The funds will be directed towards scaling up the operation of multiple fully automatic production lines, developing new products, and expanding the company’s business reach both within China…
-
Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer
•
Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview with FiercePharma.com on the margins of the JP Morgan Healthcare Conference that the company is contemplating additional strategic deals, particularly in the realm of antibody drug conjugates (ADCs), with a focus that may include Chinese…
-
Myrobalan Therapeutics Secures $24 Million in Series A Funding with Strong Chinese Investor Support
•
Myrobalan Therapeutics, a Massachusetts-based biotech firm, has successfully completed a $24 million Series A funding round, featuring significant participation from Chinese investors. The financing was led by Shenzhen-based Co-win Ventures, with contributions from both new and existing investors, including Guan Zi Equity Investment (Li Shui) Partnership, 3E Bioventures Capital, and…
-
Ji Xing Pharmaceuticals Secures Licensing Rights for Biogen’s BIIB131 in Stroke Treatment
•
Shanghai-based Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a licensing agreement with Biogen (NASDAQ: BIIB) for the global clinical development rights to the US company’s pipeline candidate BIIB131. The terms of the deal include an undisclosed upfront payment, milestone payments, and royalties on future global sales. BIIB131 is…
-
Keylights Biotechnology Raises $14 Million in Series B to Expand IVD Instrument Range
•
Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B financing round. The round was led by Luxin Venture Capital, with participation from Hanchi Venture Capital. The funds raised will be…
-
Gansu Deshengtang Partners with RELEX Solutions to Enhance Supply Chain Efficiency
•
Gansu Deshengtang Medical Science and Technology Group Co., Ltd, a prominent Chinese healthcare group, has entered into a strategic partnership with Finland-based retail technology platform RELEX Solutions. Through the adoption of RELEX’s advanced forecasting and replenishment solutions, Deshengtang aims to optimize its end-to-end supply chain operations, rectify inventory structures, and…
-
China Resources Medical Laboratory Partners with Qlife Lab for Comprehensive Mass Spectrometry Solutions
•
China Resources Medical Holdings Company Limited’s subsidiary, China Resources (Guangdong) Medical Laboratory Co., Ltd, has entered into a partnership with fellow Chinese firm Qlife Lab to deliver comprehensive mass spectrometry solutions to medical institutions. The collaboration aims to provide a one-stop service for mass spectrometry, enhancing the capabilities of medical…
-
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
•
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered into a research service agreement with Germany’s BioNTech (NASDAQ: BNTX). As part of the collaboration, WuXi Bio will leverage its patented technology platform to develop antibodies targeting two undisclosed targets for BioNTech, aimed at advancing…
-
Junshi Biosciences Regains Global Rights to JS006 as Coherus Terminates Licensing Agreement
•
Junshi Biosciences (HKG: 1877; SHA: 688180), based in Suzhou, has announced the termination of its licensing agreement with US-based Coherus BioSciences Inc. (NASDAQ: CHRS) concerning the T cell immunoglobulin and ITIM domains (TIGIT) monoclonal antibody CHS-006/JS006. The original licensing deal, established in February 2021, granted Coherus exclusive rights to Junshi’s…
-
Amgen Licenses XeriJect Technology from Xeris Biopharma for Subcutaneous Tepezza Development
•
Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for the XeriJect drug delivery technology, aimed at developing, manufacturing, and commercializing a subcutaneous formulation of its orphan drug Tepezza (teprotumumab). The XeriJect suspensions enable concentrations exceeding 400 mg/ml, which helps to reduce injection volumes, lessen…
-
Henlius Biotech Secures Exclusive Rights to Sermonix’s Lasofoxifene for Breast Cancer Treatment in China
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a partnership and licensing agreement with U.S.-based Sermonix Pharmaceuticals Inc. for exclusive development, manufacturing, and commercialization rights in China for the investigational drug lasofoxifene. This ESR1 antagonist is being developed as a treatment for breast cancer. Under the terms of the…
-
GSK’s Acquisition of Aiolos Bio Bolsters Respiratory Medicine Portfolio with AIO-001
•
UK pharmaceutical giant GSK plc (LON: GSK) has announced a deal to acquire Aiolos Bio, a US/UK-based biotechnology company focused on the development of the respiratory antibody AIO-001. Aiolos was established in October 2023 when it secured the rights to develop AIO-001 outside of Greater China from Jiangsu Hengrui Pharmaceuticals…
-
Bio-Link Partners with Verdot to Distribute Innovative Bioprocessing Products in China
•
Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd., a leading provider of life sciences industry solutions in China, has entered into a strategic partnership with French bioprocessing company Verdot. The collaboration, facilitated by Cathay Capital, will position Bio-Link as the primary distributor of Verdot’s innovative chromatography columns within the Chinese market.…
-
Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies
•
Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare Capital (SHC), has reportedly secured nearly RMB 200 million (approximately USD 28 million) in a Series A financing round led by Lapam Capital, with participation from SHC. The funds will be allocated to clinical and…
-
Sinocare Partners with Illumina to Localize iScan Chip Scanners for Precision Health Applications
•
Sinocare Inc. (SHE: 300298), a China-based company, has entered into a partnership agreement with U.S. giant Illumina (NASDAQ: ILMN) to localize the iScan high-end chip scanners. This collaboration aims to harness their technological strengths and resources to enhance the application of genomics in precision health management, with a particular focus…
-
Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion
•
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to acquire Ambrx Biopharma (NASDAQ: AMAM), a U.S.-based developer of antibody drug conjugates (ADCs). The deal is valued at approximately USD 2 billion in equity and carries a net cash requirement of USD 1.9 billion, with…
-
MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline
•
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its intention to acquire Harpoon Therapeutics (NASDAQ: HARP) for approximately USD 680 million. The acquisition is expected to be completed in the first half of 2024, subject to approval by Harpoon’s stockholders and the fulfillment of…
-
Bain Capital-Backed Tenacia Strikes Deal with Praxis Precision Medicines for Essential Tremor Treatment
•
Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital, has entered into an exclusive cooperation and licensing agreement with US-based Praxis Precision Medicines Inc. (NASDAQ: PRAX). The Shanghai-based firm has been granted the rights to develop and commercialize ulixacalamide for the treatment of essential tremor in Greater China.…
-
Bebig Medical Group Secures Over USD 14 Million in Series B Financing to Boost Radiotherapy Technology
•
Bebig Medical Group, a Germany-based provider of high-quality radiation therapy products with a presence in China and the United States, has reportedly secured over RMB 100 million (USD 14 million) in a Series B financing round. The sole investor in this round was Cathay Capital. The funds raised are intended…
-
Chengdu Kanghua Strikes Licensing Deal with HilleVax for Recombinant Norovirus Vaccine
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a licensing agreement with HilleVax Inc. (NASDAQ: HLVX), granting the US firm exclusive rights to develop, manufacture, and commercialize Kanghua’s recombinant hexavalent norovirus vaccine on a worldwide basis, excluding the Greater China region…
-
Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders
•
Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow Chinese firm Nanjing Kangerjia Medical Technology Co., Ltd to collaboratively develop modified drugs aimed at treating sleep disorders. This strategic alliance combines Triastek’s expertise in 3D printing technology with Kangerjia’s commercialization experience in the field…
-
Biocytogen Strikes Exclusive Licensing Deal with US-Based Radiance Biopharma for Innovative BsADC
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China , has announced the signing of an Exclusive Option and License Agreement with Radiance Biopharma Inc., a specialist in antibody drug conjugates (ADCs) headquartered in Boston, U.S. The agreement provides Radiance with the option to license…
-
AstraZeneca Secures Exclusive Rights to Omniose’s Enzyme Platform for Bacterial Vaccine Development
•
AstraZeneca (AZ; NASDAQ: AZN) has secured an exclusive licensing agreement with biotechnology firm Omniose for up to three years, gaining access to Omniose’s enzyme-based bioconjugation platform. This platform will be utilized for the development of vaccines targeting bacterial pathogens, including those that are multidrug-resistant. Omniose’s proprietary enzyme technology enables the…
-
AbbVie Partners with Umoja Biopharma to Develop Next-Generation CAR-T Therapies
•
AbbVie (NYSE: ABBV) has entered into a collaboration agreement with Umoja Biopharma, a US-based company specializing in next-generation in-situ CAR-T cell therapies. Under the partnership, the two companies will develop up to four programs targeting selected cancer therapies chosen by AbbVie. AbbVie has also secured an exclusive option to license…
-
Weigao Blood Purification Aims for USD 190 Million in Shanghai Stock Exchange IPO
•
Shandong Weigao Blood Purification Products Co., Ltd, a dominant player in China’s blood purification sector, has submitted an initial public offering (IPO) application to the Shanghai Stock Exchange (SSE). The exchange has accepted the filing for review, with the company eyeing a substantial capital injection of RMB 1.351 billion (USD…
-
Bayer AG Leads Series D Investment in Jixing Pharmaceuticals, Eyeing Commercialization Rights
•
Bayer AG (ETR: BAYN, OTCMKTS: BAYRY), a leading German pharmaceutical company, has announced a long-term collaboration with Jixing Pharmaceuticals, a China-based firm, following its leadership in a Series D financing round. The investment is being made in conjunction with RTW Investments, the fund that established and supported Jixing. Bayer’s venture…
-
Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates
•
Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing agreement with Novartis (NYSE: NVS), the Swiss pharmaceutical giant. The deal grants Novartis global rights to a Phase I drug candidate and ex-Greater China rights to another program currently in Phase I/IIa. In return, Argo…
-
Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China
•
Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares in SanReno Therapeutics, a Shanghai-based developer of kidney drugs. This move is aimed at bolstering Novartis’s kidney product portfolio in China. The financial details of the transaction have not been disclosed. SanReno Therapeutics was established…
-
Ningbo Linstant Polymer Materials Secures Over USD 14 Million in Series B Financing to Boost Production and Global Reach
•
Ningbo Linstant Polymer Materials Co., Ltd, a Chinese manufacturer specializing in polymer accessories for medical devices, has reportedly secured over RMB 100 million (USD 14 million) in a Series B financing round. The funding was led by Fenghua VC, with additional investments from NTG. The company plans to use the…
-
Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases
•
Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into a partnership with U.S. firm MaxCyte Inc. to harness mRNA technology for the development of TCR-T therapies. These therapies are aimed at treating solid tumors and virus-related diseases. The collaboration will enable Lion to utilize…
-
OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC
•
OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising USD 100 million. The round was led by Novo Holdings, OrbiMed, and F-Prime Capital, with significant contributions from BioTrack Capital, a Chinese investor involved in OnCusp’s seed funding, Catalio Capital Management, Marshall Wace, Forge Life…
-
Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential
•
Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna, aimed at inhibiting the creatine transport channel SLC6A8. The drug is currently undergoing Phase II trials for RAS-mutated advanced or metastatic colorectal cancer (mCRC). The agreement also encompasses additional follow-on compounds targeting SLC6A8. In return…
-
Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies
•
German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T Biosciences to advance next-generation T-cell-based immuno-oncology therapies. BI will contribute its proprietary patient-derived T-cell receptor (TCR) data to help identify binding antigens using 3T’s discovery platform. Under the terms, BI will provide an undisclosed upfront…
-
Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances
•
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces with biotech incubator Flagship Pioneering to drive pre-clinical breakthroughs for cardiometabolic disorders. This collaboration marks the initial phase of a strategic alliance inked in 2022, spotlighting novel therapeutics for cardiometabolic and rare diseases. As part…
-
Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with China’s Insilico Medicine to develop a KAT6A inhibitor originating from Insilico’s AI-driven platform. The candidate, targeted for hormone-sensitive cancers and other oncological indications, shows promise as a potent KAT6A inhibitor based on preclinical data. KAT6A,…
-
Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round
•
Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China, has reportedly raised more than RMB 100 million (USD 14 million) in its first-ever financing round. The funding was co-led by Jifeng Ventures and SND Rongsheng Investment, with additional investments from SIDVC, Qiaojing Capital, New…
-
Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor
•
China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the US firm global development and commercialization rights (excluding Greater China) to Allorion’s cyclin-dependent-kinases 2 (CDK2) inhibitor. The agreement also includes an exclusive option for a pre-clinical program anticipated for IND filing in 2025. As part…
-
Daiichi Sankyo and Esperion Therapeutics Amend Collaboration on Antilipidemic Drugs
•
Daiichi Sankyo (TYO: 4568)’s European subsidiary, a Japanese pharmaceutical company, has entered into a collaboration amendment agreement with US-based Esperion Therapeutics (NASDAQ: ESPR) concerning Esperion’s antilipidemic drugs Nilemdo (bempedoic acid) and Nustendi (bempedoic acid + ezetimibe). The revised agreement stipulates that Esperion will receive an immediate payment of USD 100…
-
IASO Biotechnology and Umoja Biopharma Join Forces for Innovative Cell and Gene Therapies Development
•
IASO Biotechnology, a China-based company, and Umoja Biopharma, a California-headquartered developer of off-the-shelf cell therapies, have announced a collaboration agreement to research, develop, and commercialize innovative in vitro and in vivo cell and gene therapies (CGTs). This collaboration expands on a previous agreement in November 2022, where the two companies…
-
Full-Life Technologies Secures USD 63.3 Million in Financing to Boost Radiotherapeutics Pipeline and Manufacturing
•
Full-Life Technologies Ltd, a global radiotherapeutics company with a presence in Belgium, Germany, and China, has announced the successful completion of a financing round, raising a total of USD 63.3 million. This includes a Series B funding round of USD 47.3 million and a credit facility of USD 16 million.…
-
GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
•
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced that the closing conditions for a licensing agreement between its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), and the Swiss pharmaceutical giant Novartis AG (NYSE: NVS) have been met. The agreement, initially revealed in November 2023,…
-
Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic
•
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with fellow domestic firm Xiling Lab for the commercialization of its generic version of the breast cancer treatment eribulin, originally marketed as Halaven by Eisai. The agreement grants Xiling commercial and supply rights in 36 countries,…
-
Bio-Thera Solutions Grants Macter International Exclusive Rights to Avzivi in Pakistan and Afghanistan
•
Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement with Macter International Ltd., a company based in Pakistan. Under the terms of the agreement, Bio-Thera will transfer Avzivi (bevacizumab), a biosimilar version of Roche’s Avastin, to Macter. Macter will gain exclusive distribution and marketing…
-
Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH
•
Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou Ribo Life Science Co., Ltd, a Chinese biotechnology firm, to co-develop small interfering RNA (siRNA) drugs for the treatment of non-alcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). This strategic partnership aims to leverage Ribo’s proprietary RIBO-GalSTAR…
-
JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China
•
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration agreement with US biotech firm 2seventy Bio Inc. (NASDAQ: TSVT) to jointly develop, manufacture, and commercialize an unspecified chimeric antigen receptor (CAR)-T cell therapy product for autoimmune diseases in the Greater China region. JW will…
-
Frontage Laboratories Expands European Footprint with Acquisition of Accelera’s DMPK Businesses
•
Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou, and Shanghai, has announced the completion of its acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics (DMPK) businesses from Italy-based CRO Accelera S.r.l. The specifics of the deal were not disclosed. This acquisition is…
-
China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend Global Medical Services Pte., Ltd (PharmaGend), has entered into a lease agreement with Strides Pharma Global Pte., Ltd for a manufacturing facility in Singapore, which includes the acquisition of certain production machinery and equipment. This…
-
WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has recently announced a memorandum of understanding (MOU) with South Korea-based IntoCell. The collaboration aims to comprehensively work on new toxin linker technology and contract research,…
-
Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization
•
Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement with AstraZeneca (AZ, NASDAQ: AZN) to develop and commercialize a novel allosteric inhibitor targeting the L858R mutation of the epidermal growth factor receptor (EGFR). The drug is intended for the treatment of advanced EGFR mutant…
-
Orient Gene Biotech to Acquire Hangzhou Laihe Biotech, Expanding POCT and AI in Healthcare
•
Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to acquire Hangzhou Laihe Biotech Co., Ltd, a move that will grant its subsidiary full control over the latter. This strategic acquisition is set to create synergies, given Laihe Bio’s specialization in drug testing and infectious…
-
Shanghai Teogen Life Technology and China National Medical Device Form Strategic Partnership
•
Shanghai Teogen Life Technology Co., Ltd, a Chinese-based company, has announced a strategic partnership with its compatriot, China National Medical Device Co., Ltd. The collaboration aims to integrate the respective resource advantages of both companies, optimizing their cooperation layout and enhancing practical collaboration in product promotion and marketing. The financial…
-
Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China, has entered into a comprehensive partnership with the French pharmaceutical giant Sanofi (NASDAQ: SNY). The collaboration aims to address major disease areas on a nationwide scale, establishing an end-to-end value chain system that spans from…
-
Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology
•
Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative diagnostic technology from UK-headquartered LumiraDx (OTCMKTS: LMDXF). The transaction, expected to close in mid-2024, involves an upfront payment of $295 million, complemented by up to an additional $55 million to support LumiraDx’s point-of-care business during…
-
Roche Secures Diagnostics Deal with LumiraDx for $295M
•
Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology from UK-based LumiraDx. The transaction, valued at $295 million, is anticipated to conclude in mid-2024, with an additional payment of up to $55 million to cover LumiraDx’s point-of-care business expenses until the deal’s closure. The…
-
Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug
•
vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based Huadong Medicine Co., Ltd (SHE: 000963) regarding their collaboration on the type 2 diabetes drug TTP273. Huadong confirmed the news, stating that TTP273 was considered inferior to its in-house developed drug HDM1002. TTP273, a first-in-class…
-
CareRay Digital Medical Technology to Acquire 30% Stake in UK’s ISDI for USD 15.2 Million
•
CareRay Digital Medical Technology Co., Ltd, a company based in Suzhou (SHA: 688607), has announced plans to acquire a 30% stake in UK-headquartered ISDI Ltd for a consideration of GBP 12 million (USD 15.2 million). ISDI specializes in the research and development, manufacturing, and marketing of CMOS X-ray detectors and…
-
Jiangsu Hengrui’s SHR-A2009 Earns Fast-Track Status for Metastatic NSCLC Treatment
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its in-house developed antibody-drug conjugate (ADC), SHR-A2009, has received fast-track status. This designation underscores the drug candidate’s potential as a treatment for metastatic non-small cell lung cancer (NSCLC) patients with EGFR mutations who have progressed after treatment with third-generation EGFR…
-
Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for USD 1.8 Billion
•
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish pharmaceutical company, has announced the formation of an alliance with Haier Group, a Chinese electronics and appliances giant. Under the agreement, Grifols will sell a 20% equity stake in Shanghai RAAS (SRAAS) for RMB 12.5 billion (USD 1.8 billion). Following the transaction, Grifols…
-
MicroPort CardioFlow Medtech to Acquire Controlling Stake in La Ronda for USD 20 Million
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced that a conditional agreement has been reached to acquire a 51% stake in fellow Chinese firm La Ronda for a cash consideration of RMB 141 million (USD 20 million). La Ronda, based…
-
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
•
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement with Swiss pharmaceutical giant Roche concerning YL211, an antibody drug conjugate (ADC) targeting c-Mesenchymal-epithelial transition factor (c-MET) for the development of a treatment for solid tumors. This agreement marks Medilink’s fifth out-license deal for ADC…
-
Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development
•
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, based in China, has successfully closed its Series B funding round, raising RMB 1 billion (approximately USD 140 million). The round was jointly led by CS Capital and IDG Capital, with additional contributions from YanChuang Group, Cathay Capital, and existing investor Bain Capital. The…
-
Eli Lilly Teams Up with Fauna Bio to Uncover New Anti-Obesity Drug Targets
•
Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio to explore novel anti-obesity drug targets, marking a significant step in the competitive weight-loss therapies market. The financial terms of the deal include an undisclosed upfront payment, potential sales royalties, and up to $494 million…
-
IVD Medical Ends Strategic Partnership with Japan’s Sysmex in Coagulation Products
•
IVD Medical Holding Ltd (HKG: 1931), a China-based in vitro diagnostic (IVD) specialist, has announced the termination of its strategic partnership agreement with Japan’s Sysmex Corporation concerning its coagulation product business. The partnership, initially established in November 2023, involved Sysmex investing in IVD Medical’s subsidiary, thereby becoming a shareholder and…
-
Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio
•
Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT) this week, following the clearance of the last regulatory requirement last month. As part of the acquisition, Lilly gains access to Point’s PNT2002, a PSMA-targeting radiopharmaceutical currently in Phase III trials for metastatic castration-resistant prostate…
-
CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies
•
China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm PersonGen BioTherapeutics (Suzhou) Co., Ltd. to collaboratively develop in vivo chimeric antigen receptor (CAR)-T cell therapies utilizing CATUG’s mRNA-lipid nanoparticle (LNP) technology for global markets. As of November 2023, a total of ten CAR-T therapies…
-
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
•
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly RMB 200 million (approximately USD 28 million). The round was led by Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553), with additional investments from CICC Capital, Changxing Financial Holding, and the Huzhou Talent Fund. Founded in…
-
Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors
•
Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration and supply agreement with Xuanzhu Biopharma to explore the combination therapy of Tyvyt (sintilimab) with KM-501, a novel HER-2 bispecific antibody drug conjugate (ADC). This partnership aims to develop potential treatment options for advanced solid…
-
Janssen Acquires Rights to Gene Therapy Botaretigene Sparoparvovec from MeiraGTx for XLRP Treatment
•
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), announced last week its acquisition of development, manufacturing, and commercialization rights for the gene therapy botaretigene sparoparvovec from MeiraGTx Holdings (NASDAQ: MGTX) for the treatment of X-linked retinitis pigmentosa (XLRP). Janssen will pay an upfront fee of USD 65…
-
Elpiscience Partners with Astellas for Bi-Specific Macrophage Engager Research
•
China-based Elpiscience Biopharmaceuticals has announced a research collaboration and licensing agreement with Japan’s Astellas Pharma Inc. (TYO: 4503), focusing on Elpiscience’s innovative bi-specific macrophage engager, ES019, along with another program. The partnership will involve joint early-stage research on these two initiatives, with Elpiscience granting Astellas the option to include up…
-
Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation
•
Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou Panlin Xukang Fund, which will concentrate on innovative biopharmaceuticals, medical devices, and biotechnology sectors. This marks the first fund established by Panlin Capital in Hangzhou and the second venture capital fund raised by the firm…
-
XRGenesis Raises $14 Million in Series A to Advance Ophthalmic Surgical Technology
•
XRGenesis, a developer of high-end ophthalmic surgical equipment based in Hangzhou, has reportedly raised nearly RMB 100 million (USD 14 million) in a Series A financing round. The round was led by Legend Capital, with participation from existing investors TIgerYeah Capital, Proxima Ventures, Dalton Venture, and Tao Capital. The funds…
-
J&J’s Janssen Secures Exclusive Global Rights to Develop LCB84 ADC from LegoChem Biosciences
•
Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical subsidiary, Janssen, has entered into an exclusive global agreement with South Korean-based LegoChem Biosciences (LCB; KOSDAQ: 141080) to develop and commercialize the antibody drug conjugate (ADC) LCB84. Under the terms of the agreement, LCB is set to receive $100 million in upfront payments…
-
BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition
•
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a clinical-stage developer of actinium-based radiopharmaceutical therapeutics (RPT), bolstering its oncology portfolio. BMS will purchase all outstanding shares of RayzeBio for an estimated $4.1 billion, with the transaction anticipated to close in the first half of…
-
Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug
•
China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc. to co-develop the small interfering RNA (siRNA) candidate drug SGB-3908 for the treatment of hypertension. Innovent Biologics has secured the exclusive option to license global development, manufacturing, and commercialization rights for the drug. Upon the…
-
Jianzhijia Health-Chain to Purchase Local Drug Retailer for $23.5 Million
•
Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266), a Chinese healthcare company, has announced plans to fully acquire Chongqing Hongrui Lebang Renjia Pharmacy Chain Co., Ltd for a consideration of RMB 167.8 million (USD 23.5 million). With this acquisition, Hongrui Lebang, a local drug retailer operating 190 drugstores, will become a…
-
Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have announced significant progress in the co-development of their trispecific T cell connector, having identified a WT1/HLA-A02 targeted T-cell connector, WT1×CD3×4-1BB trispecific antibody, as part of their collaboration initiated last year. Pre-clinical data for this product…
-
Aidea Pharmaceutical Co. Terminates ACC006 Technology Transfer Deal with Lixin Bio
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement with Guangzhou Lixin Biological Technology Co., Ltd. concerning the drug candidate ACC006. Initially inked in December 2021, the agreement saw Aidea Pharma bestow upon Lixin Bio the rights to its cancer drug candidate ACC006 for…
-
AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal
•
Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies Inc., (NASDAQ: GRCL), a China-based developer of chimeric antigen receptor (CAR) T cell therapies. This marks the first major merger and acquisition (M&A) deal by a foreign company targeting one of China’s newest generation biotechs.…
-
AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial
•
AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely cease enrollment in a Phase II trial for the T-cell stimulatory pathways inhibitor acazicolcept in systemic lupus erythematosus (SEL). This move allows for an early assessment of the trial data and enables Alpine to redirect…
-
Suzhou Ribo Life Science Strikes Deal with Qilu Pharmaceutical for PCSK9 siRNA Drug
•
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based in China, has entered into a licensing agreement with Qilu Pharmaceutical, granting the company clinical development, manufacturing, and commercialization rights to its PCSK9 siRNA drug RBD7022 in Greater China, which includes mainland China, Hong Kong,…
-
CStone Pharmaceuticals Regains Exclusive Rights to Tibsovo in Greater China and Singapore
•
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced an agreement with French pharmaceutical company Servier that returns exclusive development, manufacturing, and commercialization rights to Tibsovo (ivosidenib) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan, as well as Singapore. Originally developed by US-based Agios Pharmaceuticals,…
-
Takeda Ends Gene Therapy Collaboration with JCR Pharmaceuticals, Returns IP
•
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced the termination of a 2022 collaboration agreement with fellow Japanese firm JCR Pharmaceuticals Co., Ltd. (TYO: 4552) for the development of gene therapies. As a result of the termination, Takeda will return all research outcomes and patents to JCR. This strategic decision…
-
BMS to Acquire Karuna Therapeutics for $14 Billion, Expanding Psychosis Treatment Portfolio
•
Bristol Myers Squibb (BMS; NYSE: BMY), a leading US pharmaceutical company, has announced its intention to acquire Karuna Therapeutics, Inc. (NASDAQ: KRTX) for a total consideration of USD 14 billion. This acquisition will bolster BMS’s product pipeline with the inclusion of the antipsychotic drug KarXT (xanomeline-trospium), which is currently awaiting…
-
Roche Diagnostics and Beijing Strong Biotechnologies Deepen Ties to Innovate in Hemostasis Diagnostics
•
Roche Diagnostics (SWX: ROG), the Swiss diagnostics heavyweight, has furthered its collaboration with Beijing Strong Biotechnologies Inc. (SHE: 300406), a Chinese partner, to craft more holistic and pioneering laboratory solutions for hemostasis and thrombotic disorders. Building on their initial partnership established in 2016, which focused on biochemical reagents and resulted…
-
Kossel Medtech Secures Over $14 Million in Series B Financing to Boost International Expansion
•
Kossel Medtech (Suzhou) Co., Ltd., a company specializing in coronary and peripheral intervention medical devices, electrophysiology series products, and related accessories, has reportedly secured over RMB 100 million (USD 14 million) in a Series B funding round. The round was led by Fortune Capital, with additional investments from SIDVC, SND,…
-
China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to acquire a 75.35% controlling stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation for a consideration of HKD 400 million (USD 51 million). This strategic move signifies CGP’s expansion into a broader range…
-
Beijing Strong Biotechnologies Strikes Distribution Deal with ELITechGroup for Immunohistochemical Staining Systems
•
Beijing Strong Biotechnologies Inc., (SHE: 300406) a Chinese company, has entered into a product distribution agreement with US-based ELITechGroup Inc. (EGI). Under the terms of the agreement, EGI will source the fully automated immunohistochemical staining systems Titan and Titan S, along with associated detection reagents and cleaning solutions, from Strong…
-
Sanofi Broadens Collaboration with Exscientia, Licensing New Precision Drug Program
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug design company Exscientia (NASDAQ: EXAI) by in-licensing a program in an undisclosed therapeutic area. This move builds on a 2022 agreement aimed at developing up to 15 novel small-molecule candidates across oncology and immunology. The…
-
Zhiyi Biotechnology and Henlius Biotech Partner to Develop Novel Drug Products and Platforms
•
Guangzhou-based Zhiyi Biotechnology has entered into a strategic partnership with Shanghai Henlius Biotech Inc. (HKG: 2696), a fellow Chinese firm. The collaboration aims to develop innovative drug products and technology platforms, with a particular focus on the advancement of engineered bacterial drugs and new functional strains. The joint efforts will…
-
Shanghai Novopathway and PONY Biomedicine Join Forces for Pre-Clinical Drug Development Platform
•
Shanghai Novopathway Biotechnology, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese firm PONY Biomedicine to co-develop a comprehensive one-stop service platform for small and large molecule drugs in the pre-clinical stage. This collaboration aims to offer competitive technical services and solutions to biopharmaceutical clients on…
-
GSK Secures Exclusive Rights to Hansoh’s ADC Candidate HS-20093 in New Licensing Deal
•
GlaxoSmithKline (GSK; NYSE: GSK), a major UK pharmaceutical company, has entered into its second licensing agreement with Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) within two months, focusing once again on an antibody-drug conjugate (ADC) product candidate. Hansoh has granted GSK exclusive rights to develop, manufacture, and commercialize its novel…
-
3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension
•
3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma’s in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed. Eltrombopag…
-
LianBio Board Turns Down Concentra Biosciences Buyout Offer
•
China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not to proceed with a buyout proposal from Concentra Biosciences LLC, deeming the offer not to be in the best interests of shareholders. In early December, Concentra Biosciences LLC, a company under the control of private…
-
Gilead Acquires Pre-Clinical IL-18BP Targeting Antibody Candidate from Compugen in $848 Million Deal
•
Gilead (NASDAQ: GILD) has licensed a potential first-in-class IL-18 binding protein (IL-18BP) targeting antibody candidate from cancer immunotherapy developer Compugen (NASDAQ: CGEN), which is currently in the pre-clinical stage. Gilead will assume development responsibilities from Phase II onwards and will pay USD 60 million upfront, with up to USD 788…
-
Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement
•
China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics, an RNA drug developer. The collaboration will focus on mRNA raw materials, lipid chemistry, lipid nanoparticle (LNP) technology, and complex preparations, among other areas. Financial details of the agreement have not been disclosed. Synthgene and…
-
Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform
•
Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese firm non-exclusive global rights to Escugen’s EZWi-Fit linker-payload platform for the development of next-generation tumor-associated antigen (TAA)-targeting antibody drug conjugates (ADCs). Under the terms of the license agreement, InxMed is authorized to utilize the EZWi-Fit…
-
MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers
•
US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership with French firm Owkin to develop and commercialize a pre-screening procedure for identifying the microsatellite instability- (MSI) H biomarker in various cancers. The initiative aims to test for MSI-H in endometrial, gastric, small intestinal, and…
-
Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma
•
Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors from France-based Innate Pharma (NASDAQ: IPHA), as per an agreement reached in 2022. Sanofi will pay an initial fee of EUR 15 million (USD 16.4 million) and is committed to potential milestone payments of up…
-
Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service agreement with domestic firm Impact Therapeutics, securing exclusive market promotion rights for Impact’s senaparib in mainland China. Under the agreement, Huadong will pay an initial fee of RMB 100 million (USD 14 million) and is…
-
Tower Cold Chain Expands into China with Partnership with Tower & Winner Solutions
•
Tower Cold Chain, a UK-based specialist in pharmaceutical container solutions, has announced a partnership with Shanghai-based Tower & Winner Solutions (TWS) to expand its operations into the Chinese market. The collaboration will make Tower Cold Chain’s temperature-controlled passive containers accessible to local pharmaceutical manufacturers, airlines, and third-party logistics companies for…
-
Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option agreement with US firm Neurocrine Biosciences Inc. The agreement grants Neurocrine access to Biocytogen’s fully human antibodies targeting multiple specified therapeutic areas, with an option to license selected antibodies for global development, manufacturing, and commercialization.…
-
China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing Purevalley Biotechnology Co., Ltd and Chengdu Purevalley Biotechnology Co., Ltd, have entered into a distribution agreement with Australian firm Sirtex Medical Ltd. This agreement centers on the distribution of Sirtex’s SIR-Spheres (Y-90 microsphere) injection, a…
-
Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market
•
Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and Rayvow (lasmiditan) from U.S. partner Eli Lilly (NYSE: LLY) for the European market. Under the agreement, Lilly will receive an upfront payment of $50 million, along with milestone payments, pending regulatory approval expected in Q1…
-
Blue Sail Medical Partners with Weifang Government on Healthcare Initiative
•
China’s Blue Sail Medical Co., Ltd. (SHE: 002382) has announced strategic cooperation agreements with the local government of Weifang, Shandong province, as well as Linqu county, also within Weifang. Under this partnership, the Weifang government plans to invest in Blue Sail, facilitating the introduction of various medical and healthcare-related projects…
-
Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector, has entered into a supply and production licensing agreement with a leading pharmaceutical company based in Bahrain. This partnership focuses on a range of vaccines, including the 13-valent pneumococcal polysaccharide conjugate vaccine, the 23-valent pneumococcal…
-
Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody evaluation, option, and licensing agreement with Spain’s Ona Therapeutics. According to the terms of the agreement, Biocytogen will provide Ona with access to evaluate its proprietary RenMice-derived fully human antibodies targeting a specific tumor. Ona…
-
WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into a partnership agreement with Visen Pharmaceuticals, a joint venture between Denmark’s Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital. Under the terms of the deal, Visen Pharmaceuticals will entrust WuXi Biologics…
-
Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial
•
Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY 500 million (USD 3.3 million) from the Japan-based Global Health Innovative Technology (GHIT) Fund for a Phase III trial of a triple artemisinin combination drug aimed at treating malaria. Fosun Pharmaceutical is developing a fixed-dose…
-
Novo Nordisk Acquires Alkermes’ Irish Production Site for $92.5 Million to Boost GLP-1 Output
•
Novo Nordisk (CPH: NOVO-B), a Danish pharmaceutical giant, has reached an agreement to acquire a production facility in Ireland from Alkermes (NASDAQ: ALKS), a drug manufacturer, along with related assets for a total consideration of USD 92.5 million. The transaction, which is subject to customary adjustments and fulfillment of closing…
-
Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round
•
Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence with medical diagnostics, has reportedly secured over RMB 100 million (USD 14 million) in a Series B2 financing round. The round was led by CAS Investment and a prominent Chinese fund, with additional participation from…
-
Mingyi Zhizao Secures $14 Million to Scale Gene Sequencing Platform and Production
•
Shenzhen Mingyi Zhizao Technology Co., Ltd, a Chinese company specializing in the gene sequencing industry, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B++ funding round led by Tenykin Capital and Jiangsu Jinqiao Private Equity Fund. The fresh capital is earmarked for the expansion of…
-
Youcare Pharmaceutical Partners with Sinopharm Heilongjiang to Broaden Market Presence
•
Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with Sinopharm Group Heilongjiang Co., Ltd., a major player in China’s pharmaceutical distribution sector. This collaboration is aimed at expanding Youcare’s market reach and resource pool, leveraging Sinopharm’s (HKG: 1099) extensive distribution channels and resource advantages.…
-
Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response
•
German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health to delve into the study of treatment response and resistance in metastatic hormone-sensitive prostate cancer. The collaborative project will leverage ClearNote’s epigenomic platform, which employs machine learning algorithms to analyze patient blood samples, monitor DNA-based…
-
BMS Partners with Terray Therapeutics for AI-Driven Drug Discovery
•
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with U.S.-based Terray Therapeutics to discover and develop multiple small-molecule drugs in undisclosed therapeutic areas. Under the terms of the agreement, BMS will receive development and commercialization rights, and in return, will provide Terray with upfront payments and potential…
-
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have jointly announced the licensing of their co-developed antibody-drug conjugate (ADC), HBM9033 (YL215), to Pfizer Inc.’s (NYSE: PFE) unit Seagen Inc. (NASDAQ: SGEN). According to the agreement, Seagen will secure global clinical development and commercialization rights…
-
VectorBuilder Partners with Sino Biological to Boost Global Biological Reagents Market
•
VectorBuilder, a genetic engineering specialist based in Guangzhou and nurtured by the state-owned Guangzhou Industrial Investment and Capital Operation Holding Group, has entered into a partnership with Sino Biological, Inc. (SHE: 301047), a global leader in the provision of mammalian cell-based recombinant proteins, antibodies, and related contract research services. This…
-
CATUG Biotechnology Partners with Carcell Biopharma to Advance Nucleic Acid Drug Development
•
CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with domestic firm Carcell Biopharma, a developer of medical technology service platforms. The collaboration will focus on technical cooperation in the global development of Lipid Nanoparticle (LNP) delivered mRNA and other nucleic acid drugs, aiming to…
-
AbelZeta Pharma Expands Janssen Partnership to Include Commercial Rights in China
•
AbelZeta Pharma Inc., a Sino-US biotechnology company with operations in Rockville, Maryland, and Shanghai, China, has announced an updated global collaboration and licensing agreement with Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ). According to the revised agreement, Janssen will now secure commercialization rights to CAR-T therapies C-CAR039…
-
Fosun Pharmaceutical and Insightec Form JV to Bring MRgFUS Brain Therapy to China
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to establish a joint venture (JV) with Israeli company Insightec. The new JV will concentrate on the commercial development and clinical application of a magnetic resonance guided focused ultrasound (MRgFUS) brain therapy system in China, targeting patients with Parkinson’s…
-
HighTide Therapeutics Inc. Raises USD 25 Million in Hong Kong IPO
•
HighTide Therapeutics Inc., (HKG: 2511) a China-based biopharmaceutical company, has successfully completed an initial public offering (IPO) on the Hong Kong Stock Exchange this week. The company issued 24 million shares, each priced at HKD 11.5, resulting in a net proceeds amount of HKD 194.1 million (USD 25 million). Founded…
-
AstraZeneca Acquires Icosavax to Boost Infectious Disease Pipeline with VLP Vaccine Technology
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the acquisition of US vaccines specialist Icosavax (NASDAQ: ICVX), including its protein virus-like particle (VLP) platform. AstraZeneca will pay approximately USD 800 million upfront for all outstanding shares, plus about USD 300 million in milestone payments. The acquisition is set to…
-
Sanofi Partners with Minapharm for Local Production of Anticoagulant Clexane in Egypt
•
Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally manufacture and supply its leading anticoagulant, Clexane (enoxaparin). The technology transfer agreement is aimed at enabling the French pharmaceutical giant to navigate “changing market dynamics,” as stated in a press release. Production of the medication…
-
Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark licensing and cooperation agreement with US pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY). The agreement focuses on Biokin’s antibody-drug conjugate (ADC) candidate, BL-B01D1, which targets EGFR and HER3. The deal was conducted specifically between…
-
Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into an agency and technology transfer agreement with Egyptian firm Gennvax Egypt concerning Kangtai’s 13-valent pneumococcal polysaccharide conjugate vaccine. Under the terms of the agreement, the two companies will collaborate to advance the marketing approval of…
-
Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China
•
Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN) have jointly announced the production line completion of the first NextSeq 2000Dx-CN-HAP gene sequencing system, a domestically produced product manufactured in Shenzhen. The collaboration will now concentrate on local manufacturing of high-end life sciences equipment…
-
Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a research partnership with Evive Biotech Ltd, a subsidiary of Chinese pharmaceutical company Yifan Pharmaceutical Co., Ltd (SHE: 002019). The collaboration will utilize Nona’s antibody technology platform, Harbour Mice, to focus on the discovery of dual…
-
Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging
•
Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT firm Salus Optima to provide precision health solutions that promote healthy aging through data-driven lifestyle recommendations on mobile devices. This collaboration will leverage Bayer’s extensive global network to distribute Salus Optima’s AI-powered lifestyle analysis technology.…
-
Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement with Grand Life Sciences Co., Ltd., aimed at advancing the commercialization of Zelgen’s recombinant human thrombin product in Greater China. Under the terms of the agreement, Grand Life will serve as the sole marketing promotion…
-
AbelZeta and AstraZeneca Team Up for Co-Development of GPC3-Targeted CAR-T Therapy
•
AbelZeta Pharma Inc., a Sino-U.S. biotech firm based in Rockville, Maryland, and Shanghai, has announced a co-development agreement with AstraZeneca (AZ, NASDAQ: AZN) for its C-CAR031 chimeric antigen receptor (CAR) T cell therapy. C-CAR031 is an autologous, armored CAR-T therapy specifically targeting GPC3, currently under development for hepatocellular carcinoma (HCC).…
-
Shanghai Henlius Partners with China Resource Medicine to Enhance Product Accessibility
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic partnership with China Resource Medicine Commercial Holdings Ltd. aimed at enhancing product accessibility across the market. Under the terms of the agreement, the two companies will collaborate on product marketing promotion, channel expansion, and supply chain management, although financial details…
-
Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges
•
U.S.-based Medtronic plc has announced its withdrawal from a previously agreed deal to fully acquire South Korea’s EOFlow (KOSDAQ: 294090), a developer of wearable insulin pumps. According to a recent SEC filing, the original agreement, signed in May 2023 and valued at up to USD 738 million, included separate share…
-
BMS Broadens Scope of IMID Collaboration, Aiming for Deeper Insights into Sjögren’s and Atopic Dermatitis
•
Bristol Myers Squibb (BMS; NYSE: BMY) has expanded its 2016 partnership with IMIDomics, broadening the collaboration’s focus to include the collection of clinical and epidemiological data from patients with Sjögren’s disease and atopic dermatitis. This initiative aims to enhance the understanding of the underlying mechanisms of these immune-mediated inflammatory diseases…
-
AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion, Strengthening Neuroscience Portfolio
•
AbbVie (NYSE: ABBV) has announced its agreement to acquire Cerevel Therapeutics (NASDAQ: CERE) for approximately $8.7 billion, with the transaction expected to close in mid-2024, pending customary conditions. This acquisition is set to enhance AbbVie’s neuroscience portfolio by incorporating Cerevel’s promising drug candidates, which boast multibillion-dollar sales potential across various…
-
Quinovare Partners with AIM Vaccine to Enhance Vaccine Accessibility in China
•
Quinovare Medical Technology Co., Ltd., a China-based specialist in needle-free injectors, has announced a strategic partnership with AIM Vaccine Co., Ltd. (HKG: 6660) to enhance the accessibility and affordability of vaccines through their combined resources and expertise. Financial terms of the collaboration were not disclosed. AIM Vaccine is a major…
-
Hisilicon Medical Technology Secures Nearly RMB 100 Million in Series A Funding
•
Guangdong Hisilicon Medical Technology Co., Ltd., a China-based firm, has successfully raised nearly RMB 100 million (approximately USD 13.9 million) in a Series A financing round led by Qiaojing Capital. The funding round also attracted participation from notable investors including Hongcheng Investment, RongTong Capital, Chiron Ventures, and Zhejiang Innovation and…
-
Boehringer Ingelheim Partners with Ten63 Therapeutics to Discover Novel Drug Molecules
•
Boehringer Ingelheim (BI), based in Germany, has announced a collaboration with U.S. drug discovery firm Ten63 Therapeutics, aimed at identifying multiple novel molecules across various indications with significant unmet medical needs. Financial details of the partnership have not been disclosed. This collaboration will leverage BI’s extensive pre-clinical and clinical expertise…
-
Innovent Biologics Expands Partnership with Synaffix for New ADC Development
•
Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a subsidiary of Lonza (SWX: LONN). This follows an initial agreement from June 2021, during which Innovent successfully utilized Synaffix’s antibody-drug conjugate (ADC) technology platforms on a non-exclusive basis to develop IBI343, an anti-CLDN18.2 ADC that…
-
Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection
•
Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics, focusing on cell therapies aimed at preventing allograft rejection in solid organ transplants. Under the agreement, Taiwan Bio will leverage its manufacturing expertise in cell therapy to enhance TRACT’s immune-modulating regulatory T cell therapy platform.…
-
AbbVie Partners with BigHat Biosciences to Develop Next-Gen Antibodies for Oncology and Neuroscience
•
AbbVie (NYSE: ABBV) has enlisted the expertise of BigHat Biosciences, a US-based company specializing in machine learning and wet lab platforms, to discover and develop next-generation antibodies for multiple therapeutic targets in oncology and neuroscience. BigHat will receive an upfront payment of USD 30 million, with the potential for up…
-
Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement with German pharmaceutical giant Merck KGaA for its in-house developed colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). According to the agreement, Merck will secure an exclusive license to commercialize pimicotinib in mainland China, Hong…
-
Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu Pharmaceutical Technology Co., Ltd, a China-based company previously established as a wholly foreign-owned enterprise (WFOE) by Hong Kong WD Pharmaceutical Co., Ltd. The financial details of the agreement have not been disclosed. This collaboration aims…
-
Gedeon Richter Acquires Rights to Mithra’s Contraceptive and Menopause Treatments for Chinese Market
•
Gedeon Richter Plc, a Hungarian pharmaceutical company, and Belgium’s Mithra (OTCMKTS: MITPF) have entered into a licensing agreement that grants Gedeon the rights to develop and commercialize two of Mithra’s products in the Chinese market. The products in question are the oral contraceptive Estelle, which contains 15 mg estetrol (E4)…
-
Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary
•
Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its footprint in the Chinese market with the full acquisition of Sandoz’s (SWX: SDZ) China subsidiary, Sandoz (China) Pharmaceutical Co., Ltd. This acquisition will grant Aspen all commercial and intellectual property rights to the subsidiary’s existing…
-
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
•
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech firm Carmot Therapeutics, a specialist in anti-obesity and diabetes drugs, in a transaction valued at USD 2.7 billion with potential milestone payments of up to USD 400 million. The acquisition is expected to close in…
-
Autobio Diagnostics and China National Medical Device Form Strategic Partnership
•
Autobio Diagnostics Co., Ltd (SHA: 603658), a Chinese in-vitro diagnostics company, has entered into a partnership with China National Medical Device Co., Ltd, another domestic firm. The collaboration aims to capitalize on the strengths of both parties to jointly promote and apply high-quality domestic products, thereby expanding the scale of…
-
AbbVie to Acquire ImmunoGen for USD 10.1 Billion, Expanding Oncology Portfolio
•
AbbVie (NYSE: ABBV) has reached an agreement to acquire fellow U.S. biotech ImmunoGen (NASDAQ: IMGN) for an equity value of approximately USD 10.1 billion. The transaction is anticipated to close in mid-2025, pending the fulfillment of customary regulatory conditions. This acquisition will enhance AbbVie’s portfolio with Elahere (mirvetuximab soravtansine), an…
-
SanegeneBio Secures Over USD 80 Million in Series A+ Funding to Advance RNAi Therapeutics
•
SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80 million in a Series A+ financing round co-led by Tencent Investment and YuanBio Venture Capital. The funding round also saw participation from Northern Light Venture Capital, C&D Emerging Industry Equity Investment, Yuanhe Holding, Shanghai Healthcare…
-
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona’s proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for…
-
Concentra Biosciences Targets China-Based Biotech LianBio in Unsolicited Takeover Bid
•
LianBio (OTCMKTS: LIANY), a China-based biotech firm, has become the target of an unsolicited takeover bid by Concentra Biosciences LLC, a company controlled by private equity fund Tang Capital Partners LP. The cash offer is set at USD 4.30 per share for 100% of LianBio’s equity, a significant premium that…
-
Bayer Partners with CrossBay Medical to Enhance Hormonal IUS Delivery System
•
Germany’s Bayer (ETR: BAYN) has announced a strategic partnership with women’s health innovator CrossBay Medical to develop a user-friendly inserter designed for the delivery of Bayer’s hormonal intrauterine systems (IUSs) via the cervix. This collaboration seeks to enhance CrossBay’s CrossGlide inserter, transforming it into a single-handed device aimed at minimizing…
-
Johnson & Johnson Acquires Laminar for $400 Million to Enhance Heart Rhythm Solutions
•
Johnson & Johnson (J&J; NYSE: JNJ) has finalized the acquisition of medical device manufacturer Laminar for $400 million, along with potential milestone payments, integrating the company into its MedTech subsidiary, specifically within Biosense Webster, a division focused on heart rhythm disorders. Laminar’s innovative technology employs rotational motion to eliminate the…
-
MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion of its IT infrastructure to Amazon Web Services (AWS), a move aimed at enhancing efficiency in drug discovery and clinical trial development. This multiyear initiative, revealed by parent company Amazon (NASDAQ: AMZN) this week, will…
-
Perpetual Medicines Launches with $8 Million Seed Round, Led by Chengwei Capital
•
Perpetual Medicines, a biotech firm with operations in Shanghai and Boston, has officially launched, announcing an $8 million seed financing round led by Chengwei Capital. The company has appointed Dr. Kerry Blanchard as co-founder and CEO, following his recent departure from Everest Medicines in August. Perpetual aims to develop an…
-
Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic AI to leverage the latter’s single-cell transcriptomics platform for the discovery of drug targets in stroma-rich cancers, including colorectal and pancreatic tumors. In return for the option to license the identified targets and secure development…
-
Eli Lilly Partners with Prism BioLab to Discover Peptide-Mimicking Small Molecule Inhibitors
•
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with Japan-based biotechnology firm Prism BioLab to discover peptide-mimicking small molecule inhibitors (SMIs) for up to three protein-protein interaction (PPI) targets. Under the agreement, Lilly will be responsible for the clinical development and commercialization of any successful candidates, while…
-
Bosscome Science & Technology Secures Series A Funding for Precision Medical Navigation Systems
•
Bosscome Science & Technology, a Chongqing-based developer of integrated optical and magnetic navigation systems, has reportedly secured “tens of millions” of renminbi in a Series A financing round led by Zhongxi Life Investment Partnership and Rayfund Investment. The funds raised will be allocated towards market promotion of its submillimeter level…
-
Pfizer Enters Strategic Alliance with Guangdong Government to Boost Biomedicine R&D
•
Pfizer (NYSE: PFE), the US pharmaceutical powerhouse, has signed a strategic memorandum of understanding with the People’s Government of Guangdong Municipality to collaborate on various initiatives within the biomedicine sector. This partnership will focus on research and development innovation, R&D translation, and talent cultivation, with the overarching goal of enhancing…
-
Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce
•
Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s saliva-based Chronomics biological age tests through electronic channels. Based in the UK, Hurdle specializes in diagnostics, and its at-home biomarker tests utilize epigenetic markers to measure biological age, positioning them as precision health solutions aimed…
-
BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal
•
Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ: RNA) focused on the discovery, development, and commercialization of cardiology-oriented antibody oligonucleotide conjugates (AOCs). This innovative class of RNA therapeutics merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, building on insights…
-
Blue Sail Medical and China National Medical Device Forge Strategic Partnership for Growth
•
Blue Sail Medical Co., Ltd (SHE: 002382), a prominent player in China’s medical device sector, has announced a cooperation framework agreement with fellow domestic firm China National Medical Device Co., Ltd. The partnership aims to capitalize on the respective strengths of both companies, focusing on market channels, product offerings, brand…
-
Mabwell Bioscience Enters Thai Market with Licensing Deal with Innobic
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a Chinese biopharmaceutical company, has announced the signing of a licensing and supply agreement with Thailand-based Innobic. Under the terms of the deal, Innobic will support the registration and commercialization of Mabwell’s products in Thailand, a member country of the Pharmaceutical Inspection Co-operation…
-
Taihe Weiye Biotechnology Secures RMB 300 Million in Series A+ Financing to Expand Production
•
Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has reportedly secured nearly RMB 300 million (USD 42 million) in a Series A+ financing round, following its RMB 200 million (USD 28 million) Series A funding in August this year. The latest round was co-led…
-
Beijing QL Biopharmaceutical Boosts Pipeline with RMB 200 Million Series B+ Round
•
Beijing QL Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company, has reportedly secured nearly RMB 200 million (USD 28 million) in a Series B+ financing round. The round was led by IMEIK Technology and China-US Green Fund, with additional investments from Jiayuan Fund, Chengdu Capital Group, Lanchi Ventures, and other parties.…
-
Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy
•
Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive endoscopy, has entered into a partnership with Olympus Corporation, a major player in the digestive endoscopy field. The collaboration aims to explore innovative applications and development of AI technology within the digestive endoscopy sector. Financial…
-
DxVx Secures License for OVM-200 Anti-Cancer Vaccine from Oxford Vacmedix
•
South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to further develop the anti-cancer vaccine. OVM is anticipated to initiate a Phase Ib study for the vaccine in the UK in the near future, while DxVx will launch a study in Asia, encompassing South Korea…
-
KingWise Partners with Truking Technology for Gynecological Tumor Gene Therapy Facilities
•
KingWise, a Wuhan-based specialist in gynecological tumor diagnostics, has entered into a partnership with local firm Truking Technology Ltd (SHE: 300358) concerning KingWise’s facilities for gynecological tumor gene therapy products. Truking will offer KingWise a comprehensive end-to-end (EPC) solution for biopharmaceutical front-end processes, including factory design, purification engineering, water distribution…
-
OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika
•
OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular intervention based in Shenzhen, is poised to acquire an 84% stake in Indonesia-headquartered PT Revass Utama Medika for a consideration between USD 10.08 million to USD 20.16 million. PT Revass Utama Medika, which is focused…
-
Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has announced the termination of a licensing agreement between its subsidiary Broncus Medical and Hangzhou Norchant, which was originally signed in September 2021.…
-
Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China
•
China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the rights to develop the anti-inflammatory monoclonal antibody rademikibart from US-based Connect Biopharma Holdings Ltd (NASDAQ: CNTB). The deal, negotiated with Connect Bio’s China-based subsidiaries, Connect Biopharma Hong Kong Ltd and Suzhou Connect Biopharma Co., Ltd,…
-
Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development
•
China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop antibody drug conjugates (ADCs) leveraging Escugen’s linker-payload technology, EZWi Fit, and Foreseen’s first-in-class antibodies and targets. This collaboration aims to create ADCs with enhanced drug efficacy and resistance in various tumor models, offering differentiated clinical…
-
Zhejiang Huanqing Medical Technology Secures Series A Financing for Heart Failure Innovations
•
Zhejiang Huanqing Medical Technology Co., Ltd, a Chinese specialist in heart failure solutions, has reportedly raised “tens of millions” of renminbi through a Series A financing round. This funding was facilitated by notable investors including Zhangjiang Leading VC, Haining Juan Lake Dream Technology Fund, Tailong VC, and Tahoe Venture Investment.…
-
True Health Secures Over RMB 100 Million in Series B+ Financing for Surgical Robot Development
•
True Health, a Guangdong-based surgical robot developer backed by Gree Group, has reportedly raised over RMB 100 million (approximately USD 14 million) in a Series B+ financing round. This significant funding will be allocated to enhance research and development efforts, accelerate innovation in the surgical robot sector, and procure essential…
-
Stada Arzneimittel AG Partners with CR Sanjiu for Distribution in China
•
Germany-based Stada Arzneimittel AG has announced a strategic distribution and promotion partnership with China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999). This collaboration aims to enhance the reach of Stada’s cough and cold brands across hospital, pharmacy, and e-commerce channels in China. Key Brands Included in the Partnership The brands…
-
Boehringer Ingelheim Acquires T3 Pharmaceuticals to Boost Immuno-Oncology Portfolio
•
Germany’s Boehringer Ingelheim has announced the purchase of Switzerland-based biotechnology firm T3 Pharmaceuticals this week, in a strategic move to expand its immuno-oncology pipeline. The transaction is valued at up to CHF 450 million (USD 510 million), highlighting Boehringer Ingelheim’s commitment to advancing cancer treatments. T3 Pharmaceuticals’ Innovative Approach to…
-
Venus Medtech Partners with Valgen Holding on DragonFly Valve System
•
China-based Venus Medtech (Hangzhou) Inc., (HKG: 2500), has entered into a strategic partnership with Valgen Holding Corporation concerning Valgen’s DragonFly transcatheter mitral valve clamp system (DF). The financial terms of the agreement have not been disclosed. Commercial Collaboration and Market ExpansionUpon obtaining market approval for the DragonFly system, the two…
-
Oculotronics Secures Pre-Series A Funding for Ophthalmic Surgical Robotics
•
Oculotronics, a Guangzhou-based developer of ophthalmic surgical robots, has reportedly raised tens of millions of renminbi in a pre-Series A financing round. The funds raised will be allocated towards the clinical study and industrialization of its flagship product, a micron-level high-precision ophthalmic surgical robot. Additionally, the capital will support the…
-
Genentech and NVIDIA Collaborate to Advance Drug Discovery with AI
•
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has entered into a collaboration agreement with semiconductor manufacturer NVIDIA (NASDAQ: NVDA) to expedite drug discovery and development. This partnership aims to harness the power of artificial intelligence (AI) by integrating Genentech’s biological and molecular datasets with NVIDIA’s advanced supercomputing…
-
MSD to Acquire Caraway Therapeutics for USD 610 Million to Boost Neurodegenerative Disease Portfolio
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an agreement to purchase Caraway Therapeutics, a US-based pre-clinical company, for a potential total of USD 610 million, which includes upfront and milestone payments. This acquisition will enhance MSD’s portfolio with a range of small-molecule candidates targeting neurodegenerative and rare diseases.…
-
EC Healthcare Partners with Jiangxi Rimag Group to Expand Medical Imaging Services
•
China-based EC Healthcare (HKG: 2138) has entered into a partnership with Jiangxi Rimag Group Co., Ltd (HKG: 2522) to strengthen the development of medical imaging in the Greater Bay Area and to extend the medical imaging business from Hong Kong to other countries and regions. The financial details of the…
-
Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments
•
China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into a cooperation framework agreement with Wuxi Gaofa Investment Development Group Co., Ltd to establish a joint venture (JV). The JV will focus on the research, development, manufacturing, and sale of golidocitinib and DZD8586, which are…
-
BeiGene Ltd Strikes Exclusive Global License Deal with Ensem Therapeutics for CDK2 Inhibitor
•
China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a licensing agreement with Ensem Therapeutics Inc., a biopharma company incubated by CBC Group and operating in Massachusetts, US, and Shanghai, China. According to the agreement, BeiGene will obtain an exclusive global license to Ensem’s oral cyclin-dependent…
-
XtalPi Inc. and Singapore’s EDDC Broaden Collaboration in AI-Driven Drug Discovery
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a memorandum of understanding (MOU) with the Experimental Drug Development Centre (EDDC) in Singapore to form a collaborative partnership. The two entities have pledged to expand their collaboration to include the application of automated synthesis experiments and large language models…
-
Asia Regenerative Medicine Secures Pre-Series A Financing for Bioartificial Organ Development
•
Shenzhen-based bioartificial organ developer, Asia Regenerative Medicine, has reportedly raised tens of millions of renminbi in a pre-Series A financing round. The round was led by Dee Capital, with additional investments from West Lake Photonics, HWealth Capital, Topology Capital, Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd, and Ke Xi…
-
Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project
•
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a partnership with compatriot firm Asclepius Technology Company Group. The agreement, with financial details undisclosed, will see Porton provide development, production, and application services in China for Asclepius’s NK cell project, which has applications in cancer…
-
VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round
•
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of a financing round, securing close to USD 210 million with backing from Temasek, Highlight Capital (HLC), and True Light. The Viva Biotech Holdings group obtained nearly USD 150 million through the transfer of approximately 24.21%…
-
Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases
•
Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), acquiring rights to the latter’s reversible dipeptidyl peptidase 1 (DPP1) inhibitor, HSK31858, for respiratory diseases. Chiesi will assume development, manufacturing, and commercial rights to the molecule in markets outside Greater China, excluding…
-
Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments
•
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma USA, is partnering with Treehill Partners, a US-based financial and deal-making advisory firm specializing in the healthcare sector. The collaboration aims to establish a jointly operated investment vehicle targeting individual clinical-stage assets. Targeting High-Potential Clinical-Stage…
-
Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria
•
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation agreement with Nigeria-based Fidson Healthcare plc. The partnership aims to facilitate the import of innovative HIV/AIDS therapies into Nigeria, a country with a significant population of 1.9 million HIV-infected individuals. Multi-Layered Collaboration on HIV/AIDS TreatmentsThe…
-
GE Healthcare’s Shanghai Innovation Hub Onboards Initial Start-Ups
•
GE Healthcare’s (NASDAQ: GEHC) newly established Shanghai innovation center, dedicated to advancing healthcare projects, has onboarded its first four start-ups. The selected companies include Ronovo Surgical, a manufacturer of abdominal surgery robots; MiDIVI, a developer of extended reality technology; RayShape Medical Technology, specializing in artificial intelligence ultrasound imaging diagnostics; and…
-
WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange
•
WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds…
-
Winning Health Partners with Shanghai Seventh People’s Hospital on Medical AI Services
•
Shanghai-based medical information industry player, Winning Health (SHE: 300253), has announced a partnership with Shanghai Seventh People’s Hospital to focus on medical artificial intelligence (AI) services. Collaboration on Medical AI Development and ApplicationThe collaboration aims to deepen research and development, application, and implementation of medical AI technologies. Together, Winning Health…
-
Thermo Fisher Scientific Expands Partnership with Sangon Biotech to Include GC/MS
•
US-based life sciences giant Thermo Fisher Scientific Inc., (NYSE: TMO) has announced an expansion of its strategic partnership with China-based contract research organization (CRO) Sangon Biotech. This development builds upon their initial agreement signed in August 2023, which now encompasses gas chromatography-mass spectrometry (GC/MS) in addition to the gene science…
-
Usynova Pharmaceuticals Inks Licensing Deal with AstraZeneca for KRASG12D Inhibitor UA022
•
Shanghai-based Usynova Pharmaceuticals Ltd has announced a licensing agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) concerning its pipeline candidate, UA022. UA022 is a small-molecule drug targeting the KRASG12D mutation, currently in the pre-clinical stages of development. Terms of the Agreement and FinancialsUnder the agreement, AstraZeneca (AZ) will secure…
-
Amgen Partners with PostEra for Small-Molecule Drug Discovery Initiative
•
Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra, covering up to five small-molecule programs. As part of the agreement, Amgen will also secure a future option to leverage PostEra’s AI technology for its own pipeline development. Financial Details and PostEra’s Track RecordWhile the…
-
Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology
•
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio’s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT.…
-
University of Hong Kong to Host Infectious Disease Labs by UN’s Vaccine Institute and Cambridge University
•
The University of Hong Kong (HKU) is poised to host new infectious disease laboratories established in collaboration with the United Nations’ (UN’s) International Vaccine Institute and Cambridge University. As reported by The South China Morning Post, the labs are anticipated to be operational by the second quarter of 2024 and…
-
Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services
•
Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an initial public offering (IPO) on the Hong Kong Stock Exchange, with details currently being compiled. The company has previously raised a war chest of RMB 900 million through several financing rounds. Founded in 2014, Rimag…
-
Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen
•
Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights to its anti-IL-7Rα biologic, bempikibart, from US-based Amgen (NASDAQ: AMGN). The biologic is currently in middle-stage trials for autoimmune diseases. This move follows Amgen’s acquisition of Horizon Therapeutics earlier this year, which had entered into…
-
Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry
•
Daewoong Pharma, a leading South Korean pharmaceutical company, has reportedly signed a memorandum of understanding (MoU) with China Meheco International, a move that will facilitate the export of Daewoong’s pharmaceutical products into the Chinese market. This comprehensive agreement encompasses the entire portfolio of Daewoong’s products, including their innovative in-house novel…
-
Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies
•
Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership with Arcellx (NASDAQ: ACLX), a US-based biotechnology firm. The collaboration includes the in-licensing of ACLX-001, a multiple myeloma (MM) engineered cell therapy, and the extension of their CART-ddBCMA program to include lymphomas . Financial Terms…
-
AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management
•
US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group Co., Ltd, (HKG: 1099) a leading Chinese pharmaceutical company, to improve access to novel drugs and explore standardized patient management practices in China. Expanding Access and Patient SupportThe collaboration will utilize Sinopharm’s extensive SPS+ professional…
-
Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment
•
Japan’s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US biopharmaceutical company Propella Therapeutics this week, with a transaction value of USD 175 million. The deal is anticipated to be finalized by March 2024, subject to the fulfillment of customary conditions. With this acquisition, Astellas…
-
Novartis Acquires HDAC6 Inhibitor CKD-510 from CKD Pharmaceutical in a $1.31 Billion Deal
•
Swiss pharmaceutical major Novartis (NYSE: NVS) announced last week that it has struck a deal to acquire the HDAC6 small-molecule inhibitor (SMI) CKD-510 from South Korea’s Chong Kun Dang (CKD) Pharmaceutical. The transaction includes an upfront payment of USD 80 million, with the potential for up to USD 1.23 billion…
-
Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition
•
The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer of a radioactive materials license from Point Biopharma (NASDAQ: PNT) to Eli Lilly (NYSE: LLY). This decision marks the final regulatory clearance necessary for Eli Lilly’s acquisition of Point Biopharma, which was announced last month.…
-
Hubei Topgene Biotechnology and Shanghai Genechem Partner on Drug Toxicological Safety and Clinical Research
•
Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with Shanghai Genechem Co., Ltd to collaborate on integrated drug toxicological safety evaluation, clinical research translation projects, and resource allocation. The partnership aims to leverage the strengths of both companies to enhance drug development processes. Financial…
-
PRECEDO Secures Over RMB 100 Million in Financing to Build Living Primary Cancer Cell Bank
•
PRECEDO, a leading cell engineering specialist headquartered in Hefei, has reportedly secured more than RMB 100 million (USD 13.8 million) in a recent financing round. This capital injection, which includes investment from Sunland Fund and other financial backers, will be directed towards the construction of the renewable Living Primary Cancer…
-
Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to establish a joint venture (JV) with Germany’s Eckert & Ziegler Radiopharma Projekte UG. This strategic partnership aims to combine the expertise of both companies in the field of medical isotopes. Investment and JV FormationThe joint…
-
Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership agreement with Chongqing Yuyan Pharmaceutical Co., Ltd. This strategic alliance involves a significant investment and the acquisition of exclusive commercialization rights for Yuyan’s medical aesthetics product in key regions. Investment and Stake AcquisitionAs per the…
-
Zeiss Group and China’s Healthcare Cloud Collaborate on Ophthalmic Services in China
•
Germany-based Zeiss Group, a leader in optical systems and optoelectronic product manufacturing, has entered into a partnership with China’s Healthcare Cloud, an online health services provider, during the recent China International Import Expo (CIIE) meeting. The collaboration aims to enhance ophthalmic services in China by leveraging the strengths of both…
-
Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal
•
China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric antigen receptor (CAR) T cell therapies with Novartis Pharma AG (NYSE: NVS) in a landmark USD 1.1 billion deal. The Swiss pharmaceutical giant has acquired exclusive global development, manufacturing, and commercialization rights to certain assets…
-
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has entered into a partnership with China-based GeneQuantum Healthcare. The collaboration aims to integrate the core technology platforms and professional expertise of both companies to empower the early discovery…
-
Autobio Diagnostics Expands Strategic Partnership with Guorun Medical Supply Chain Services
•
China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with Guorun Medical Supply Chain Services (Shanghai) Co., Ltd, along with 11 shareholding companies. This collaboration aims to enhance the procurement and distribution of in vitro diagnostic (IVD) products and services, ensuring a robust supply chain and fostering…
-
Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics
•
Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led a GBP 4.3 million (USD 5.3 million) seed funding round for Scotland-based biotechnology company Glox Therapeutics. The investment will enable Glox to establish new laboratories and expand its team, bolstering its mission to develop precision…
-
AnchorDx Medical Partners with DiaCarta for Global Molecular Diagnostics Development
•
AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing based in China, has entered into a partnership with DiaCarta, Ltd, a US-based precision molecular diagnostics company. The collaboration aims to focus on the development and commercialization of cancer screening products, leveraging their proprietary technologies in DNA methylation and mutation…
-
Beijing-Based Immupeutics Medicine Secures Tens of Millions in Pre-Series A+ Financing
•
Immupeutics Medicine, a Beijing-based developer in the field of tumor immunotherapy, has reportedly secured tens of millions of renminbi in a pre-Series A+ financing round. The funding round was led by Beijing state-owned Capital Operation and Management Center, with additional investments from Junshi Bio, Alwin Capital, and the company’s founder.…
-
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
•
Among the series of deals secured by multinational corporations at the 6th China International Import Expo (CIIE), Italy-based Chiesi Farmaceutici S.p.A. has inked a partnership with Shanghai Pharmaceuticals Co., Ltd (SHA: 601607, HKG: 2607). This strategic alliance aims to capitalize on Shanghai Pharmaceutical’s extensive distribution network. As reported by Shine,…
-
Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology
•
Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration with US biotechnology firm Recursion Pharmaceuticals (NASDAQ: RXRX). The partnership, which was initially focused on fibrosis, will now shift its attention to precision oncology. This strategic move will see the initiation of up to seven…
-
Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent
•
On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans for its subsidiary, Lizhu Reagent. The company has decided to terminate its initial plan to spin off Lizhu Reagent for a listing on the Shenzhen Stock Exchange’s ChiNext board. Instead, it will file for a…
-
Aiming Med Partners with Becton, Dickinson and Co. to Advance Tumor Precision Medicine
•
Aiming Med, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a strategic partnership with Becton, Dickinson and Co. (BD) during the 6th China International Import Expo (CIIE) in Shanghai this week. This collaboration aims to enhance the application of advanced tumor organoid and single-cell multi-omics…
-
Danaher Corporation Partners with CHEA to Boost Oncology Centers in Chinese Counties
•
US-based science and technology services giant Danaher Corporation (NYSE: DHR) has entered into a partnership with the hospital management unit of the China Health Economics Association (CHEA). The collaboration aims to promote the development of oncology prevention and control centers at the county hospital level in China, with no financial…
-
SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases
•
Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm Huadong Medicine Co., Ltd (SHE: 000963). The collaboration will utilize SanegeneBio’s Ligand and Enhancer Assisted Delivery (LEAD) technology platform to develop small interfering RNA (siRNA) drugs targeting chronic metabolic diseases, with the potential to expand…
-
Shanghai Qingyun Pharmaceutical Teams Up with Organon at CIIE for Remeron Marketing
•
China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon (NYSE: OGN) during the 6th China International Import Expo (CIIE) in Shanghai. The collaboration is centered around Organon’s Remeron (mirtazapine), with Qingyun playing a role in implementing omnichannel marketing strategies for the drug. Mirtazapine’s Mechanism…
-
Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements
•
Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with Shenzhen Eureka Biotechnology Co., Ltd, a domestic CGT-focused Contract Development and Manufacturing Organization (CDMO) service provider. Combining Expertise for Large-Scale Virus Vector ProductionThe collaboration aims to capitalize on Biosmelt’s GMP grade lentivirus vector suspension production…
-
Bayer Secures Multiple Procurement Deals at the 6th CIIE
•
At the 6th China International Import Expo (CIIE) in Shanghai, Germany-headquartered Bayer (ETR: BAYN) announced a series of procurement agreements with several Class 3A hospitals in China. Among these institutions is the prestigious Fourth Affiliated Hospital of China Medical University. Bayer’s Commitment to Healthcare Partnerships in ChinaThe agreements signed during…
-
ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions
•
Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550), focusing on the digestive enzyme field. The collaboration aims to explore and promote product development in the digestive tract health sector, with no financial details disclosed. Focus on Digestive Tract Health and…
-
CStone Pharmaceuticals Enters Licensing Agreement with Allist Pharmaceuticals for Gavreto in China
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced a licensing agreement with Allist Pharmaceuticals Co., Ltd, granting the Shanghai-based biotech exclusive commercial promotion rights to Gavreto (pralsetinib) in mainland China. CStone retains development, regulatory filing, and other rights excluding promotion in mainland China. Under the agreement, CStone will receive an undisclosed…
-
Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004
•
Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will take over the development and commercialization rights to Eccogene’s GLP-1 receptor agonist drug candidate, ECC5004, for the treatment of obesity, type 2 diabetes,…
-
Zhejiang Boner Medical Secures Over RMB 800 Million in Pre-IPO Financing for Strategic Expansion
•
Zhejiang Boner Medical Investment Management Co., Ltd., known as Bang-er Orthopedics, a leading hospital investment operator focused on orthopedics and rehabilitation, has reportedly raised over RMB 800 million (USD 110 million) in a pre-IPO financing round. The round was led by C&D Emerging Industry Equity Investment, with participation from Sunshine…
-
Suzhou Porton Biologics Partners with BioMap to Enhance AAV Vector Design in Gene Therapy
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with US biotech company BioMap, an AI-based drug discovery platform co-founded by Baidu’s CEO Robin Li and Baidu Ventures CEO Wei Liu. This collaboration aims to develop an AAV assembly efficiency model…
-
CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships
•
The 6th China International Import Expo (CIIE) held in Shanghai this week has been a platform for multiple companies to announce their strategic partnerships in China. Among the notable participants are Danaher (NYSE: DHR), Boehringer-Ingelheim (BI), Merck Sharp & Dohme (MSD, NYSE: MRK), Johnson & Johnson (J&J, NYSE: JNJ), BeiGene…
-
Zymeworks and BeiGene Terminate Licensing Agreement for ZW49 ADC
•
Zymeworks Inc. (NASDAQ: ZYME), a Canada-based biotech company, has announced in its Q3 financial report that the licensing agreement with China’s BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) for the antibody drug conjugate (ADC) zanidatamab zovodotin (ZW49) has been cancelled. This development affects the HER2-targeted ADC that BeiGene had…
-
Worg Pharmaceuticals Expands into Spain with Acquisition of Diater for EUR 150 Million
•
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has formally entered the Spanish market by obtaining the necessary regulatory approval and completing the acquisition of local biopharmaceutical company Diater from fund manager Nazca Capital for approximately EUR 150 million (USD 160 million). This strategic move marks a significant expansion for…
-
AstraZeneca Expands China Presence with Over 30 Agreements at CIIE
•
At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc (AZ; NASDAQ: AZN) has signed over 30 agreements with Chinese provincial governments and other entities, marking a significant expansion in China. The agreements include substantial investments and collaborations aimed at enhancing local production, improving access…
-
Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China
•
Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti’s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will…
-
Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China
•
Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading China-based pharmaceutical distribution giant, to collaborate on the Alzheimer’s disease (AD) drug Leqembi (lecanemab). The deal is potentially valued at RMB 1.5 billion (USD 205 million) and…
-
Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China
•
Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a partnership with Shanghai Pharmaceuticals, a leading China-based pharmaceutical distribution giant (SPH; HKG: 2607; SHA: 601607), to co-construct a new life sciences incubator named Co.Lab. This collaboration is designed to foster cutting-edge innovation in cell and…
-
Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based medical device company Insightec Ltd, a leader in magnetic resonance (MR)-guided Focused Ultrasound equipment. This partnership aims to apply Insightec’s advanced Focused Ultrasound brain therapy technology for the treatment of idiopathic tremors and Parkinson’s disease…
-
Qingdao’s Raise Care Secures Over RMB 100 Million in Series B Financing Led by CITIC Capital
•
Qingdao-based Raise Care has reportedly secured upwards of RMB 100 million (USD 13.7 million) in a Series B financing round, according to recent reports. The round was led by CITIC Capital’s healthcare fund, with participation from CICC Capital, Jufeng S&T Venture Investment, and other investors. Company Background and FocusFounded in…
-
WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), is preparing for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 178.4 million shares, priced between HKD 19.9…
-
Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery
•
China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic partnership with Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) at the 6th China International Import Expo (CIIE) in Shanghai. The collaboration focuses on the science research, application, and translation of metaverse visualization surgery,…
-
SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China
•
China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with the Italy-headquartered Menarini Group. This agreement grants SciClone exclusive development and commercialization rights to Menarini’s Orserdu (elacestrant) in China. SciClone will be responsible for conducting clinical trials, regulatory filings, and marketing and distribution of Orserdu…
-
Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA
•
Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong’s logistics and supply chain management expertise to support the introduction of Teva’s migraine therapy, fremanezumab, in the Greater Bay…
-
Takeda Partners with New Horizon Health Technology to Manage Helicobacter pylori in China
•
At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a partnership with China-based New Horizon Health Technology Co., Ltd (HKG: 6606), a leading cancer diagnostics developer. The collaboration aims to develop a comprehensive management solution for Helicobacter pylori patients in China, underscoring Takeda’s (TYO: 4502)…
-
BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal
•
Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based Biotheus Inc., focusing on the development and commercialization of the bispecific antibody (BsAb) PM8002. The deal grants BioNTech development, manufacturing, and commercial rights to PM8002 in all markets outside of Greater China, marking a significant…
-
Baheal Pharmaceutical Partners with AstraZeneca for Exclusive Distribution of Losec in China
•
China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with AstraZeneca (AZ, NASDAQ: AZN), securing exclusive retail distribution rights for the renowned digestive drug Losec (omeprazole) in mainland China. The financial details of this agreement have not been disclosed. This partnership follows Baheal’s previous acquisition…
-
Ji Xing Pharmaceuticals Partners with WuXi STA for Sterile Nasal Spray Production
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a strategic partnership with WuXi STA, a subsidiary of WuXi AppTec (HKG: 2359, SHA: 603259), to establish a sterile nasal spray production line. This collaboration aims to leverage the strengths of both companies, with the new production facility set to…
-
HKU and SIIDB Collaborate on Drug Development for Infectious Diseases
•
The Department of Microbiology at the University of Hong Kong (HKU) and the Shanghai Institute of Infectious Disease and Biosecurity (SIIDB) have entered into a Memorandum of Understanding (MoU) to collaborate on drug development. This strategic partnership aims to establish the United Research Center of Innovative Drugs for Major Infectious…
-
XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has announced a strategic partnership agreement with China-based CK Life Sciences (HKG: 0775). The collaboration aims to leverage AI and clinical diagnosis data, including biomarker information from cancer patients and healthy populations, to develop molecular diagnostic models that predict cancer prognosis risk based…
-
Bayer Extends Collaboration with Broad Institute to 2028 for Oncology Drug Targets and Therapies
•
Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the US-based research center, the Broad Institute, until 2028. The partnership focuses on identifying new drug targets in oncology and developing innovative cancer therapies. The financial details of the extended agreement have not been disclosed. Combining…
-
AbbVie Secures Option Agreement with Aldeyra Therapeutics for RASP Modulator Reproxalap
•
AbbVie (NYSE: ABBV) has entered into an option agreement with Aldeyra Therapeutics (NASDAQ: ALDX), a US-based biopharmaceutical company, to acquire a development, manufacturing, and commercialization license for the reactive aldehyde species (RASP) modulator, reproxalap. The agreement grants AbbVie co-exclusive rights in the US and exclusive rights in all other territories…
-
Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals
•
BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, have announced a significant agreement. Sanofi has reacquired the exclusive development and commercialization rights to Rezurock (belumosudil), the world’s first ROCK2 inhibitor, in mainland China from BK Pharmaceuticals Ltd and BioNova…
-
AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies
•
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA: ALCLS; NASDAQ: CLLS) to develop next-generation therapeutics, focusing on areas of high unmet need such as oncology, immunology, and rare diseases. This collaboration aims to leverage Cellectis’s gene editing technologies and manufacturing capabilities to advance…
-
WE LINKING Secures Angel Financing for Implantable Brain Computer Interface Development
•
Shenzhen-based company WE LINKING, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens of millions of renminbi in an angel financing round. The round was led by Gaorong Capital, with additional investments from Beijing Life Science Park Innovation Investment Fund, Qiji Investment, and existing investor CDH Investments.…
-
3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab
•
China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with compatriot firm CStone Pharmaceuticals (HKG: 2616), focusing on CStone’s anti-programmed death-1 (PD-1) antibody, nofazinlimab. This partnership signifies a significant expansion in the immuno-oncology space for both companies. Financial Terms and Agreement DetailsUnder the terms of…
-
Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma
•
US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali Medpharma. While the financial details of the deal remain undisclosed, this strategic move significantly expands Resolian’s bioanalysis laboratory capabilities to China, complementing its existing operations in the US, UK, and Australia. This expansion allows Resolian’s…
-
Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round
•
Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be…
-
ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development
•
ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in…
-
AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib
•
China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma Nippon Kayaku Co., Ltd. This strategic partnership grants Nippon Kayaku marketing and distribution rights for AnHeart’s leading pipeline candidate, taletrectinib, a next-generation ROS1 inhibitor. Taletrectinib: A Promising Treatment for ROS1-Positive NSCLCTaletrectinib is an oral, potent,…
-
BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences
•
Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based in China, focusing on the development of BioLineRx’s multiple myeloma drug, motixafortide. This strategic partnership grants Gloria exclusive rights to develop motixafortide across all indications throughout Asia. As part of the agreement, Gloria is making…
-
Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals
•
China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with German giant BASF SE. This collaboration aims to explore and enhance research and development of new materials for application in drug 3D printing. Financial details of the partnership have not been disclosed. Triastek utilizes a…
-
Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform
•
Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive global license to a molecular cargo delivery platform from Vect-Horus, a French specialist in targeted drug delivery. This strategic move is aimed at addressing unmet needs within the treatment of serious chronic diseases. Terms of…
-
Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor
•
Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276). This agreement grants Merck development, manufacturing, and commercial rights to the next-generation PARP1 inhibitor HRS-1167 for all global territories outside of China. Additionally, Merck has an option…
-
Danyang Huichuang Secures Over USD 13.7 Million in Series B Funding for fNIRS Development
•
Danyang Huichuang Medical Equipment Co., Ltd, a China-based specialist in functional near-infrared spectroscopy (fNIRS), has reportedly secured over RMB 100 million (USD 13.7 million) in a Series B financing round. The funding round was led by Zhongke Haichuang, with additional contributions from Addor Capital, and existing investors Tsingyua Capital and…
-
BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma
•
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with Karyopharm Therapeutics (NASDAQ: KPTI) to evaluate the combination of BMS’s cereblon E3 ligase modulator (CELMoD) candidate, mezigdomide, with Karyopharm’s first-in-class Exportin 1 (XPO1) inhibitor, Xpovio (selinexor), plus dexamethasone. This combination is targeted at relapsed/refractory multiple…
-
Shanghai Henlius Biotech and Intas Pharmaceuticals Ink New Licensing Deal for PD-1 mAb
•
China’s Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new licensing agreement with India-based Intas Pharmaceuticals Ltd, granting Intas exclusive development and commercialization rights to its anti-programmed death-1 (PD-1) monoclonal antibody (mAb) HanSiZhuang (serplulimab) in Europe and India. This strategic partnership further expands the global reach of Henlius’s innovative…
-
Strategic Alliance Formed by uBriGene, Fraserna, and Virogin for Cell and Gene Therapy Services
•
In a significant move to bolster the cell and gene therapy (CGT) sector, China-based biotechnology firms uBriGene, Fraserna, and Virogin have entered into a strategic partnership agreement. While the financial details of the agreement remain undisclosed, the collaboration is poised to integrate the global resources of the three companies, offering…
-
Sinotau Pharmaceutical Group Secures Rights to Blue Earth Diagnostics’ Flotufolastat in China
•
Sinotau Pharmaceutical Group, a Beijing-based nuclear medicine enterprise, has entered into a licensing agreement with UK molecular imaging company Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A. Through this deal, Sinotau will gain development, manufacturing, and commercialization rights to Blue Earth’s PSMA targeted PET imaging agent, Flotufolastat (18F).…
-
Shanghai Pharmaceuticals Partners with Asymchem for Advanced Drug Development and Production
•
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a strategic partnership with compatriot firm Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading Contract Development and Manufacturing Organization (CDMO). This collaboration will span synthetic biotechnology, continuous reaction technology, and the development and production of…
-
Sonosemi Medical Secures Over USD 27.3 Million in Series B Funding for Vascular Intervention Devices
•
Sonosemi Medical Co., Ltd., a Shenzhen-based innovator in vascular graft intervention devices, has reportedly secured over RMB 200 million (USD 27.3 million) in a Series B financing round. The round was co-led by Yuexiu Industrial Investment Fund and CCB PE, with significant contributions from Tencent Investment, Eight Roads, and Alwin…
-
Aiolos Bio Inc. Raises USD 245 Million in Series A Funding Led by Top Investors
•
Aiolos Bio Inc., a US-based biotech company, has officially launched with the successful completion of a Series A financing round, raising USD 245 million. The round was co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments, with additional participation from RA Capital Management. Lead Candidate AIO-001Aiolos Bio…
-
AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design expert Nanoform Finland (HEL: NANOFH) for Starmap, an innovative AI-enabled platform. This platform facilitates confidential in silico testing of molecule candidates prior to chemical synthesis, aiming to reduce clinical attrition throughout the drug development pipeline.…
-
AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment
•
AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at accelerating the late-stage development of the JAK inhibitor Rinvoq (upadacitinib) for the treatment of systemic lupus erythematosus (SLE). This partnership marks a significant step in expanding the therapeutic applications of Rinvoq, which is already approved…
-
Leadinno Medical Valley Secures Series A+ Funding for Neuroregulation Device R&D
•
Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured over RMB 100 million (USD 15.7 million) in a Series A+ financing round. The funding, led by Dachen Caizhi Fortunevc with additional contributions from Wuxi Zhaoze Lifeng Investment, is earmarked for the research and development…
-
Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development
•
The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to support the development of CS-2036, a recombinant polio vaccine by China-based CanSino Biologics (SHA: 688185, HKG: 6185). This investment underscores the foundation’s dedication to global health initiatives and the eradication of polio. Innovative Approach to…
-
OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare
•
US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion for its latest private investment funds. The capital will be distributed among OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV, reflecting the firm’s commitment to expanding its reach…
-
BMS Regains Full Rights to Mavacamten in China and Asia from LianBio
•
Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment for hypertrophic cardiomyopathy (HCM), from China’s LianBio (NASDAQ: LIAN) in China and other Asian markets. This strategic move follows LianBio’s previous acquisition of development rights for mavacamten in Greater China, Singapore, and Thailand from MyoKardia…
-
Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio
•
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings, a biotechnology firm co-owned by UK’s Roivant Sciences (NASDAQ: ROIV) and US-based Pfizer (NYSE: PFE). The acquisition will grant Roche rights to RVT-3101, a potential best-in-class and first-in-class anti-TL1A subcutaneous antibody, in the US and…
-
J&J MedTech Partners with CED Medical for Neurointerventional Solutions
•
Johnson & Johnson MedTech’s (J&J, NYSE: JNJ) Shanghai-based subsidiary, Johnson Johnson Medical Equipment Co., Ltd, has entered into a strategic partnership with CED Medical, a neuroscience device marker headquartered in Nantong, near Shanghai. The collaboration aims to expand market reach, promote technology, and foster innovation in the field of neurointerventional…
-
MSD Cancels Development of Two Pre-Clinical ADCs from Sichuan Kelun-Biotech
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its innovative drug development subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) have announced that their US partner Merck, Sharp & Dohme (MSD; NYSE: MRK) has decided to cancel the development of one pre-clinical antibody drug conjugate (ADC) and will not…
-
AcuVu Medical Partners with Hologic for US Distribution of HummingScope Hysteroscopy System
•
AcuVu Medical, a specialist in electronic endoscopes with operations in California, USA, and Suzhou, China, has entered into an exclusive distribution and cooperation development agreement with Hologic Inc., a leading women’s health device maker headquartered in the United States and also present in China. Under the terms of the agreement,…
-
CBC HIP Secures USD 875 Million for Life Science Real Assets Venture CLSRA
•
CBC Healthcare Infrastructure Platform (CBC HIP), a prominent independent life science real assets investor in China, has reportedly closed its second funding round at USD 875 million for its inaugural life science real assets venture, CLSRA Venture I. This significant milestone includes the participation of Abu Dhabi-based sovereign investor Mubadala…
-
Hotgen Biotech Partners with Genoval Therapeutics for RNAi Drug Development
•
China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging focused controlling subsidiary and Genoval Therapeutics Co., Ltd, a Shanghai-based developer of RNAi therapeutics. The collaboration aims to advance the development of multiple pioneering small nucleic acid drugs targeting the liver and extrahepatic tissues, addressing…
-
Hansoh Pharmaceutical and GSK Ink Global Licensing Deal for Innovative ADC HS-20089
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with UK pharmaceutical giant GSK (NYSE: GSK), granting GSK development, manufacturing, and commercialization rights to its pipeline antibody drug conjugate (ADC) HS-20089 for all global territories outside Greater China. HS-20089: Targeting B7-H4 in OncologyHS-20089 is an…
-
Foundation Medicine Expands Genomic Profiling Partnership with Sequanta Technologies in China
•
US-based Contract Research Organization (CRO) Foundation Medicine Inc. has announced the expansion of its existing partnership with Chinese firm Sequanta Technologies Co., Ltd, to provide genomic profiling services in support of clinical research and development of oncology therapies in China. Historical Collaboration and Future PlansSince 2014, Foundation Medicine has utilized…
-
Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9 million (USD 34 million) in the acquisition of 97.22 million new shares of UnitedHealthcare, securing a 14% stake in the insurance firm. This strategic investment aims to diversify Fosun’s portfolio and enhance its presence in…
-
Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases
•
Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE HealthCare (NASDAQ: GEHC) to develop peripheral focused ultrasound (PFUS) technology. This non-invasive approach aims to regulate metabolic function in the treatment of chronic diseases such as type 2 diabetes (T2D) and obesity. PFUS Technology and…
-
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based Daiichi Sankyo (TYO: 4568) focused on the development and commercialization of three potential first-in-class deruxtecan-based antibody-drug conjugate (ADC) candidates. This partnership aims to advance innovative treatments for various types of cancer. ADC Candidates and Development…
-
Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with fellow Chinese firm Shaanxi Lifegen Co. Ltd. The collaboration aims to deepen efforts in platform construction, sequencing, and full product development, although financial details of the partnership were not disclosed. Scope of the PartnershipThe partnership…
-
Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China
•
Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX: ROG), securing exclusive promotion rights to Mircera (methoxy polyethylene glycol-epoetin beta) in mainland China. The financial terms of the deal remain undisclosed, highlighting the strategic nature of the partnership without revealing specific monetary details. Mircera:…
-
AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development
•
AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens of millions” of US dollars in a seed financing round co-led by Eight Roads. The funds will be instrumental in accelerating the clinical development of the company’s Pb-212 pipeline and in constructing a state-of-the-art radiopharmaceutical…
-
Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron’s expansion into the Southeast Asian market, aiming to provide…
-
Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio
•
US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink Bioscience, a biotechnology firm specializing in next-generation antibody-drug conjugates (ADCs). This strategic move is set to enhance Eli Lilly’s capabilities in developing innovative oncology treatments through Mablink’s advanced ADC technology. Mablink’s Proprietary ADC TechnologyMablink Bioscience’s…
-
Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia
•
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s Takeda Pharmaceutical Company (TYO: 4502), granting Takeda commercialization rights for its investigational product, BBM-H901. This agreement encompasses the territories of mainland China, Hong Kong, and Macau. Financial details of the partnership have not been disclosed.…
-
Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development
•
German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ Shanghai unit. The collaboration aims to develop a next-generation integrated antibody drug conjugate (ADC) platform technology, marking a significant step in the advancement of oncology treatments.…
-
Bayer Partners with HALO Precision Diagnostics to Develop Gadoquatrane for MRI Applications
•
Germany-based Bayer (ETR: BAYN) has announced a strategic partnership with US radiology expert HALO Precision Diagnostics to jointly develop gadoquatrane, a late-stage contrast agent candidate. This collaboration focuses on advancing three Phase III studies aimed at evaluating the pharmacokinetics, safety, and efficacy of this gadolinium-based molecule in both adults and…
-
Hong Kong WinHealth Pharma Enters Strategic Partnership with Nippon Shinyaku for Irsogladine
•
Hong Kong-based WinHealth Pharma Group Ltd has announced a strategic partnership with Nippon Shinyaku Co Ltd’s wholly owned subsidiary in Tianjin, China, focusing on the promotion of Gaslon N (irsogladine). While specific financial details of the collaboration remain undisclosed, this partnership marks a significant step for both companies in the…
-
Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection
•
China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South Korea’s ATGC, granting Huadong exclusive global rights (excluding India) to ATGC’s botulinum toxin A injection, ATGC-110. The agreement also provides a non-exclusive license for South Korea, encompassing clinical development, regulatory filing, and commercialization rights across…
-
Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced a significant ten-year partnership agreement with Wuhan Hesheng Technology Co., Ltd. While the financial specifics of the deal remain undisclosed, the collaboration is poised to enhance both companies’ capabilities in the pharmaceutical sector. Collaboration Focused…
-
Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development
•
Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in a Series B financing round. This funding is specifically allocated for the clinical development of its siRNA therapy product pipelines and the advancement of next-generation nucleic acid molecular delivery technologies. The financing round was led…
-
SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group
•
China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) and Italy-headquartered Menarini Group. While specific details of the partnership remain undisclosed, this alliance marks a significant step for all parties involved. Focus on Oncology and Infectious Diseases SciClone is dedicated…
-
Novo Nordisk Strikes $1.3 Billion Deal for KBP Biosciences’ Ocedurenone
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) announced a significant deal this week, valued at up to USD 1.3 billion, for the acquisition of the potential best-in-class antihypertensive drug ocedurenone from Singapore’s KBP Biosciences. The transaction, anticipated to close by the end of the year, is subject to meeting customary…
-
Ascentage Pharma and AstraZeneca Expand Collaboration on CLL/SLL Treatment
•
China’s Ascentage Pharma (HKG: 6855) and UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) have entered into a second clinical collaboration agreement to further study the combination of Ascentage’s Bcl-2 inhibitor lisaftoclax with AZ’s BTK inhibitor acalabrutinib (Calquence). This partnership is specifically aimed at conducting a registrational Phase III trial to…
-
EpimAb Biotherapeutics Licenses Bispecific Antibody Platform to Almirall
•
Shanghai-based EpimAb Biotherapeutics has entered into a strategic license agreement with Spanish pharmaceutical company Almirall for the development of bispecific antibodies (BsAbs) against up to three undisclosed target pairs. This partnership marks a significant step in leveraging EpimAb’s innovative Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to generate BsAbs, with Almirall securing exclusive…
-
MSD Partners with Phanes Therapeutics for Innovative Cancer Combo Therapy
•
Global pharmaceutical leader Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic partnership with US-based biotechnology firm Phanes Therapeutics to develop a novel combination therapy. The collaboration will see MSD’s anti-PD-1 blockbuster Keytruda (pembrolizumab) paired with Phanes’s first-in-class CD47×claudin 18.2 drug PT886, targeting claudin 18.2-positive gastric or gastroesophageal…
-
Jiangsu Hengrui Licenses Camrelizumab-Apatinib Combo to Elevar Therapeutics
•
China-based pharmaceutical giant Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has signed a significant licensing agreement with US-headquartered Elevar Therapeutics. The deal grants Elevar global exclusive development and commercialization rights to Hengrui’s programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab in combination with apatinib for the treatment of hepatocellular carcinoma (HCC),…
-
Suzhou Inhal Pharma Secures Series A Funding for Expansion and Clinical Advances
•
Suzhou Inhal Pharma Co., Ltd, a China-based company dedicated to the research and development of inhalation formulations, inhalers, and filling equipment, has reportedly secured over RMB 50 million (USD 6.8 million) in a Series A financing round. The investment round was spearheaded by Shining Capital, marking a significant boost for…
-
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company with operations in the Netherlands, the United States, and China, has formed a strategic partnership with Ingenia Therapeutics, a pre-clinical biotech with a presence in the United States and South Korea. The collaboration aims to…
-
Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671
•
China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly raised over RMB 600 million (USD 82 million) in a Series D financing round. This follows a GTJA Investment-led Series C financing round in January 2022, which raised RMB 300 million (USD 41 million). The…
-
Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round
•
Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607), has reportedly secured RMB 500 million (USD 68 million) in a Series C financing round. This substantial investment underscores the company’s robust growth and potential within the healthcare sector.…
-
Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China
•
China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement with fellow Chinese firm LanssonPharm. The agreement grants Livzon exclusive rights to Lansson’s phosphodiesterase 4 (PDE4) inhibitor, LS21031, in Greater China, marking a strategic move to expand Livzon’s portfolio in the mental health space. Terms…
-
Genetron Holdings Enters Privatization Agreement with Consortium
•
Beijing-based Genetron Holdings Ltd (NASDAQ: GTH) has officially entered into a privatization and merger agreement with a consortium comprising CICC, Wealth Strategy Holding Limited, Wuxi Guolian Development, CCB Trust (Beijing) Investment Fund Management, among others, as reported by Xinhua News Agency. The consortium will acquire Genetron’s American Depository Shares (ADSs)…
-
BMS Expands CAR-T Collaboration with Cellares on Automation Tech
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares, a company specializing in automated manufacturing platforms for cell therapies. This marks the second collaboration between the two entities, focusing on the production of an unnamed CAR-T cell therapy. The agreement highlights BMS’s commitment to…
-
Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates
•
Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech SE (NASDAQ: BNTX). Under this partnership, the two companies will collaborate to develop next-generation antibody drug conjugates (ADCs) targeting the human epidermal growth factor receptor 3 (HER3). Leveraging TMALIN Technology for Enhanced Efficacy The ADC…
-
Jiangsu Recbio Forms Strategic Cooperation for Vaccine Production in Zimbabwe
•
China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced a tripartite strategic cooperation agreement with the Zimbabwe National Biotechnology Authority (Zimbabwe NBA) and the International Centre for Genetic Engineering and Biotechnology China Regional Research Centre (ICGEB). This collaboration aims to enhance vaccine production capabilities in Zimbabwe, starting with the…
-
Sanofi Partners with BioMap to Accelerate AI-Driven Drug Discovery
•
France-based pharmaceutical giant Sanofi (EPA: SAN) has entered into a strategic partnership with US biotech firm BioMap, an AI-driven drug discovery platform founded by Robin Li, CEO of Chinese internet leader Baidu (NASDAQ: BIDU; HKG: 9888), and Wei Liu, CEO of Baidu Ventures. The collaboration includes an upfront payment of…
-
Sino Biopharmaceutical Sells 84.2% Stake in Shanghai CP General Pharmaceutical
•
China-based biotech company Sino Biopharmaceutical Ltd (HKG: 1177) has announced the sale of an 84.2% stake in its former subsidiary, Shanghai CP General Pharmaceutical Co., Ltd. This strategic divestiture is expected to generate approximately RMB 290 million (USD 40 million) for the company. Focus on Core Competencies Amid Financial Losses…
-
Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange
•
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an initial public offering (IPO) on the Hong Kong Stock Exchange, although specific pricing and additional details remain undisclosed at this time. This strategic move aims to enhance the company’s visibility and funding capabilities in the…
-
China NT Pharma Group Enters MOU with Global Fund to Expand Orthopedic Product Line
•
China NT Pharma Group Company Ltd (HKG: 1011), a China-based pharmaceutical company, has announced the signing of a non-binding memorandum of understanding (MOU) with the Global New Normal Anti Inflation Limited Partner Fund. This cooperation is aimed at bolstering NT Pharma’s presence in the orthopedic products sector, with the fund…
-
BioCity Biopharma Partners with AstraZeneca for Phase Ib/II Study in Hepatocellular Carcinoma
•
China-based biotech firm BioCity Biopharma has entered into a clinical study partnership with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The collaboration aims to conduct a Phase Ib/II study assessing the safety and efficacy of BioCity’s BC3402 in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of advanced hepatocellular cell…
-
Shanghai Shende Wuchuang Secures $28 Million in Series D Financing for Medical Device Innovation
•
Shanghai Shende Wuchuang Times Medical Technology Co., Ltd has reportedly secured nearly RMB 200 million (USD 28 million) in a Series D financing round, bringing the company’s total funding to RMB 400 million (USD 56 million). The investors in this round include Zhuji Huiri Yingtian Equity Investment and Hefei Industrial…
-
AbbVie Acquires Mitokinin, Advancing PINK1 Activator for Parkinson’s Disease
•
AbbVie (NYSE: ABBV) has announced the acquisition of US-based biotechnology company Mitokinin, exercising an exclusive right obtained in 2021. The acquisition was contingent upon the successful completion of pre-clinical studies on Mitokinin’s lead program, a potential first-in-class PINK1 activator for the treatment of Parkinson’s disease (PD). Details of the AcquisitionAbbVie…
-
AffaMed Technologies Secures Exclusive Rights to SIFI’s Intraocular Lens Products in Greater China
•
AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced a significant licensing agreement with the SIFI Group. This deal grants AffaMed exclusive rights to manufacture, develop, and commercialize SIFI’s range of intraocular lens (IOL) products in the Greater China region. The financial details of…
-
Simcere Pharmaceutical Secures Exclusive Rights to AnDiCon’s Anti-Influenza Candidate ADC189
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced a strategic collaboration agreement with domestic firm AnDiCon Bio. The collaboration centers on AnDiCon’s pipeline candidate, ADC189, with Simcere now holding exclusive commercialization rights for the drug in China. ADC189: A Novel Anti-Influenza TreatmentADC189 is an innovative anti-influenza polymerase acidic protein (PA)…
-
BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology specialist Mirati Therapeutics (NASDAQ: MRTX) in a transaction valued at USD 4.8 billion, with an additional potential contingent value right (CVR) payment of up to USD 1.0 billion to Mirati stockholders. The companies anticipate completing…
-
Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology
•
The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen Inc. (SHA: 688222). This collaboration will leverage HitGen’s DNA-encoded library (DEL) technology platform to screen under-represented targets identified by SGC. The resulting screening datasets will be made available on a publicly accessible portal, enabling global…
-
Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million
•
Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on the Nasdaq exchange last week. The company issued 2.5 million American depositary shares at a price of USD 23 each, resulting in a gross proceeds of USD 57.5 million. In addition, Adlai Nortye secured USD…
-
Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas
•
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery specialist Twist Bioscience (NASDAQ: TWST) to develop antibodies targeting undisclosed disease areas. This collaboration is set to enhance Bayer’s capabilities in antibody discovery and development. Financial Terms of the Collaboration Under the terms of the…
-
ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform
•
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with domestic firm Glyco-Therapy. This collaboration aims to create a comprehensive resource cooperation and service platform for the development of next-generation antibody drug conjugates (ADCs). Innovative Approach to ADC Development The partnership will focus on the…
-
Alphamab Oncology Enters Licensing Agreement with Grand Life Sciences for KN057 in Greater China
•
China-based Alphamab Oncology (HKG: 9966) has announced a licensing agreement with fellow Chinese firm Grand Life Sciences for its monoclonal antibody, KN057. This innovative therapy targets the tissue factor pathway inhibitor (TFPO) and is aimed at treating hemophilia A and hemophilia B in the Greater China region. Agreement Details and…
-
Chongqing Zhifei Partners with GSK for Shingrix Distribution in China
•
China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and co-promotion agreement with UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) for its shingles vaccine, Shingrix (recombinant zoster vaccine; RZV). This partnership marks a significant step in enhancing the availability of Shingrix in the Chinese market.…
-
Mabwell Bioscience Enters Licensing Agreement with Laboratorios Legrand for Biosimilars in Colombia and Ecuador
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a strategic licensing agreement with Colombia-headquartered Laboratorios Legrand S.A. Under this agreement, Laboratorios Legrand will manage the regulatory filing and commercialization of Mabwell’s biosimilars, MAILISHU and 9MW0321, which are both biosimilars of denosumab. This deal specifically covers the territories of…
-
Jiangsu Hengrui Licenses Pyrotinib to Dr. Reddy’s for Indian Market
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has entered into a licensing agreement with India-headquartered Dr. Reddy’s Laboratories, granting the latter exclusive development and commercialization rights for its HER1/HER2/HER4 inhibitor, pyrotinib, in India. Financial Terms of the Agreement Under the terms of the agreement, Hengrui will receive an upfront…
-
Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development
•
Sanofi (NASDAQ: SNY) has entered into a collaboration agreement with Teva (NYSE: TEVA) for the joint development and commercialization of Teva’s Phase II drug candidate, TEV’574, targeting inflammatory bowel diseases (IBD). This investigational molecule is designed as a potential best-in-class anti-TL1A therapy aimed at treating ulcerative colitis (UC) and Crohn’s…
-
Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio
•
Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma (NASDAQ: PNT) in a strategic move to bolster its oncology portfolio with several pre-clinical and clinical radioligand candidates. The acquisition, valued at USD 1.4 billion, will involve Lilly purchasing all outstanding shares of Point through…
-
Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing
•
Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in antibodies and recombinant proteins, has successfully raised nearly RMB 200 million (approximately USD 27.8 million) in a Series B+ financing round. The funding was led by China Medical System Holdings…
-
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic partnership with Sanofi (NASDAQ: SNY) to develop and commercialize a groundbreaking 9-valent vaccine targeting extraintestinal pathogenic Escherichia coli (ExPEC). Currently in late-stage trials, this vaccine aims to prevent invasive E. coli disease (IED) in adults…
-
Kyowa Hakko Kirin to Acquire Orchard Therapeutics for $477.6 Million
•
Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total consideration of USD 477.6 million. The deal comprises USD 387.4 million in cash and USD 90.2 million in Contingent Value Rights (CVRs), with the transaction expected to close in the first quarter of 2024. Acquisition…
-
PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development
•
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO). This agreement grants PharmaEssentia exclusive rights for research and development, manufacturing, and marketing of specific antibody sequences targeting the myeloid immune checkpoint,…
-
Boehringer Ingelheim Collaborates with Zeiss Medical Technology on Retinal Disease Detection
•
Germany’s Boehringer Ingelheim (BI) has entered into a collaboration agreement with fellow German firm Zeiss Medical Technology to advance early detection and vision loss prevention methods for serious retinal diseases. While financial details of the agreement remain undisclosed, the partnership aims to leverage cutting-edge technology in ophthalmology. Harnessing AI for…
-
Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio
•
US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a total consideration of USD 1.135 billion. This transaction includes a USD 35 million investment made in 2022, a USD 200 million upfront payment in 2023, and additional regulatory milestone payments totaling USD 125 million, along…
-
Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation
•
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements with AstraZeneca (AZ, NASDAQ: AZN), Tigermed (SHE: 300347), Simcere (HKG: 2096), and a total of 20 other companies. This initiative is set to generate cumulative investments of HKD 30 billion (approximately USD 3.83 billion) in…
-
Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan
•
Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and cancer, has announced a strategic research collaboration with SRL Inc., a premier Japanese healthcare service provider. This partnership is designed to enhance the distribution of Vela Diagnostics’ advanced molecular diagnostic solutions within Japan, although financial…
-
Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases
•
Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have jointly launched LAB eN², a drug discovery accelerator dedicated to translating academic research into innovative therapeutics for cardiometabolic conditions, rare blood diseases, and rare endocrine disorders. This initiative marks a significant step in bridging the…
-
Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop, manufacture, and commercialize two early-stage drug candidates for Alzheimer’s disease (AD) and Huntington’s disease (HD) from Ionis Pharmaceuticals (NASDAQ: IONS). This strategic move is set to bolster Roche’s pipeline in central nervous system (CNS) disorders…
-
RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy
•
China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in collaboration with fellow Chinese firm Akeso Biopharma (HKG: 9926). The study will assess the combination of RemeGen’s antibody-drug conjugate (ADC) candidate, disitamab vedotin (RC48), with Akeso’s bispecific antibody, cadonilimab (AK104), for the treatment of gastric…
-
Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline
•
China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured RMB 150 million (USD 20.5 million) in a pre-Series C financing round. The investment, led by Guoxin Investment, includes participation from Gold Mine Multi-Family Office and Zheng Xiaodong, chairman of Shanghai Tofflon Sci &Tech Co.,…
-
MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices
•
MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD 100 million in a Series C financing round. The funding was led by Centurium Capital and 6 Dimensions Capital, with contributions from Shanghai Jiading Industrial Development Group, Shanghai Jiajia Group, Hefei Haiheng Holdings, Hefei Industrial…
-
Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments
•
Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene therapies for hearing loss, following an agreement reached last month. This strategic move expands Regeneron’s portfolio in the field of genetic therapies and underscores the company’s commitment to addressing hearing loss conditions. Decibel’s Pipeline and…
-
Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company Valo Health. The collaboration aims to leverage Valo Health’s patient genetic database, artificial intelligence (AI) capabilities, and tissue modelling platform for the target identification, discovery, and development of novel treatments for cardiometabolic diseases. Additionally, Novo…
-
Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership
•
Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application solutions in China, has entered into a strategic partnership with Shanghai Model Organisms Center, Inc. (SHA: 688265). The collaboration aims to combine the companies’ expertise on a global scale, focusing on technology and commerce. Novoprotein…
-
Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development
•
China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation with South Korean biotech firm Panolos Bioscience. The partnership aims to accelerate the development of multi-specific proteins, although no financial details have been disclosed. Focus on Multi-Specific TherapeuticsPanolos Bioscience is a biopharmaceutical company specializing in…
-
Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing
•
Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised over RMB 100 million (USD 13.8 million) in a pre-Series B financing round. The funds will be allocated to support product iteration and global development initiatives over the next four years, marking a significant step…
-
Everest Medicines Partners with Kezar Life Sciences to Commercialize Zetomipzomib in Asia
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license agreement with US firm Kezar Life Sciences Inc. (NASDAQ: KZR) to develop and commercialize zetomipzomib, Kezar’s novel first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea, and Southeast Asia. This partnership aims to leverage the…
-
I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
•
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises Ltd, announcing the termination of their license and collaboration agreement concerning CD47 antibody compounds and products. The agreement, initially signed on September 3, 2020, and amended on August 15, 2022, will officially end on November…
-
Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million
•
Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk (NYSE: NVO), have completed the acquisition of biopharmaceutical company Paratek Pharmaceuticals (NASDAQ: PRTK) this week. The acquisition solidifies the group’s position in the market and expands their portfolio with the addition of the antibiotic Nuzyra…
-
Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies
•
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with Belgium-based Orionis Biosciences to discover molecular glue-class small-molecule treatments in oncology and neurodegeneration. This strategic collaboration aims to leverage Orionis’s proprietary platform for high-throughput discovery, rational design, and optimization of candidates that modulate intermolecular interactions,…
-
Inmagene Biopharmaceuticals and Aditum Bio Launch JV Celexor Bio to Target Autoimmune Diseases
•
Inmagene Biopharmaceuticals, a China-based biopharmaceutical company, has announced a strategic collaboration with US firm Aditum Bio to establish Celexor Bio, a joint venture (JV) focused on utilizing the mechanism of clearing pathological cells to treat autoimmune and inflammatory diseases. This collaboration aims to leverage the expertise of both companies to…
-
Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
•
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm mAbxience for select markets in Latin America, Southeast Asia, the Middle East, and Africa. mAbxience, which had its majority stake acquired by German group Fresenius (ETR: FRE) from Argentina-based Insud Pharma last year, specializes in…
-
Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery
•
German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial intelligence-driven precision drug design companies BenevolentAI (AMS: BAI) and Exscientia (NASDAQ: EXAI). These partnerships aim to discover potential first-in-class and best-in-class small-molecule therapies in the fields of oncology, neurology, and immunology. Terms of Collaboration and…
-
Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy
•
Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based therapeutics and diagnostics specialist, Peptidream (TYO: 4587). The collaboration aims to discover and develop potential first-in-class peptide-drug conjugates (PDCs) for the targeted delivery of radioisotopes against specific disease targets. Details of the PartnershipUnder the terms…
-
Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline
•
Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its Series C2 financing round. The round saw participation from the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund, managed by China Grand Prosperity Investment, Haibang Venture, and Howbuy Primary Fund, with existing shareholders New…
-
Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors
•
Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to clinically develop Boundless’s CHK1-targeting small-molecule inhibitor (SMI) BBI-355 in combination with Lilly’s CDK4/6 inhibitor Verzenio (abemaciclib). This collaboration aims to target locally advanced or metastatic solid tumors with oncogene amplifications, with Boundless highlighting its candidate…
-
Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into licensing agreements with undisclosed pharmaceutical companies in Pakistan and India. These strategic partnerships aim to strengthen the regulatory filing, marketing, and distribution of Kangtai Bio’s varicella attenuated live vaccines in both countries. Vaccine Description and…
-
Tianjin Century Kangtai Biomedical Raises Hundreds of Millions in Series A+ and B Financings
•
Tianjin Century Kangtai Biomedical Engineering Co., Ltd, a China-based company, has reportedly secured hundreds of millions of renminbi through Series A+ and Series B financing rounds. The Series B round was led by SDIC, with participation from Efung Capital, Lake VC, Morning Spring Venture, and Jinju Capital. The funds raised…
-
Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with Muscat Changming Investments LLC, leveraging business development plans and market demand in Oman and the Middle East. Joint Venture Establishment and ObjectivesThe partnership aims to establish a joint venture (JV) in the Sultanate of Oman,…
-
BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion
•
Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative peptides for ophthalmology and degenerative joint diseases, has announced the successful issuance of 22,500 shares at a premium of USD 2.03, raising a total of USD 45.8 million. The rights issue was fully paid on…
-
Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round
•
China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company’s…
-
Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products
•
UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic acquisition of four central nervous system (CNS) products from French pharmaceutical giant Sanofi (NASDAQ: SNY). This move signifies Pharmanovia’s commitment to enhancing its neurology offerings and aligns with Sanofi’s strategy to divest its Consumer Health…
-
Tonghua Dongbao Pharmaceuticals Partners with King-Friend Biochemical on Insulin Development
•
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SH). The collaboration focuses on the development and manufacturing of insulin glargine, insulin aspart, and insulin lispro, with the goal of filing for approval with the US FDA. King-Friend…
-
BMS Expands Partnership with Samsung Biologics for Oncology Drug Manufacturing
•
Global pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has announced an expansion of its existing partnership with Samsung Biologics (KRX: 207940) for the production of an unnamed oncology antibody drug. This new agreement signifies a further step in the collaboration between the two companies, focusing on enhancing the manufacturing capabilities…
-
GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models
•
Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in mouse models, has entered into a partnership with Daxiang Biotech, a leading domestic company in the organoid-on-a-chip field. The collaboration aims to promote the technical integration of mouse models and organoids, with the goal of…
-
Baidu Health Partners with HOB Biotech to Innovate Allergy Detection and Treatment
•
Baidu Health has entered into a strategic partnership with HOB Biotech Group, a leading in vitro diagnostic (IVD) specialist in China, to develop a new model that combines allergy detection, desensitization treatment, and Internet+ technologies. The collaboration aims to create a comprehensive approach to allergy management without disclosing financial details.…
-
Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), has entered into an exclusive licensing agreement with the Affiliated Hospital of Southwest Medical University. The agreement pertains to TBM-001, a radionuclide drug conjugate (RDC) designed for early diagnosis and…
-
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona’s proprietary technology to enhance BeiGene’s research capabilities. Financial details of the agreement have not…
-
Dialaibo Biotechnology Secures Series A Funding to Boost R&D and Manufacturing
•
China-based Dialaibo (Zhangjiagang) Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A finance round. The round was led by Grand Yangtze Capital, with participation from Shulan Junjie Capital, Zhangjiagang Jinmao Venture Capital, Zhangjiagang Talent No.1 Fund, and Zhangjiagang Bonded Area Wisdom…
-
Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion
•
Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic drugs, has reportedly raised over RMB 300 million (USD 27.5 million) in a Series C financing round. The round was led by SDIC Venture Capital, with additional investments from Guangdong Technology Financial Group, Taipu Life…
-
Menarini Group Secures Exclusive License for Astellas’ Smyraf in Taiwan
•
A. Menarini Asia-Pacific Holdings Pte. Ltd, a subsidiary of the Italy-based Menarini Group, has entered into a long-term exclusive licensing agreement with Japan-headquartered Astellas Pharma Inc (TYO: 4503). The partnership grants Menarini the rights to develop, manufacture, and commercialize the orally administered Janus kinase (JAK) inhibitor Smyraf (peficitinib hydrobromide) in…
-
Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline
•
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm BRL Medicine Inc. The collaboration aims to deepen their involvement in the gene and cell therapy (GCT) pipeline, enhance clinical studies, and expedite the commercialization of novel therapies. BRL Medicine’s…
-
Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine
•
Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development cooperation agreement with Yikang Biological (Suzhou) Co., Ltd to develop a recombinant respiratory syncytial virus (RSV) vaccine aimed at preventing RSV-induced respiratory diseases. Under the terms of the agreement, Yikang will contribute its self-designed RSV…
-
Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion
•
China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to release 68 million shares priced at HKD 38.30 (USD 4.90), offering an 8.8% discount to the September 11, 2023, closing price. Morgan Stanley is acting as the agent for the placement, responsible for securing purchasers…
-
JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development
•
China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ: TSVT) have announced plans to build on their 2022 collaboration agreement. The latest deal grants JW Therapeutics the option to develop up to two additional candidate drugs from 2seventy Bio’s product portfolio, including a T…
-
Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO
•
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs and drug immunotherapies, is poised to raise HKD 220 million (USD 28.4 million) through an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 11,001,200 shares at a price…
-
Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
•
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement with US firm Exelixis Inc., (NASDAQ: EXEL), granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1. USP1 has been identified as a synthetic lethal target in the…
-
Hasten Biopharmaceutical Secures Licensing Deal for LIB’s Lerodalcibep in Greater China
•
China-based Hasten Biopharmaceutical Co., Ltd has entered into a licensing agreement with US firm LIB Therapeutics Inc., securing the development and commercial rights to LIB’s lerodalcibep for the Greater China territory, which includes mainland China, Hong Kong, Macau, and Taiwan. The agreement involves an upfront payment of USD 20 million…
-
Wecare Medical Secures Pre-Series A Funding to Advance Brain Health Technology
•
Hangzhou-based Wecare Medical, a developer of brain disease diagnosis, monitoring, and treatment products, has reportedly raised tens of millions of renminbi in a Pre-Series A financing round. The round was led by Noyu Capital, with the proceeds earmarked for accelerating the development of temporal interference-based non-invasive deep brain electrical stimulation…
-
Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17
•
The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of ustekinumab biosimilar SB17 from South Korea’s Samsung Bioepis. The agreement covers the markets of Canada, the European Economic Area (EEA), Switzerland, UK, and the US. The biosimilar references Johnson & Johnson (J&J; NYSE: JNJ) subsidiary…
-
Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds
•
China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA： 688131) has announced plans to raise up to RMB 1.16 billion (USD 160 million) through the issuance of an undisclosed amount of convertible bonds (CDs). This strategic financing move is expected to strengthen the company’s financial position…
-
Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to acquire a 9.45% stake in start-up biopharma company Shanghai Anlingke Biopharmaceutical Co., Ltd for a consideration of RMB 30.6 million. This strategic acquisition is set to be completed through the transfer of two cancer therapy…
-
Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai, Hangzhou (China), and San Jose, Seattle (United States), is set to fully acquire Fibernova Holding Corporation for a total consideration of USD 2.7 million. The acquisition includes a USD 1.7 million equity exchange…
-
EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies
•
Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the formation of a strategic research collaboration agreement to co-develop innovative therapeutics for novel targets in inflammatory diseases of the gastrointestinal (GI) system and liver. The collaboration aims to leverage the combined expertise of both companies…
-
GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline
•
China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB 400 million (USD 54.8 million). The round was led by CICC, with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership, and existing investors Sherpa Healthcare Partners, Decheng Capital, and Matrix Partners China.…
-
Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening
•
Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection, has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series B+ financing round. The round was led by Fortune Capital, with additional investments from Tao Capital, Hotgen Biotech, and the company’s…
-
Biotyx Medical Secures Over RMB 200 Million in Series B Financing for Iron-Based Stents
•
China-based Biotyx Medical (Shenzhen) Co.,Ltd, known as the world’s only developer of iron-based absorbable stents, has reportedly raised over RMB 200 million (USD 27.4 million) in a Series B financing round. The investors in this round include Gongqingcheng Huayi Private Equity Fund Management, Guangfa Qianhe Investment, IDG Capital, and Shanghai…
-
iotaSciences Partners with Quantum Design China for Single-Cell Handling Platform Distribution
•
UK-based cell-line engineering firm iotaSciences has announced an exclusive partnership with Quantum Design China, a subsidiary of US-based Quantum Design International. Under this agreement, Quantum Design will provide distribution services for iotaSciences’ proprietary single-cell handling platforms within China. iotaSciences’ Single Cell Handling Technologies and Their ApplicationsiotaSciences specializes in the production…
-
Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative
•
Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as part of a broader program to invest up to USD 100 million in potentially disruptive startups and biotechnology companies in the discovery and development phase. This 5-year project aims to support up to 25 companies…
-
Otsuka and Shape Therapeutics Partner on Ophthalmology Gene Therapies Development
•
Japan drug maker Otsuka (OTCMKTS: OTSKY) and US firm Shape Therapeutics have announced a strategic partnership aimed at developing a range of ophthalmology gene therapies. The collaboration will leverage Shape’s machine learning-backed capsid discovery platform to create viral vectors with high target precision, enabling lower doses, and its transgene engineering…
-
Biocytogen Pharmaceuticals Enters Agreement with Myricx Bio for ADC Development
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody evaluation, option, and license agreement with Myricx Bio, a UK biotech company specializing in the discovery and development of a novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs). These payloads are based on inhibitors of…
-
Danaher Partners with Beijing’s Changping District to Accelerate Science and Technology Innovation Center
•
US-headquartered Danaher (NYSE: DHR), a Fortune 500 science and technology innovator, has entered into a partnership with the Changping District People’s Government of Beijing Municipality. The collaboration aims to jointly accelerate the construction of Danaher’s science and technology innovation center in the North and a leading synthetic biology innovation service…
-
ClouDr Partners with Hong Kong Magicure Medical Center to Enhance Cross-Border Medical Access
•
Hangzhou Kang Ming Information Technology Co., Ltd, known as “ClouDr” (HKG: 9955), has entered into a partnership with Hong Kong Magicure Medical Center with the goal of streamlining the supply chain and accelerating domestic access to the world’s leading medical resources in China. This collaboration aims to provide patients with…
-
Novo Nordisk and Broad Institute Collaborate on Diabetes and Cardiometabolic Research
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a collaboration with the US academic institution, the Broad Institute, on three cutting-edge research projects focusing on diabetes and cardiometabolic diseases. This strategic partnership aims to drive innovation in the understanding and treatment of these conditions. Type 2 Diabetes Drug Target…
-
uBriGene and YolTech Therapeutics Join Forces to Advance mRNA Therapy and Gene Therapy
•
China-based uBriGene Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, has announced a partnership with YolTech Therapeutics, a leading developer in mRNA therapy and gene therapy. This collaboration aims to combine YolTech’s expertise in lipid nanoparticles (LNP) technology for nucleic acid drug…
-
Sino Medical Sciences Technology to Acquire Majority Stake in US Endovascular Device Firm eLum
•
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced plans to acquire a 72.73% stake in eLum Technologies Inc., an early-stage endovascular medical device company based in California, US, for USD 20.73 million. Upon completion of the deal, eLum will become the controlling subsidiary of Sino Medical Sciences Technology.…
-
Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer
•
China-based Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its Board of Directors has unanimously determined that the partial tender offer by Alternative Liquidity Index LP to acquire up to 10,000,000 common shares of Sinovac for USD 0.03 apiece in cash is not advisable and is not in the best interests…
-
Abbott to Acquire Insulin Management Firm Bigfoot Biomedical
•
Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company specializing in insulin management systems. The transaction is expected to be completed this month, subject to the fulfillment of customary conditions. Financial details of the acquisition were not disclosed. History of Collaboration and Continued PartnershipAbbott…
-
Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases
•
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation agreement with Zenas BioPharma, investing USD 50 million for development and commercial rights to Zenas’s obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. Under the terms of the agreement,…
-
MGI Tech Partners with Eight Companies to Expand G99-Based Sequencing Applications
•
China-based MGI Tech, a subsidiary of BGI Group (SHE: 300676), has entered into cooperation agreements with eight companies to develop applications based on the G99 sequencing platform. The financial details of these agreements have not been disclosed. DNBSEQ-G99: A Miniaturized Sequencing PlatformDNBSEQ-G99, launched by MGI Tech, is a miniaturized dual…
-
ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock Exchange this morning, with a positive start as its share price surpassed the issuance price of RMB 18.6 per share in early trading. The initial public offering (IPO) is anticipated to raise over HKD 300…
-
Bloomage Biotech Terminates Joint Venture with Medytox Inc. for Botulinum Toxin Development
•
China-based Bloomage Biotech (SHA: 688363) has revealed that a termination agreement has been signed with South Korea-headquartered Medytox Inc., and its subsidiary Bloomage Cayman, along with the joint venture (JV) Medybloom Ltd. This termination signifies the cancellation of two key agreements. Cancellation of Joint Venture and Sole Agency AgreementsThe first…
-
Pilot Gene Technology Secures $13.8 Million in Series B Financing for Diagnostic Expansion
•
China-based diagnostic reagents specialist, Pilot Gene Technology (Hangzhou) Co., Ltd, has reportedly raised RMB 100 million (USD 13.8 million) in a Series B financing round led by Simao Capital. The funds raised will be directed towards the research and development of fully automated instruments and equipment, including Point-of-Care Testing (POCT),…
-
Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition
•
Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with the US Federal Trade Commission (FTC), which they anticipate will resolve the antitrust agency’s legal challenges to Amgen’s acquisition of Horizon. The conflict arose from a preliminary injunction motion and temporary restraining order (TRO) filed…
-
Shanghai Biotech Cataya Secures $35 Million in Series B Financing for Synthetic Biology
•
Shanghai-based biotech company Cataya, which specializes in synthetic biology, has reportedly raised RMB 250 million (USD 35 million) in a Series B financing round. The round was co-led by Hengxu Capital and Eight Roads Ventures, with additional investments from Hui Rong Technology Service and Bits x Bites. Cataya’s DBTL Platform…
-
XtalPi Partners with Parthenon Therapeutics to Harness AI for Solid Tumor Antibody Development
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a strategic partnership with US cancer therapy developer Parthenon Therapeutics Inc. to develop antibodies targeting solid tumors. This collaboration aims to leverage the power of AI to advance oncology treatments. Access to XtalPi’s XupremAb Platform and “Experiment+AI” SolutionsUnder the terms…
-
EOC Pharma Group and Nanopeptide Biotechnology Forge Partnership for siRNA Drug Development
•
China-based EOC Pharma Group has announced a strategic partnership with fellow country siRNA firm, Nanopeptide (Qingdao) Biotechnology Ltd., to delve into the research and development of small nucleic acid drugs within the cardiovascular field. Agreement Terms and Regional RightsUnder the terms of the agreement, Nanopeptide has granted EOC Pharma Group…
-
Huadong Medicine Secures Exclusive Rights to MC2 Therapeutics’ Plaque Psoriasis Therapy in China
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a licensing agreement with Denmark-headquartered MC2 Therapeutics A/S, securing exclusive development and commercialization rights to MC2’s Wynzora cream, a therapy for plaque psoriasis. The agreement covers the Greater China territory, which includes mainland China, Hong Kong, Macau, and Taiwan. Financial Terms…
-
Innovac Therapeutics Secures $18 Million in Pre-Series A Financing for mRNA Vaccine Development
•
Innovac Therapeutics, a Massachusetts-based mRNA vaccine developer, has announced the successful completion of its Pre-Series A financing round, raising $18 million. The funding was led by Lichen Capital, Vision Plus Capital, Couplet Health fund, TG Sino-Dragon Fund, and other investors. The proceeds from this round will be directed towards the…
-
Watchmaker Genomics and Exact Sciences Corporation Ink Deal to Advance TAPS Technology
•
US-based Watchmaker Genomics has announced a multi-year, co-exclusive agreement with compatriot firm Exact Sciences Corporation to develop and commercialize the breakthrough DNA methylation analysis technology known as TET-assisted pyridine borane sequencing (TAPS). Watchmaker will utilize its expertise in engineering DNA-modifying enzymes to enhance the TAPS chemistry, enabling advanced applications such…
-
XtalPi Inc. Partners with Edelweiss Connect to Revolutionize Skincare Safety Assessment
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has announced a strategic partnership with Edelweiss Connect, a Swiss company specializing in next-generation product design and risk assessment solutions. This collaboration aims to leverage the unique strengths of both companies in chemical and pharmaceutical safety assessment, technology platforms, and market expertise. Integrating…
-
Takeda Secures Exclusive Rights to ImmunoGen’s Elahere in Japan Through New Agreement
•
Japanese pharmaceutical company Takeda (TYO: 4502) has entered into an exclusive collaboration and license agreement with ImmunoGen (NASDAQ: IMGN) to develop and commercialize ImmunoGen’s antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine) in Japan. Elahere has received accelerated approval in the United States for the treatment of FRα-positive platinum-resistant epithelial ovarian, fallopian…
-
Ronovo Surgical Secures Pre-Series B+ Funding to Advance Modular Surgical Robots
•
Shanghai-based minimally invasive surgical robot developer, Ronovo Surgical, has reportedly raised close to RMB 200 million (USD 27.5 million) in a pre-Series B+ financing round. The round was led by NRL Capital, with contributions from Kington Capital, Lilly Asia Ventures, Vivo Capital, Matrix Partners, GGV Capital, and LongRiver Investments. The…
-
Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies
•
Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by V-Capital, with additional investments from Northern Light Venture Capital, Lapam Capital, Yijing Capital, Realharmony Capital, and Yinxinggu Capital. The proceeds from this funding will…
-
Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy
•
Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has successfully raised USD 32 million in a Series A financing round. The round was co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital. The funds will be utilized to…
-
Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage…
-
Asymchem Laboratories Secures RMB 2.31 Billion Private Placement with Hill House Capital Subscription
•
Asymchem Laboratories (Tianjin) Co., Ltd, a renowned Contract Development and Manufacturing Organization (CDMO) based in China and listed on the SZSE under the ticker (002821), has unveiled a significant private placement initiative. The company will issue 18,700,000 A shares at a price of RMB 123.56 per share. Hill House Capital,…
-
Luye Pharma Expands Latin American Reach with Exclusive Seroquel Promotion Agreement in Brazil and Mexico
•
Luye Pharma Group (HKG: 2186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned subsidiary, Luye Hong Kong Limited, has secured an exclusive promotion agreement with two subsidiaries of US-based Moksha8 Pharmaceuticals, Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda. and Moksha8 Farmacéutica, S. de R.L. de C.V. This…
-
Guangzhou Pharma and BioCubaFarma Chart New Course with Joint Biologics R&D and Exchange Deal
•
Guangzhou Pharmaceutical Holdings Ltd., a prominent player in China’s pharmaceutical sector, has inked a strategic letter of intent with BioCubaFarma, Cuba’s foremost state-owned pharmaceutical juggernaut, to embark on a joint venture in research and development (R&D), manufacturing, and commercialization of avant-garde pharmaceutical products within the Chinese market, with a spotlight…
